Novartis Foundation Symposium 252
GENERATION AND EFFECTOR FUNCTIONS OF REGULATORY LYMPHOCYTES
2003
GENERATION AND EFFECTOR FUNCTIONS OF REGULATORY LYMPHOCYTES
The Novartis Foundation is an international scienti¢c and educational charity (UK Registered Charity No. 313574). Known until September 1997 as the Ciba Foundation, it was established in 1947 by the CIBA company of Basle, which merged with Sandoz in 1996, to form Novartis. The Foundation operates independently in London under English trust law. It was formally opened on 22 June 1949. The Foundation promotes the study and general knowledge of science and in particular encourages international co-operation in scienti¢c research. To this end, it organizes internationally acclaimed meetings (typically eight symposia and allied open meetings and 15^20 discussion meetings each year) and publishes eight books per year featuring the presented papers and discussions from the symposia. Although primarily an operational rather than a grant-making foundation, it awards bursaries to young scientists to attend the symposia and afterwards work with one of the other participants. The Foundation’s headquarters at 41 Portland Place, London W1B 1BN, provide library facilities, open to graduates in science and allied disciplines. Media relations are fostered by regular press conferences and by articles prepared by the Foundation’s Science Writer in Residence. The Foundation o¡ers accommodation and meeting facilities to visiting scientists and their societies.
Information on all Foundation activities can be found at http://www.novartisfound.org.uk
Novartis Foundation Symposium 252
GENERATION AND EFFECTOR FUNCTIONS OF REGULATORY LYMPHOCYTES
2003
Copyright & Novartis Foundation 2003 Published in 2003 by John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester PO19 8SQ, UK National 01243 779777 International (+44) 1243 779777 e-mail (for orders and customer service enquiries):
[email protected] Visit our Home Page on http:// www.wileyeurope.com or http://www.wiley.com All Rights Reserved. No part of this book may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1T 4LP, UK, without the permission in writing of the Publisher. Requests to the Publisher should be addressed to the Permissions Department, John Wiley & Sons Ltd,The Atrium, Southern Gate, Chichester,West Sussex PO19 8SQ, England, or emailed to
[email protected], or faxed to (+44) 1243 770620. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the Publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought. Other Wiley Editorial O⁄ces John Wiley & Sons Inc., 111 River Street, Hoboken, NJ 07030, USA Jossey-Bass, 989 Market Street, San Francisco, CA 94103-1741, USA Wiley-VCH Verlag GmbH, Boschstr. 12, D-69469 Weinheim, Germany John Wiley & Sons Australia Ltd, 33 Park Road, Milton, Queensland 4064, Australia John Wiley & Sons (Asia) Pte Ltd, 2 Clementi Loop #02-01, Jin Xing Distripark, Singapore 129809 John Wiley & Sons Canada Ltd, 22 Worcester Road, Etobicoke, Ontario, Canada M9W 1L1 Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books. Novartis Foundation Symposium 252 x+315 pages, 42 ¢gures, 19 tables Library of Congress Cataloging-in-Publication Data Generation and e¡ector functions of regulatory lymphocytes / [editors, Gregory Bock and Jamie Goode]. p. cm. ^ (Novartis Foundation symposium ; 252) Includes bibliographical references and index. ISBN 0-470-85074-4 (alk. paper) 1. Lymphocytes. 2. Tcells. 3. Immune response ^Regulation. I. Bock, Gregory. II. Goode, Jamie. III. Series. QR185.8.L9G46 2003 571.9’6^dc22 2003057598 British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library ISBN 0 470 85074 4 Typeset in 1012 on 1212 pt Garamond by DobbieTypesetting Limited, Tavistock, Devon. Printed and bound in Great Britain by T. J. International Ltd, Padstow, Cornwall. This book is printed on acid-free paper responsibly manufactured from sustainable forestry, in which at least two trees are planted for each one used for paper production.
Contents Symposium on Generation and e¡ector functions of regulatory lymphocytes, held atthe Novartis Foundation, London, 9^11July 2002 Editors: Gregory Bock (Organizer) and Jamie Goode This symposium was based on a proposal made by Matthias von Herrath and Je¡rey Bluestone Jean-Francois Bach
Chair’s introduction 1
Shimon Sakaguchi, Shohei Hori,Yoshinori Fukui,Takehiko Sasazuki, Noriko Sakaguchi and Takeshi Takahashi Thymic generation and selection of CD25+CD4+ regulatory T cells: implications of their broad repertoire and high self-reactivity for the maintenance of immunological self-tolerance 6 Discussion 16 Ethan M. Shevach, Ciriaco A. Piccirillo, Angela M. Thornton and Rebecca S. McHugh Control of T cell activation by CD4+CD25+ suppressor T cells 24 Discussion 36 Adam P. Kohm, Pamela A. Carpentier and Stephen D. Miller Regulation of experimental autoimmune encephalomyelitis (EAE) by CD4+CD25+ regulatory T cells 45 Discussion 52 Elisa Boden, Qizhi Tang, Helene Bour-Jordan and Je¡reyA. Bluestone The role of CD28 and CTLA4 in the function and homeostasis of CD4+CD25+ regulatory T cells 55 Discussion 63 Clare Baecher-Allan, Julia A. Brown, Gordon J. Freeman and David A. Ha£er CD4+CD25+ regulatory cells from human peripheral blood express very high levels of CD25 ex vivo 67 Discussion 88 v
vi
CONTENTS
Fiona Powrie, Simon Read, Christian Mottet, Holm Uhlig and Kevin Maloy Control of immune pathology by regulatory T cells 92 Discussion 98 General discussion I TGFb 106 Maria Grazia Roncarolo, Silvia Gregori and Megan Levings Type 1 T regulatory cells and their relationship with CD4+CD25+ Tregulatory cells 115 Discussion 127 Leonard C. Harrison, Natasha R. Solly and Nathan R. Martinez speci¢c regulatory T cells 132 Discussion 141
(PRO)insulin-
Qing-Sheng Mi, Craig Meagher and Terry L. Delovitch CD1d-restricted NKT regulatory cells: functional genomic analyses provide new insights into the mechanisms of protection against Type 1 diabetes 146 Discussion 160 Eli Sercarz, Emanual Maverakis, Peter van den Elzen, Loui Madakamutil and Vipin Kumar Seven surprises in theTCR-centred regulation of immune responsiveness in an autoimmune system 165 Discussion 171 Kathryn J.Wood, Hidetake Ushigome, Mahzuz Karim, Andrew Bushell, Shohei Hori and Shimon Sakaguchi Regulatory cells in transplantation 177 Discussion 188 Kim J. Hasenkrug Discussion 199
CD4+ regulatory T cells in chronic viral infection 194
General discussion II
203
Marca H. M.Wauben, Esther N. M.’t Hoen and Leonie S.Taams Modulation of T cell responses after cross-talk between antigen presenting cells and T cells: a giveand-take relationship 211 Discussion 220 Jacques Banchereau, Joseph Fay,Virginia Pascual and A. Karolina Palucka Dendritic cells: controllers of the immune system and a new promise for immunotherapy 226 Discussion 235
vii
CONTENTS
Chrystelle Asseman and Matthias von Herrath autoimmune responses 239 Discussion 253 General discussion III
Regulation of viral and
Active immune regulation 257
MargaretJ. Dallman, Brian Champion andJonathan R. Lamb in the peripheral immune system 268 Discussion 276
Notch signalling
Lucienne Chatenoud CD3 antibody treatment stimulates the functional capability of regulatory T cells 279 Discussion 286 Allan McI Mowat, Anne M. Donachie, LucyA. Parker, Neil C. Robson, Helen Beacock-Sharp, Lindsay J. McIntyre, Owain Millington and Fernando Chirdo The role of dendritic cells in regulating mucosal immunity and tolerance 291 Discussion 302 Index of contributors Subject index
308
306
Participants Abul K. Abbas Department of Pathology, University of California San Francisco, Room M 590, 513 Parnassus Avenue, San Francisco, CA 94143, USA Chrystelle Asseman (Novartis Foundation Bursar) LaJolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121, USA Jean-Francois Bach (Chair) Laboratoire d’Immunologie, Ho“pital Necker, 161 rue de Se' vres, 75743 Paris Cedex 15, France Jacques Banchereau Baylor Institute for Immunology Research, 3434 Live Oak, Suite 205, Dallas,TX 75204, USA Je¡rey Bluestone UCSF Diabetes Center, 513 Parnassus Ave Box 0540, San Francisco, CA 94143-0540, USA Lucienne Chatenoud Laboratoire d’Immunologie, Ho“pital Necker, 161 rue de Se' vres, F-75743 Paris Cedex 15, France Cristina Cuturi INSERM U437, CHU de Nantes, 30 solJ. Monnet, 44093, Nantes, France Margaret Dallman Department of Biology, Sir Alexander Fleming Building, Imperial College of Science,Technology and Medicine, South Kensington, London SW7 2AZ, UK Terry Delovitch TheJohn P. Robarts Research Institute, 1400 Western Road, London, Ontario, Canada N6G 2V4 Richard Flavell Department of Immunobiology,Yale University School of Medicine, HHMI, 310 Cedar Street, FMB412, Box 208011, New Haven, CT 06520-8011, USA David Ha£er Center for Neurologic Diseases, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA viii
ix
PARTICIPANTS
Leonard Harrison Autoimmunity and Transplantation Division,The Walter and Eliza Hall Institute of Medical Research,The Royal Melbourne Hospital PO, Parkville, 3050 Victoria, Australia Kim Hasenkrug Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, Hamilton, MT 59840, USA Stephen Miller Immunobiology Center, Northwestern University School of Medicine, 303 E. Chicago Avenue, Chicago, IL 60611-3072, USA Av Mitchison Department of Immunology,Windeyer Institute of Medical Science, University College London Medical School, 46 Cleveland Street, London W1P 6DB, UK Allan Mowat Department of Immunology and Bacteriology,Western In¢rmary, Glasgow G11 6NT, UK Virginia Pascual Baylor Institute for Immunology Research, 3434 Live Oak, Suite 205, Dallas,TX 75204, USA Fiona Powrie University of Oxford, Sir William Dunn School of Pathology, South Parks Road, Oxford OX1 3RE, UK Maria Grazia Roncarolo San Ra¡aeleTelethon Institute for GeneTherapy (HSR-TIGET),Via Olgettina 58, I-20132 Milano, Italy Shimon Sakaguchi Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, 53 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan Eli Sercarz The LaJolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121, USA Ethan Shevach Cellular Immunology Section, NIAID Laboratory of Immunology, Building 10, Room 11N315, 10 Center Drive, MSC1892, Bethesda, MD 20892-1892, USA Matthias von Herrath Department of Immune Regulation, LaJolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121, USA
x
PARTICIPANTS
MarcaWauben Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, PO Box 80.165, NL-3508 TD Utrecht, The Netherlands Christoph Walker Novartis Pharma UK, Novartis Horsham Research Centre, Wimblehurst Road, Horsham RH12 5AB, UK Kathryn Wood The Nu⁄eld Department of Surgery, University of Oxford, John Radcli¡e Hospital, Headley Way, Headington, Oxford OX3 9DU, UK
Chair’s introduction Jean-Franc ois Bach Laboratoire d’Immunologie, Ho“ pital Necker, 161 Rue de Se' vres, 75743 Paris, Cedex 15, France
The notion of T cell-mediated suppression/regulation is not new. In 1971, Richard Gershon published a classical paper describing the capacity of T cells from mice immunized by sheep red blood cells (SRBCs) to down-regulate the production of anti-SRBC antibodies in na|« ve recipients (Gershon & Kondo 1970). This so-called infectious tolerance opened the ¢eld of suppressor T cells which gave rise to an unusually abundant future in the following decade. It is not necessary to review here all the claims that were made in this period and all the problems that were then raised both at the experimental and the interpretational levels. In any event, these problems ineluctably led to the discredit of the whole ¢eld, which disappeared from the scene in the early 1980s. It was only a few years later that new experiments were performed and eventually published indicating that T cellmediated regulation was a real phenomenon, probably important in the control of the development of autoimmune and alloimmune responses. This resurrection relied on three sets of observations. The ¢rst one was undoubtedly the proposal by Mosmann & Co¡man (1989) of the Th1/Th2 paradigm. The demonstration that Th1 cytokine could down-regulate Th2 cell di¡erentiation and function, and reciprocally Th2 cytokines could down-regulate Th1 cells through a non-antigenspeci¢c cytokine-mediated mechanism provided a new explanation for the suppressor T cells which had been described 10 years earlier. Fifteen years later, the Th1/Th2 paradigm is still very vivid, even if its generality is not as apparent as it was initially thought. A second observation which proved to be crucial for the emergence of the suppressor cell concept was that of bystander suppression. Oral administration of an autoantigen can induce tolerance to that antigen. Surprisingly enough, this tolerance extends to antigens other than the tolerogen in as much as this antigen is expressed at the same site (organ or cell) as the tolerogen (Al Sabbagh et al 1994). Here again, cytokines were implicated in the phenomenon. It was assumed that the initial regulatory reaction produced by a tolerogen led to the local production of cytokines that show suppressive activity against immune responses directed at other antigens at the lesion site. The third set of observations dealt with the reappraisal of the thymectomy experiments performed in the late 1960s. It had been shown at that time that 1
2
BACH
thymectomy at day 2^5 induced polyautoimmune syndrome (Nishizuka & Sakakura 1969). It was shown in the early 1990s that such polyautoimmune syndrome could be prevented by the administration of CD4+CD25+ T cells (Asano et al 1996), excluding other explanations of the thymectomy induced autoimmunity (e.g. absence of selection in the thymus). One should lastly mention experiments performed in various laboratories including ours showing the presence in healthy mice of regulatory cells capable of preventing disease onset in various autoimmune models. We indeed showed in non-obese diabetic (NOD) mice that CD4+ T cells from pre-diabetic NOD could prevent the transfer of diabetes a¡orded by diabetogenic T cells (derived from diabetic NODs) when injected into immunoincompetent recipients (Boitard et al 1989). Still unanswered questions If there is a general although not absolute consensus about the existence of regulatory T cells today, many questions remain unanswered. CD4+ T cells may be regulatory. How many distinct T cell subsets comprise the CD4+ regulatory T cells? The study of phenotypes is helpful, looking either at membrane markers or at cytokine production, pro¢le and dependency. It must be admitted, however, that study of phenotypes and cytokine production has not yielded convergent results. As far as markers are concerned, CD25 is probably the most reliable marker, although CD45RB (Powrie et al 1993) and CD62L (Herbelin et al 1998) are also useful and do not de¢ne exactly the same cells. Maybe other markers such as CTLA4 and glucocorticoid-induced tumour necrosis factor (TNF) receptor GITR (Zelenika et al 2002, McHugh et al 2002, Shimizu et al 2002) will prove useful, perhaps in a complementary fashion to CD25 and CD62L. The mode of action of regulatory T cells is very uncertain, and probably variable from one subset to another. Cytokines are logical candidates. They probably play a central role for Th2 cells and Treg1 cells (Groux et al 1997). Their role for CD25+ T cells is more dubious, although a number of data have recently incriminated transforming growth factor (TGF)b (Nakamura et al 2001). A special role could be played by interleukin (IL)10, at least in certain models, such as colitis. It could be of crucial importance to determine the respective role of cytokines for the various T cell subsets, both in terms of their mode of action but also of their growth and di¡erentiation. Antigen speci¢city is a very open question, except of course for Th2 cells and Treg1 cells, the de¢nition of which is based on stimulation by antigen. More work is needed to determine the speci¢city of CD25+ T cells. Do CD25+ T cells act in a speci¢c fashion particularly with regard to organ-speci¢c antigens? Can the antigen-speci¢c CD25+ T cells recently described in allograft and tumour
CHAIR’S INTRODUCTION
3
immunity be assimilated to the CD25+ T cells controlling the expression of physiological autoimmunity? Candidate regulatory T cells may be used with bene¢t for immunotherapy Soluble autoantigens and altered peptide ligands apparently act by stimulating Th2 cells (Bach & Chatenoud 2001). CD3 antibody appears to act by stimulating CD25+ T cells and, more precisely, by enhancing TGFb production by such cells (Chatenoud 2003, this volume). a galactosyl ceramide acts by stimulating NKT cells and has been shown to protect from diabetes onset in NOD mice (Sharif et al 2001, Hong et al 2001). It would be important to search for other methods leading to the stimulation of the various regulatory T cell subsets and to analyse the feasibility of their clinical applications. Conclusions: working hypothesis More than 10 types of regulatory T cells have been described so far (Table 1). One may assume that some of these T cell types represent the variable expression of a single T cell lineage, although this has not been proven. Theoretically one may believe that totally di¡erent lines of suppressor T cells exist. If this is the case, it would be important to determine the conditions of their di¡erentiation. At ¢rst glance, one is tempted to separate cells which appear spontaneously in ontogeny without deliberate intervention, such as CD25+ T cells or NKT cells. It is interesting to note that depletion of these cells or genetic prevention of their appearance leads to an increase of autoimmune disease in mice genetically prone to develop the disease. Thus, depletion of CD25+ T cells in NOD mice accelerates diabetes onset and absence of NKT cells as a¡orded by genetic invalidation of CD1d (Wang et al 2001) leads to accelerated diabetes onset in TABLE 1
Classi¢cation of regulatory cells
Natural/innate
Adaptive
CD25+ T cells NKT cells NK cells g/d T cells Veto cells
Th1 cells Th2 cells Tr1 cells CD45RBlow T cells CD8+ T cells Anti-idiotypic T cells
4
BACH
NOD mice. On the other hand, as mentioned above, Th2 cells, Treg1 cells and maybe g/d CD8+ T cells (Harrison et al 1996) appear after administration of antigens either as immunogens as in the case of experimentally induced autoimmune disease, or as tolerogens as is the case when tolerance is induced in spontaneously autoimmune mice by administration of soluble autoantigens. This distinction is reminiscent of the opposition classically made between innate and adaptive immunity. The word innate in the context of immunoregulation may be misleading since it is usually reserved to TCR-mediated immunity. Maybe it would be more adequate to use the word ‘natural’ which relates to the appearance of the cells in question independently of any contact with foreignness. References Al Sabbagh A, Miller A, Santos LM, Weiner HL 1994 Antigen-driven tissue-speci¢c suppression following oral tolerance: orally administered myelin basic protein suppresses proteolipid protein-induced experimental autoimmune encephalomyelitis in the SJL mouse. Eur J Immunol 24:2104^2109 Asano M, Toda M, Sakaguchi N, Sakaguchi S 1996 Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 184:387^396 Bach JF, Chatenoud L 2001 Tolerance to islet autoantigens and type I diabetes. Annu Rev Immunol 19:131^161 Boitard C, Yasunami R, Dardenne M, Bach JF 1989 T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice. J Exp Med 169:1669^1680 Chatenoud L 2003 CD3 antibody treatment stimulates the functional capability of regulatory T cells. In: Generation and e¡ector functions of regulatory lymphocytes. Wiley, Chichester (Novartis Found Symp 252) p 279^290 Gershon RK, Kondo K 1970 Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 18:723^737 Groux H, O’Garra A, Bigler M et al 1997 A CD4+ T-cell subset inhibits antigen-speci¢c T-cell responses and prevents colitis. Nature 389:737^742 Harrison LC, Dempsey-Collier M, Kramer DR, Takahashi K 1996 Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes. J Exp Med 184:2167^2174 Herbelin A, Gombert JM, Lepault F, Bach JF, Chatenoud L 1998 Mature mainstream TCR ab+CD4+ thymocytes expressing L-selectin mediate ‘active tolerance’ in the nonobese diabetic mouse. J Immunol 161:2620^2628 Hong S, Wilson MT, Serizawa I et al 2001 The natural killer T-cell ligand a-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 7:1052^1056 McHugh RS, Whitters MJ, Piccirillo CA et al 2002 CD4+CD25+ immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16:311^323 Mosmann TR, Co¡man RL 1989 TH1 and TH2 cells: di¡erent patterns of lymphokine secretion lead to di¡erent functional properties. Annu Rev Immunol 7:145^173 Nakamura K, Kitani A, Strober W 2001 Cell contact-dependent immunosuppression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor b. J Exp Med 194:629^644 Nishizuka Y, Sakakura T 1969 Thymus and reproduction: sex-linked dysgenesia of the gonad after neonatal thymectomy in mice. Science 166:753^755
CHAIR’S INTRODUCTION
5
Powrie F, Leach MW, Mauze S, Caddle LB, Co¡man RL 1993 Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal in£ammation in C. B-17 scid mice. Int Immunol 5:1461^1471 Sharif S, Arreaza GA, Zucker P et al 2001 Activation of natural killer T cells by alphagalactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med 7:1057^1062 Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S 2002 Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3:135^ 142 Wang B, Geng YB, Wang CR 2001 CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J Exp Med 194:313^320 Zelenika D, Adams E, Humm S et al 2002 Regulatory T cells overexpress a subset of Th2 gene transcripts. J Immunol 168:1069^1079
Thymic generation and selection of CD25+CD4+ regulatory T cells: implications of their broad repertoire and high self-reactivity for the maintenance of immunological self-tolerance Shimon Sakaguchi*{, Shohei Hori*{, Yoshinori Fukui{, Takehiko Sasazuki{, Noriko Sakaguchi*{ and Takeshi Takahashi* *Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, {Laboratory of Immunopathology, Research Center for Allergy and Immunology, The Institute for Physical and Chemical Research (RIKEN), Yokohama 230-0045, and {Division of Immunogenetics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, and CREST, Japan Science and Technology Corporation, Fukuoka 812-8582, Japan Abstract. Besides positive and negative selection of T cells, another function of the thymus in maintaining immunological self-tolerance is the production of CD25+CD4+ regulatory T cells capable of preventing autoimmune disease. They acquire the regulatory activity through the thymic selection process, and are released to the periphery as a functionally and phenotypically mature population. Our recent study with transgenic mice in which every class II MHC molecule covalently binds the same single peptide has revealed that a particular self-peptide/MHC ligand in the thymus can positively select a broad repertoire of functionally mature CD25+CD4+ regulatory T cells as well as na|« ve T cells. Interestingly, the regulatory T cells bear higher reactivity than other T cells to the selecting ligand in the thymus even after negative selection by the ligand. This broad repertoire and high self-reactivity of CD25+CD4+ regulatory T cells, together with their high level expression of various accessory molecules, may guarantee their prompt and e⁄cient activation upon encounter with a diverse range of self peptide/MHC complexes in the periphery, ensuring dominant control of self-reactive T cells. 2003 Generation and e¡ector functions of regulatory lymphocytes. Wiley, Chichester (Novartis Foundation Symposium 252) p 6^23
One aspect of peripheral self-tolerance is maintained by regulatory CD4+ cells naturally occurring in normal na|« ve animals (Sakaguchi 2000, Shevach 2000, Maloy & Powrie 2001). Direct evidence for the key contribution of these 6
THYMIC SELECTION OF CD25+CD4+ REGULATORY T CELLS
7
naturally arising regulatory T cells to self-tolerance is that removal of a subpopulation of CD4+ T cells from the normal immune system leads to spontaneous development of various autoimmune diseases in genetically susceptible animals; and reconstitution of the removed population prevents the development of autoimmunity (Sakaguchi et al 1985, Powrie & Mason 1990). The normal thymus seems to be continuously producing this autoimmunepreventive regulatory T cell population (Itoh et al 1999, Seddon & Mason 2000). Here we discuss how the thymus produces the regulatory T cells and how their sensitivity and repertoire in recognizing self-antigens contribute to their function of controlling self-reactive T cells. Self-tolerance maintained by CD25+CD4+ regulatory T cells Autoimmune diseases can be produced in normal rodents simply by removing a T cell subpopulation, without immunization with self-antigens in potent adjuvant. For example, when splenic cell suspensions from normal mice or rats are depleted of CD5high, CD45RClow, or CD25+CD4+ T cells and the remaining cells are transferred to syngeneic T cell-de¢cient animals, autoimmune disease spontaneously develops in multiple organs of the recipients within a few months; co-transfer of the removed population inhibits the development of autoimmunity (Sakaguchi et al 1985, 1995, Powrie & Mason 1990) (Fig. 1). Expression of the CD25 molecule is so far most speci¢c for such an autoimmune-preventive T cell population present in normal na|« ve animals. CD25+ T cells, which constitute 5^10% of peripheral CD4+ T cells and less than 1% of peripheral CD8+ T cells in mice and humans, are CD5high and CD45RBlow. Removal of these CD25+ T cells from normal mice produced autoimmune disease in a wider spectrum of organs and with higher incidences than removal of CD5high cells or CD45RBlow T cells (Sakaguchi et al 1995). The autoimmune diseases thus induced are immunopathologically similar to the human counterparts, e.g. Hashimoto’s thyroiditis, type A autoimmune gastritis with pernicious anaemia, insulindependent diabetes mellitus, Addison’s disease (autoimmune adrenalitis), premature ovarian failure with autoimmune oophoritis or male infertility with autoimmune orchitis. These ¢ndings indicate that the normal immune system harbours self-reactive T cells su⁄ciently pathogenic in speci¢city and a⁄nity to initiate autoimmune diseases, that their activation and expansion is held in check in the normal periphery by a regulatory CD4+ T cell subpopulation, and that elimination or reduction of this population su⁄ces to break natural self-tolerance, leading to spontaneous activation and expansion of self-reactive T cells which mediate chronic and destructive autoimmune disease (Fig. 1). The CD25+CD4+ T cells in the periphery of normal na|« ve mice have the following immunological characteristics (Takahashi et al 1998, Thornton &
8
SAKAGUCHI ET AL
FIG. 1. Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells. While the normal thymus deletes T cells highly reactive with self-antigens expressed in the thymus, it continuously produces potentially pathogenic self-reactive CD4+ T cells, which persist in the periphery at CD25 quiescent state. The normal thymus also continuously produces anergic and suppressive CD25+CD4+ T cells. On APCs, they suppress the activation and expansion of CD4+ self-reactive T cells (and CD8+ self-reactive T cells) from CD25 dormant state. They are unique in requiring a signal through CTLA4 for their activation. Signal through GITR, on the other hand, attenuates their suppressive activity. When regulatory CD25+CD4+ T cells are eliminated or substantially reduced, or their regulatory function is impaired (for example, by blockade of CTLA4 or signal transduction through GITR), CD25 self-reactive T cells become activated, expand and di¡erentiate to autoimmune e¡ector T cells.
Shevach 1998, Itoh et al 1999). First, they potently suppress the activation/ proliferation of other T cells in vitro when the two populations are co-cultured with antigen-presenting cells (APCs) and stimulated with antigen. They need stimulation through TCR to exert the suppressive activity; and, upon TCR stimulation, they suppress the proliferation of not only T cells with the same antigen speci¢city but also other T cells speci¢c for other antigens; i.e. CD25+CD4+ regulatory T cells stimulated by a speci¢c antigen exerts antigennon-speci¢c suppression (Takahashi et al 1998). Second, although CD25+CD4+ regulatory T cells require antigenic stimulation for their functional activation, they themselves are non-proliferative (i.e. anti-proliferative or anergic) to in vitro
THYMIC SELECTION OF CD25+CD4+ REGULATORY T CELLS
9
antigenic stimulation, and this anergic state is closely linked with suppression. Importantly, the anergic/suppressive state of CD25+CD4+ T cells appears to be their basal and default condition. When CD25+CD4+ T cells are TCR-stimulated and treated with interleukin (IL)2 (or anti-CD28), anergy/suppression is broken, but they spontaneously revert to their original anergic state and re-acquire the suppressive activity when IL2 (or anti-CD28 antibody) is removed (Takahashi et al 1998). Third, the roles of accessory molecules are di¡erent between CD25+ CD4+ regulatory T cells and other T cells. For example, the majority of CD25+ CD4+ T cells in normal na|« ve mice constitutively express CTLA4 (CD152) and GITR (glucocorticoid-induced tumour necrosis factor receptor family gene) at high levels. (Takahashi et al 2000, Read et al 2000, Solomon et al 2000, Shimizu et al 2002, McHugh et al 2002). Blockade of CTLA4 or active signal transduction through GITR abrogates CD25+CD4+ T cell-mediated suppression, thereby producing autoimmune diseases similar to those induced by elimination of CD25+CD4+ T cells. The expression pattern of other accessory molecules on CD25+ CD4+ regulatory T cells (e.g. CD45RBlow, CD44high, CD5high, CD54 [ICAM1]high, CD11a/CD18 [LFA1]high, partly CD62Llow) is in part similar to ‘primed’, ‘activated’, or ‘memory’ T cells (Sakaguchi et al 1995, Itoh et al 1999), suggesting that the regulatory T cells may be primed and continuously stimulated by self-antigens in the normal internal environment. Thymic production of CD25+CD4+ regulatory T cells: another key function of the thymus in self-tolerance How are such autoimmune-preventive regulatory T cells produced in the immune system? The following ¢ndings indicate that the normal thymus produces the majority, if not all, of the CD25+CD4+ regulatory T cells in a functionally mature form. First, transfer of CD4+CD8+ mature thymocyte suspensions depleted of CD25+ thymocytes produces various autoimmune diseases in syngeneic nude mice, as shown with the transfer of CD25CD4+ spleen cells (Itoh et al 1999) (Fig. 1). Neonatal thymectomy can also produce similar autoimmune diseases presumably by blocking the thymic production of CD25+CD4+ regulatory T cells from the beginning of their production (Asano et al 1996, Suri-Payer et al 1998). Second, CD25+CD4+CD8 thymocytes in normal na|« ve mice are naturally anergic and exhibit equivalent in vitro suppressive activity to that of CD25+CD4+ T cells in the periphery (Itoh et al 1999). Third, the expression pattern of cell surface accessory molecules is similar between CD25+CD4+ CD8 thymocytes and CD25+CD4+ T cells in the periphery; for example, both constitutively express CTLA4 and GITR, being CD45RBlow, CD44high, and CD5high (Itoh et al 1999, Takahashi et al 2000, Shimizu et al 2002) and are characteristically resistant to superantigen-induced clonal deletion
10
SAKAGUCHI ET AL
(Papiernik et al 1998). Furthermore, in TCR-transgenic mice, RAG2-de¢ciency abrogated both CD25+CD4+ thymocytes and T cells, which predominantly express endogenous TCRa chains (Itoh et al 1999). These ¢ndings collectively indicate that the normal thymus is continuously producing not only pathogenic self-reactive CD4+ T cells but also functionally mature regulatory CD25+CD4+ T cells that control them, and releasing both to the periphery. The ¢ndings also suggest that CD25+CD4+ regulatory thymocytes and T cells may have a developmental continuity as a common T cell lineage and constitute a T cell subpopulation functionally distinct from other T cells or thymocytes. Thymic selection of CD25+CD4+ regulatory T cells by self-peptide/MHC Several ¢ndings reported so far suggest that thymic generation of phenotypically and functionally mature CD25+CD4+ regulatory T cells may require unique selection events. For example, in mice expressing transgenic TCR speci¢c for non-self antigens, a large fraction of CD25+CD4+ T cells expressed endogenous TCR a chains whereas other CD4+ T cells mainly expressed transgenic TCR a and b chains. Furthermore, RAG2 de¢ciency, which blocks the gene rearrangement of the endogenous TCR a-chain locus, abrogated the thymic development of CD25+CD4+ T cells in TCR transgenic mice (Itoh et al 1999). In a double-transgenic strain that expressed a transgene-encoded speci¢c peptide in the thymic stromal cells at a certain high level, the majority of T cells expressing transgenic TCR a and b chains speci¢c for the peptide di¡erentiated into CD25+CD4+ regulatory T cells (Jordan et al 2001, Kawahata et al 2002). The regulatory T cells failed to develop, however, when double-transgenic mice expressed either low-a⁄nity transgenic TCR for the same peptide or a high concentration of the peptide in the thymic stromal cells because of insu⁄cient positive selection or strong negative selection, respectively. Furthermore, H2DMa-de¢cient mice, in which class II MHC molecules display a limited array of self-peptides, developed CD25+CD4+ regulatory T cells, whereas MHC class IIde¢cient mice, which can generate a small number of CD4+ T cells restricted to classical or non-classical MHC class I antigens, did not (Bensinger et al 2001). These ¢ndings altogether suggest that the thymic generation of CD25+CD4+ regulatory T cells may require rather high avidity interactions between TCRs and self-peptide/class II MHC ligands on the thymic stromal cells. To assess more directly this possible high self-reactivity of CD25+CD4+ regulatory T cells, we analysed B2L-TKO mice, a transgenic strain in which every class II MHC molecule covalently binds the same single peptide Ea52-68 (Fukui et al 1997). We addressed whether a particular single peptide/MHC ligand can positively and negatively select CD25+CD4+ regulatory T cells that are phenotypically and functionally similar to those found in normal mice, and, if
THYMIC SELECTION OF CD25+CD4+ REGULATORY T CELLS
11
FIG. 2. The presence of CD25+CD4+ regulatory T cells in the thymus and periphery of B2LTKO mice. (A) Thymocyte suspensions (top), which were depleted of CD4+CD8+ T cells by anti-CD8 and complement treatment, or lymph node and spleen cell suspensions (bottom) prepared from a 2-month-old B2L-TKO mice were stained with FITC-anti-CD25 and PEanti-CD4. (B) B2L-TKO CD25+CD4+ T cells, CD25CD4+ T cells, or the mixture of the two populations at various ratios were stimulated with anti-CD3 mAb along with irradiated autologous APCs. They were also stimulated with B6 APCs. (C) B2L-TKO CD25+ or CD25CD4+ T cells were stimulated for 3 days with B6 or autologous B2L-TKO spleen cells in the presence or absence of exogenous IL2 (100 U/ml) and the amount of incorporated [3H]TdR during last 12 h of the culture was shown. A representative of four independent experiments.
this is the case, the degree of diversity of the TCR repertoire, in particular, whether they are more reactive than other T cells to the selecting ligand. B2L-TKO mice did indeed develop CD25+ T cells as 1.73+0.5% of CD4+CD8 thymocytes (n ¼5) or 3.26+8% of CD4+ splenic T cells (n ¼11) (Fig. 2A). The majority of splenic CD25+ CD4+ T cells were CTLA4high, GITRhigh, CD5high, CD44high, CD54high, CD11a/CD18high and CD45RBlow, being similar to CD25+CD4+ T cells in normal na|« ve mice. Functionally, B2L-TKO CD25+CD4+ T cells were anergic and suppressive upon TCR stimulation whereas CD25CD4+ T cells were not (Fig. 2B). Stimulation by B6 APCs elicited proliferative responses in B2L-TKO CD25-CD4+ T cells, but not in CD25+CD4+ T cells, whereas B6 APCs and IL2
12
SAKAGUCHI ET AL
induced strong proliferation of both populations, indicating that they recognized diverse natural self-peptides bound to I-Ab molecules as non-self (Fig. 2B,C). By contrast, stimulation with autologous B2L-TKO spleen cells and IL2 constantly elicited signi¢cantly high proliferative responses in B2L-TKO CD25+CD4+ T cells but not in CD25CD4+ T cells, which showed higher responses than the former to other TCR stimuli (such as anti-CD3 antibody stimulation) (Fig. 2C). The TCR repertoire of CD25+CD4+ T cells in B2L-TKO mice is as diverse as that in normal mice, and similar to the repertoire of CD25CD4+ T cells. For example, there is no signi¢cant di¡erence between the two populations in the proportion of T cells expressing particular Vb gene segments (T. Takahashi, unpublished data). Assessment by the immunoscope technique of the CDR3 size of TCR a or b chains utilizing a particular Va or Vb family also revealed repertoire diversity (S. Hori, unpublished data). Taken together, these results indicate that a particular peptide/MHC ligand in the thymus can positively select (or fail to negatively select, or both) CD25+CD4+ regulatory T cells with a diverse TCR repertoire and that the selected CD25+CD4+ regulatory T cells have higher avidity for the ligand compared with that of other T cells also selected by the same ligand. In normal animals, summation of each broad repertoire selected by each self-peptide/MHC ligand may well form a broad repertoire of CD25+CD4+ regulatory T cells, which is almost ‘duplicated’ in the CD25+ and CD25CD4+ population, but with higher reactivity of the former in total to the thymic self-peptide/MHC ligands. Are CD25+CD4+ regulatory T cells highly self-reactive in the normal periphery? A critical question then is whether CD25+CD4+ regulatory T cells present in the periphery of normal animals are more reactive with peripheral self-antigens. This indeed appears to be the case since CD25+CD4+ T cells from normal na|« ve mice showed higher in vitro proliferative responses than CD25CD4+ T cells to autologous APCs presenting diverse self-peptides when stimulated with the APCs in the presence of IL2; and the responses could be signi¢cantly reduced by blocking class II MHC molecules with speci¢c antibody (Fig. 3). Furthermore, such self-stimulated CD25+CD4+ regulatory T cells can suppress the activation/proliferation of other T cells. For example, in the co-culture of CD25CD4+ T cells from OVA-peptide-speci¢c TCR transgenic mice and CD25+CD4+ T cells from normal non-transgenic mice, the latter stimulated by autologous APCs signi¢cantly suppressed the peptide-speci¢c proliferation of the former when the concentration of the peptide was relatively low (Fig. 3). At high peptide concentration, CD25CD4+ T cells overcame the suppression, exhibiting equivalent degrees of responses as CD25CD4+ T cells alone. Thus,
THYMIC SELECTION OF CD25+CD4+ REGULATORY T CELLS
13
FIG. 3. High self-reactivity of CD25+CD4+ regulatory T cells in the normal periphery and their suppression in the physiological state. (A) CD25+ or CD25CD4+ T cells from a normal BALB/c spleen were stimulated with autologous APCs in the presence of IL2 (100 U/ml) for 3 days. Anti-pan-class II MHC monoclonal antibody (CA4) or rat Ig was added to the wells. A representative result of four independent experiments. (B) CD25CD4+ T cells from DO11.10 TCR transgenic mice expressing the transgenic TCRs speci¢c for OVA-peptide (323^339) were co-cultured with an equal number of CD25+CD4+ T cells from the transgenic mice or normal non-transgenic wild-type (WT) BALB/c mice in the presence of various concentrations of the OVA peptide.
the self-reactive speci¢city of CD25+CD4+ regulatory T cells, their high level expressions of various accessory molecules and their speci¢c mode of intracellular signal transduction through TCR or accessory molecules (such as CTLA4) may make them highly sensitive in their ability to recognize various self-antigens in the periphery and therefore easily activated by them. The regulatory T cells continuously stimulated by self-antigens may exert suppression not only on self-reactive T cells but also on T cells with other antigen-speci¢cities as well as through antigen-nonspeci¢c suppression, leading to some degree of general immunosuppression in normal animals. The suppression may be su⁄cient to control self-reactive T cells, which generally bear low-a⁄nity TCRs, but insu⁄cient to suppress T cells with high a⁄nity TCRs for non-self antigens. Implications of high sensitivity of CD25+CD4+ regulatory T cells to self-antigens in maintaining self-tolerance The diverse TCR repertoire of CD25+CD4+ regulatory T cells and their high sensitivity to self-antigens have the following implications for their role in maintaining natural self-tolerance. First, given that the CD25CD4+ T cell population in normal na|« ve animals has a pathogenic self-reactive repertoire even after thymic negative selection (Fig. 1),
14
SAKAGUCHI ET AL
it is highly likely that CD25+CD4+ regulatory T cells also contain a similar selfreactive repertoire including the speci¢cities for the self-antigens to be targeted in autoimmune disease. Considering that suppression exerted by antigen-stimulated CD25+CD4+ regulatory T cells is antigen-nonspeci¢c, CD25+CD4+ T cells expanded by stimulating them with target self-antigens may e¡ectively suppress autoimmune responses even if the antigens may not be the primary self-antigen initiating the autoimmunity. The self-antigen-speci¢c regulatory T cells thus prepared can be used to treat or prevent autoimmune disease. Second, if CD25+CD4+ regulatory T cells, or at least a proportion of them, are continuously stimulated by self-antigens in the normal physiological state and therefore continuously exerting some degree of suppression in vivo (Fig. 3), they may hamper immune responses bene¢cial for the hosts, for example, against autologous tumour cells or invading infectious agents. Indeed, e¡ective tumour immunity can be provoked in mice by removing CD25+CD4+ T cells prior to inoculation of tumour cells (Shimizu et al 1999). Removal of CD25+CD4+ T cells also elicited strong immune responses to infecting agents in chronically infected animals (Hori et al 2002). Third, the high sensitivity of CD25+CD4+ regulatory T cells to self-antigens indicates that they may also be sensitive to self-mimicking non-self antigens, easily activated by them, hence able to suppress activation of other T cells by the mimicking antigens. Considering high cross-reactivity of the TCR in peptide/ MHC recognition and consequent promiscuity in self-non-self discrimination, exposure of self-reactive T cells to self-mimicking non-self peptides may not be rare events (Ohno 1991, Mason 1998, Hemmer et al 1998). Similarly, T cell clones established by repeated stimulation with a particular self-antigen can be activated in vitro by many structurally similar or dissimilar non-self peptides (Wucherpfennig & Strominger 1995). It is generally di⁄cult, however, to induce autoimmune disease in normal animals by immunizing with self-mimicking antigens or peptides. One reason for this di⁄culty may be the low threshold for activation of regulatory T cells by self-mimicking antigens, and resulting dominant suppression on self-reactive T cells to be activated by molecular mimicry. The regulatory T cells may have evolved to prevent autoimmunity due to molecular mimicry.
Acknowledgements We thank Dr K. J. Wood for critically reading the manuscript. This work was supported by grants-in-aid from the Ministry of Education, Science, Sports and Culture, the Ministry of Human Welfare and the Organization for Pharmaceutical Safety and Research of Japan.
THYMIC SELECTION OF CD25+CD4+ REGULATORY T CELLS
15
References Asano M, Toda M, Sakaguchi N, Sakaguchi S 1996 Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 184:387^396 Bensinger SJ, Bandeira A, Jordan MS, Caton AJ, Laufer TM 2001 Major histocompatibility complex class II-positive cortical epithelium mediates the selection of CD4+25+ immunoregulatory T cells. J Exp Med 194:427^438 Fukui Y, Ishimoto T, Utsuyama M et al 1997 Positive and negative CD4+ thymocyte selection by a single MHC class II/peptide ligand a¡ected by its expression level in the thymus. Immunity 6:401^410 Hemmer B, Vergelli M, Pinilla C, Houghten R, Martin R 1998 Probing degeneracy in T-cell recognition using peptide combinatorial libraries. Immunol Today 19:163^168 Hori S, Carvalhi TL, Demengeot J 2002 CD25+CD4+ regulatory T cells suppress CD4+ T cellmediated pulmonary hyperin£ammation driven by Pneumocystis carinii in immunode¢cient mice. Eur J Immunol 32:1282^1291 Itoh M, Takahashi T, Sakaguchi N et al 1999 Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 162:5317^5326 Jordan MS, Boesteanu A, Reed AJ et al 2001 Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol 2:301^306 Kawahata K, Misaki Y, Yamauchi M et al 2002 Generation of CD4+CD25+ regulatory T cells from autoreactive T cells simultaneously with their negative selection in the thymus and from nonautoreactive T cells by endogenous TCR expression. J Immunol 168: 4399^4405 Maloy KJ, Powrie F 2001 Regulatory T cells in the control of immune pathology. Nat Immunol 2:816^822 Mason D 1998 A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today 19:395^404 McHugh RS, Whitters MJ, Piccirillo CA et al 2002 CD4+CD25+ immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16:311^323 Ohno S 1991 To be or not to be a responder in T-cell responses: ubiquitous oligopeptides in all proteins. Immunogenetics 34:215^221 Papiernik M, de Moraes ML, Pontoux C et al 1998 Regulatory CD4 T cells: expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency. Int Immunol 10: 371^378 Powrie F, Mason D 1990 OX-22high CD4+ T cells induce wasting disease with multiple organ pathology: prevention by OX-22low subset. J Exp Med 172:1701^1708 Read S, Malmstrom V, Powrie F 2000 Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD4+ CD25+ regulatory cells that control intestinal in£ammation. J Exp Med 192:295^302 Sakaguchi S 2000 Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101:455^458 Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T 1985 Organ-speci¢c autoimmune diseases induced in mice by elimination of T-cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; de¢cit of a T-cell subset as a possible cause of autoimmune disease. J Exp Med 161:72^87 Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M 1995 Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor a-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155: 1151^1164
16
DISCUSSION
Salomon B, Lenschow DJ, Rhee L et al 2000 B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12:431^440 Seddon B, Mason D 2000 The third function of the thymus. Immunol Today 21:95^99 Shevach EM 2000 Regulatory T cells in autoimmunity. Annu Rev Immunol 18:423^449 Shimizu J, Yamazaki S, Sakaguchi S 1999 Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211^5218 Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S 2002 Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3: 135^142 Suri-Payer E, Amar AZ, Thornton AM, Shevach EM 1998 CD4+ CD25+ T cells inhibit both the induction and e¡ector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 160:1212^1218 Takahashi T, Kuniyasu Y, Toda M et al 1998 Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 10:1969^1980 Takahashi T, Tagami T, Yamazaki S et al 2000 Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192:303^310 Thornton A, Shevach EM 1998 CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188:287^296 Wucherpfennig KW, Strominger JL 1995 Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clone speci¢c for myelin basic protein. Cell 80:695^705
DISCUSSION Bach: I’d like to press you on antigen speci¢city. At the end of your talk you alluded to transplantation and tumour immunity, and also anti-infectious immunity. How would you see the speci¢city of CD25+ T cells in these models? Are they di¡erent from ordinary T cells speci¢c for a whole variety of antigens? Do you think that the reaction is restricted to the antigen that is initially recognized, or do you think that there is a phenomenon of bystander suppression, which would expand their function to other cell types? I have some di⁄culty in putting together the self-reactive CD25+ T cells and the cells that Kathryn Wood will speak about in transplantation (Wood et al 2003, this volume). Sakaguchi: They are as diverse as ordinary T cells in their usage of TCR Va/Vb subfamilies as revealed with normal mice and single-peptide/MHC transgenic mice. On the other hand, their TCR repertoire seems to be more skewed to recognizing self antigens. They need antigenic or TCR stimulation to exert suppression, which is antigen-non-speci¢c in its e¡ector phase and may mediate bystander suppression. Considering these properties of CD4+CD25+ regulatory T cells, it is highly likely that they are continuously activated to certain degrees by recognizing self-antigens in the normal internal milieu as illustrated by their cell surface phenotype, and exerting a basal level of suppression in the
THYMIC SELECTION OF CD25+CD4+ REGULATORY T CELLS
17
physiological state. This basal level of suppression may suppress immune responses in general to some degree. For example, it may hamper the development of e¡ective tumour immunity or antimicrobial immunity in chronic infection. This means that if you remove these regulatory T cells, you can enhance tumour and microbial immunity and immune responses in general. They can also suppress immune responses to alloantigens as they can be strongly stimulated by alloantigens as ordinary T cells. Abbas: I want to come back to the question of why in the thymus some cells are not deleted but turn into regulatory cells. I want to suggest an alternative idea and see how you respond. The idea is that where T cells see self antigen in the cortex of the thymus, they will be deleted, because double-positive thymocytes are poised for deletion. But if they see self-antigens in the medulla, then they have passed the deletion stage and will turn into regulatory cells. One of the surprises that has come out of work by Bruno Kyewski (Derbinski et al 2001) and others is that a huge number of self antigens are expressed in the medulla, which is not the site of negative selection. Perhaps the reason why self antigens are present in the medulla is to generate regulatory T cells: it is not avidity, it is all anatomy. Sakaguchi: For example, Bensinger et al (2001) showed that thymic cortical epithelial cells alone can contribute to the generation of regulatory T cells. In the medulla, they also succumb to clonal deletion as ordinary T cells do. We don’t know how they become anergic or acquire suppressive activity through these selection processes. Bluestone: I’d propose an alternative explanation to that of Abul Abbas. Since the repertoire looks like it is very broad, perhaps if these cells encounter self-antigens too early before they have matured their signalling complex appropriately to delete, this kind of partial signalling of T cells might divert them to the CD25+ regulatory cells. Sakaguchi: That’s possible. Harrison: Self-antigen-expressing cells referred to a moment ago are not just present in the thymus, but also the periphery. We don’t know how these selfantigens are expressed. They may be expressed on class II MHC, but this isn’t known for sure. There is also controversy about the nature of the cell type. Can you tell us something about the generation of these regulatory cells in the periphery? We have heard that they may be generated in response to oral antigen, but we don’t know much about what is happening in the periphery. Sakaguchi:It is a controversial issue. What we can say at the moment is that normal thymus is de¢nitely producing them. There are some reports showing that regulatory T cells with similar phenotype and function as naturally arising CD4+CD25+ regulatory T cells can develop in the periphery from na|« ve T cells in oral tolerance or upon exposure to low dose antigens (Thorstenson & Khoruts 2001). There are also recent reports that when certain T cells are stimulated by
18
DISCUSSION
immature DCs they can somehow become regulatory (Jonuleit et al 2000). It is critically important to determine in these experiments whether CD4+CD25+ regulatory T cells already present in the periphery are somehow expanded or strengthened in their suppressive activity, or whether na|« ve CD25 T cells can di¡erentiate into regulatory T cells upon antigen exposure. Even if the latter is the case, there is a possibility that naturally occurring regulatory T cells may be present also in the CD25 fraction (Stephens & Mason 2000), and such a population may somehow become CD4+CD25+ regulatory T cells upon antigenic stimulation. Bach: We can go further on this. You mentioned that in vitro they do not proliferate much. What is the evidence that they proliferate in vitro in response to an autoantigen? Do you have any data suggesting the enhancement of the pool of these cells in certain settings? Another way to pose the question is what kind of evidence do you have about the autoantigen speci¢city? If there was such speci¢city one might think that the autoantigen-speci¢c clones in the periphery would be expanded. Don Mason has published a paper indicating that there could be further education in the periphery (Seddon & Mason 1999). Sakaguchi: The direct demonstration of the autoantigen speci¢city of regulatory T cells in the natural population hasn’t yet been done. As I mentioned, the TCR repertoire is almost duplicated between CD25+ and CD4+CD25 cells with possible a bit skewing of the former to self. If we accept that CD4+CD25 T cells contain pathogenic self-reactive T cells causing gastritis, IDDM and other autoimmune diseases, it is natural to think that the CD4+CD25+ population contains regulatory T cells speci¢c for self-antigens in the gastric mucosa or Langerhans islets. CD4+CD25+ regulatory T cells can be expanded in vitro when they are stimulated with antigen in the presence of high dose IL2 or along with strong CD28 co-stimulation. This means that regulatory T cells recognizing selfantigens may expand in certain situations in vivo. We have evidence that alloantigen-reactive CD4+CD25+ regulatory cells can expand in vivo when stimulated with alloantigens. We haven’t directly demonstrated that self-antigenspeci¢c regulatory T cells can expand in vivo. Shevach: One way to determine the antigenic speci¢city of the CD4+CD25+ T cells is to use an e¡ector cell of de¢ned speci¢city. In the gastritis model, we have developed several transgenic mice that recognize a de¢ned peptide from the autoantigen, the H/K ATPase. Fortunately, this autoantigen has been knocked out by several groups, so the question will be, can we take CD25+ cells from mice that lack the autoantigen, and how e⁄ciently will they suppress the autoreactive T cell that recognizes an epitope on the a chain of the H/K ATPase. We are just waiting to get enough mice backcrossed onto the right backgrounds to do these experiments. Bluestone: That may be problematic. There are recent data on the plasticity of repertoire development, and the precise autoantigen may not be the only thing
THYMIC SELECTION OF CD25+CD4+ REGULATORY T CELLS
19
that those T cells develop in response to. Because of other self antigens that share peptide sequences, it could well be that you get some sharing of peptide speci¢city. Shevach: The model is good enough for us to get some idea of e⁄ciency, so we could see whether 1 million cells do it versus 20 000. One would think that if they really see the same autoantigen that if you lack the autoantigen, than the population as a whole would be less e⁄cient. Bluestone: In some ways that is Shimon Sakaguchi’s experiment. The single peptide MHC and diverse repertoire would suggest that there is a lot of plasticity in how the repertoire is developed in the CD25+ population as well. Shevach: Shimon, have you ever used one of your anti-CD3-generated clones to suppress in vivo? Sakaguchi: Not yet. Von Herrath: Returning to the question of antigen speci¢city, has anyone taken out the CD25high cells in a disease model, and just put them on antigen? This would be a parallel to the diabetes model that Jean-Franc ois Bach introduced. You could stimulate them on peptides and see after this antigen-speci¢c stimulation whether they suppress more potently. This would be the reverse experiment to what Ethan Shevach has suggested. You would expect that if they see both antigens then at some stage they should then suppress better. Shevach: We are actually doing this. Ha£er: We have done this experiment with myelin basic protein and Copaxone. Perhaps not surprisingly, stimulation with self protein did not activate the CD4+CD25+ regulatory T cells. Shevach: I think it would work, actually. We have preliminary experiments in which the e¡ector cells are a homogeneous pathogenic transgenic population and we have cured the animal by taking CD25+ cells from a normal mouse. The experiment that remains to be performed is whether CD25+ cells extracted from that mouse which has been cured be more potent suppressors in a secondary transfer? Harrison: Given that the NOD mouse T cells don’t respond well to anything, if you stimulate GITR, say in vitro, does this enhance the response to antigen? Sakaguchi: Anti-GITR antibody has some co-stimulatory activity in vitro, but this is not very strong. Harrison: So it doesn’t inhibit suppressor activity in the test-tube? If you immunize with a speci¢c antigen and you put anti-GITR in, does this enhance the recall e¡ect of the antigen? Shevach: We have done this with anti-CD3 on puri¢ed CD25 cells from normal mice, and it has no e¡ect. Delovitch: I wanted to raise a point that was mentioned by Jean-Franc ois Bach about increasing the interaction between di¡erent regulatory T cell types. Can a particular subset(s) of autoreactive regulatory T cells control the activity of the CD4+CD25+ T cells in vivo? Is there anything known about that?
20
DISCUSSION
Sakaguchi: I assume you are asking about a possible interplay between CD4+CD25+ regulatory T cells and NKT cells in immmunological selftolerance. I think it is possible. NKT cells secrete lots of IL4 and IFNg. CD4+CD25+ regulatory T cells can be expanded more easily with antigen, IL2 and IL4 than without IL4. This suggests that IL4 secreted by NKT cells can enhance the expansion of CD4+CD25+ regulatory T cells. This kind of interaction may well be occurring in the in vivo situation. Delovitch: Is there evidence for this? Sakaguchi: These are in vitro data. Von Herrath: I have a speci¢c question about your class II transgenic model. I think this is intriguing and a little surprising. What you get out is that there are CD25high cells that proliferate better as judged by BrdU incorporation, and they also proliferate better in vitro when they see the antigen on their syngeneic APCs. These mice tend to make more of these regulatory cells. Did you screen for other e¡ector molecules? I would assume that if they are proliferating they are also making molecules such as chemokines. Is there a distinctive pro¢le? One would assume that the regulatory cells should not make IFNa. Sakaguchi: We haven’t looked at chemokines much. There are a couple of reports on chemokines and CD4+CD25+ regulatory T cells (Bystry et al 2001, Iellem et al 2001). CD4+CD25+ regulatory T cells are not producing IFNg. What we found is that there is a di¡erence between in vivo and in vitro situations. When they are stimulated strongly in vitro, for example with anti-CD3 antibody, they didn’t show any proliferation. But in vivo, even in their normal physiological state they are more proliferating than other T cells. This surprised us. It must mean something, for example, they are continuously proliferating by recognizing self-antigens. Bach: Are you speaking of phenotype? How can you di¡erentiate these cells which appear in vivo from the conventionally activated T cells? Sakaguchi: All I can say is that when you inject BrdU into normal na|« ve mice, CD4+CD25+ T cells incorporate BrdU 3^5-fold more than CD4+CD25 T cells. They are not ordinary activated T cells. Hasenkrug: These may be completely di¡erent cells, but we found that if we purify CD4 cells on the basis of CD69 positivity, they are suppressive in vitro, just from normal mice. This is a small population of cells. CD69 CD4+ cells were not suppressors. Maybe they are the same cells and they are not only proliferating but also activated. Shevach: There is a slight enrichment of CD25+ cells in the CD69 pool, but I would never use it as a marker for suppressor cells. Hasenkrug: Yes, I don’t think you can use it as a marker because it is obviously an early activation marker as well. Powrie: When you look at the BrdU incorporation among the CD25+ cells, you are comparing with CD25 cells. This is a heterogeneous population of cells, the
THYMIC SELECTION OF CD25+CD4+ REGULATORY T CELLS
21
majority of which are na|« ve. If you actually compare CD25+ and CD25 cells within the CD45RBlow fraction, do you see a di¡erence? In relation to this, have you or Ethan looked at CD45RBlow cells in terms of preventing gastritis? Sakaguchi: We haven’t looked at that. Shevach: That’s a good experiment but we haven’t done it. Powrie: In relation to the idea that di¡erent populations of cells may regulate di¡erent diseases, I think it’s important to be clear which particular phenotypes work in particular models. Mitchison: What population do you normally take your CD25+ cells from? If you take them from a mature mouse, or even a mature mouse that is making an immune response to the relevant antigen, can you still ¢sh out a suppressor population, or are they downed in normal CD25s? Sakaguchi: That is an important question. Usually we are using na|« ve SPF mice. They are usually less than 4 months old. If they are immunized, we ¢nd the regulatory activity is in a CD25high population. A CD25-intermediate population may include activated T cells. Somehow we can di¡erentiate between the two by the expression level of CD25. But it is not completely clear. Bach: Speaking of ontogeny, at what age do you ¢rst see CD25+ cells in the thymus and spleen? In the NOD mouse we did a systematic study of this. In the thymus we can ¢nd them as early as 10 days of age. In the spleen we have to wait 4^5 weeks. Sakaguchi: In normal B6 or Balb/C mice we can ¢nd CD25+ cells in the periphery from day 3 onwards. In the thymus, they can be detected before day 3. Bach: I was speaking not so much of the phenotype of these cells but of their capacity to protect against diabetes in a co-transfer model. Sakaguchi: I can’t say that because it is di⁄cult to enrich CD25+ cells from newborn mice. Flavell: Many of these questions concern a general point: how homogeneous are these cells and what is their ability to mediate these functions on a cell per cell basis, either in vivo or in vitro? Part of the problem is the markers, which are relatively general. What is the evidence that the CD25+ cell population consists of one homogeneous collection of cells, each of which has the ability to do this? Ha£er: Can you de¢ne homogeneous? Flavell: Every cell can suppress. E¡ector speci¢city. Shevach: We have attempted to de¢ne a more potent subset with the CD25+ population. About 30% of the CD4+CD25+ population expresses CD103, the integrin aE. CD103+ CD25+ T cells are about 4^5 times more potent suppressors than CD103CD25+ T cells, but latter population also has signi¢cant suppressive activity. Ha£er: Getting back to the issue of which molecules are involved in suppression, it is pretty clear that the more turned on the e¡ector cells are, the
22
DISCUSSION
harder they are to suppress. When we use anti-CTLA4, anti-PDL1 or anti-GITR we ¢nd a higher proliferative response in the e¡ector cells themselves. How sure are you that the inhibition is due to the blocking of important interactions? Could it just be that the e¡ector cells are just more turned on and harder to suppress? Sakaguchi: So far we haven’t found any candidate molecule that speci¢cally mediates suppression. There is a report that a membrane form of TGFb may be involved in this suppression. In our hands we haven’t so far any evidence that TGFb directly mediates suppression. Chatenoud: There are interesting discrepancies between the in vitro and the in vivo data you showed with the anti-CTLA4 antibody. In particular, what happens if instead of using the whole antibody you inject Fab fragments in vivo? Do they have an e¡ect? Do you would need some sort of cross-linking for the in vivo e¡ect that is not needed for the in vitro blockade? What can we really extrapolate from in vitro to in vivo? Are those clones that you derive in vitro able to suppress in vivo? This is an important question. Sakaguchi: We haven’t done that. Your question is important. We are faced with this kind of discrepancy between in vitro and in vivo experiments. In the in vivo situation, even if you inject whole antibody, we can’t say how this a¡ects the T cells by blocking or through active signal transduction. In the literature there are so many di¡erent results.
References Bensinger SJ, Bandeira A, Jordan MS, Caton AJ, Laufer TM 2001 Major histocompatibility complex class II-positive cortical epithelium mediates the selection of CD4+25+ immunoregulatory T cells. J Exp Med 194:427^438 Bystry RS, Aluvihare V, Welch KA, Kallikourdis M, Betz AG 2001 B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol 2:1126^1132 Derbinski J, Schulte A, Kyewski B, Klein L 2001 Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol 2:1032^1039 Iellem A, Mariani M, Lang R et al 2001 Unique chemotactic response pro¢le and speci¢c expression of chemokine receptors CCR4 and CCR8 by CD4+CD25+ regulatory T cells. J Exp Med 194:847^853 Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH 2000 Induction of interleukin 10producing, nonproliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192:1213^1222 Seddon B, Mason D 1999 Regulatory T cells in the control of autoimmunity: the essential role of transforming growth factor beta and interleukin 4 in the prevention of autoimmune thyroiditis in rats by peripheral CD4+CD45RC cells and CD4+CD8 thymocytes. J Exp Med 189:279^288 Stephens LA, Mason D 2000 CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and CD25 subpopulations. J Immunol 165:3105^3110
THYMIC SELECTION OF CD25+CD4+ REGULATORY T CELLS
23
Thorstenson KM, Khoruts A 2001 Generation of anergic and potentially immunoregulatory CD25+CD4+ T cells in vivo after induction of peripheral tolerance with intravenous or oral antigen. J Immunol 167:188^195 Wood KJ, Ushigome H, Karim M, Bushell A, Hori S, Sakaguchi S 2003 Regulatory cells in transplantation. In: Generation and e¡ector functions of regulatory lymphocytes. Wiley, Chichester (Novartis Found Symp 252) p 177^193
Control of T cell activation by CD4+CD25+ suppressor T cells Ethan M. Shevach, Ciriaco A. Piccirillo, Angela M. Thornton and Rebecca S. McHugh Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Abstract. Although the concept of a separate lineage of T cells speci¢cally equipped to suppress immune responses was initially proposed more than 30 years ago, progress in this area of immunoregulation has been hampered by the lack of solid biochemical and molecular data to support the existence of the soluble products of these purported suppressor T cells. Studies over the past 5^10 years have identi¢ed a distinct lineage of CD4+CD25+ regulatory or suppressor T cells that control autoreactive e¡ector cells and prevent autoimmunity. The mechanism by which CD4+CD25+ T cells inhibit T cell activation in vivo or in vitro is still poorly de¢ned. While autoreactive e¡ector T cells undergo massive proliferation and expansion following injection into immunocompromised recipients, CD4+CD25+ T cells do not inhibit this lymphopaenia-induced proliferation and act later in the activation process at the site of immune damage in the target organ. The development of in vitro models that partially mimic the in vivo properties of the CD4+CD25+ regulatory T cells has facilitated their characterization. A member of the tumour necrosis receptor family, the GITR is expressed on CD4+CD25+ T cells and after interaction with its ligand down-regulates suppressor activity. Multiple methods of manipulating both the numbers of CD4+CD25+ suppressor T cells and their activation status are now available and will rapidly be applied to therapy of autoimmune, infectious and malignant diseases. 2003 Generation and e¡ector functions of regulatory lymphocytes. Wiley, Chichester (Novartis Foundation Symposium 252) p 24^44
Regulation of immune responses in vivo Organ-speci¢c autoimmunity can be induced by thymectomy of mice on day 3, but not day 7, of life (d3Tx). It was proposed that autoimmune e¡ectors emerged from the thymus during the ¢rst 3 days of life and that suppressor T cells developed slightly later in ontogeny and began to populate the peripheral lymphoid tissues between day 4 and day 7 of life (Nishizuka & Sakakura 1969). Autoimmunity could be prevented by a thymus transplant or by injection of adult CD4+ T cells by day 10^14 of life. It is also likely that in the adult animal suppressor T cells 24
CD4+CD25+ SUPPRESSOR T CELLS
25
constantly prevent the activation of autoreactive e¡ector cells. This hypothesis was much more di⁄cult to test as no markers were available to identify the regulatory T cell population. The major advance in this area was the observation by Sakaguchi et al (1995) that elimination of a minor population (*10%) of CD4+ T cells that coexpressed the CD25 antigen from adult CD4+ T cells followed by transfer of CD25 cells to an immunode¢cient host resulted in the development of a spectrum of autoimmune diseases that closely resembled the diseases seen after d3Tx. Conversely, the induction of disease post-d3Tx could be prevented by reconstitution of the animals with CD4+CD25+, but not CD4+CD25 , T cells by day 10^14 of life (Suri-Payer et al 1988). Collectively, these studies solidi¢ed the role of CD4+CD25+ T cells as the major subset of cells that plays a critical role in suppression of autoreactivity. Our studies on the in vivo function of CD4+CD25+ T cells have focused on their role in the prevention of autoimmune gastritis (AIG), the disease that develops with the highest frequency when BALB/c mice are subject to d3Tx. We have identi¢ed the major proton pump of the gastric parietal cell, the H/K ATPase, as the target antigen for the pathogenic autoreactive T cells (Suri-Payer et al 1999). CD4+ T cells from gastric lymph nodes of gastritic mice demonstrated both a vigorous proliferative response and a Th1 pattern of cytokine production when challenged with puri¢ed H/K ATPase in culture. More importantly, both Th1 and Th2 cell lines speci¢c for distinct peptide epitopes on the a chain of the H/K ATPase could transfer gastritis to immunocompromised, but not normal, recipients. The capacity of both these cell lines to transfer disease to nu/nu or SCID recipients could be inhibited by co-transfer of CD4+CD25+ T cells from normal BALB/c mice. Thus, CD4+CD25+ T cells are able to inhibit not only the initiation of disease after d3Tx, but also fully di¡erentiated e¡ector T cells at least when transferred prior to the development of disease in the target organ. Suppression of disease in vivo did not appear to be mediated by suppressor cytokines as CD4+CD25+ T cells from interleukin (IL)4-de¢cient ( / ) and IL10 / mice were as e⁄cient as CD4+CD25+ T cells from wild-type (WT) mice in their capacity to inhibit disease in co-transfer studies (McHugh et al 2001a). In addition, the suppression of disease following treatment of recipients of CD4+CD25+ and CD4+CD25 T cells could not be reversed by administration of high concentrations of anti-transforming growth factor (TGF)b (Piccirillo et al 2002). In order to de¢ne more fully the pathogenesis of organ-speci¢c autoimmune disease and the role of CD4+CD25+ T cells in disease prevention, we have developed a TCR transgenic (Tg) model that allows a clear dissection of e¡ector vs. suppressor T cell function. We generated a TCR Tg mouse expressing the TCR from the Th1 clone described above (McHugh et al 2001b). All of the Tg mice developed severe AIG relatively early in life that closely resembled the AIG seen
26
SHEVACH ET AL
after d3Tx or after transfer of CD4+CD25 T cells to immunode¢cient recipients. Thymocytes from the TCR Tg mice could readily transfer disease into BALB/c nu/nu recipients but not into normal WT animals. As few as 103 thymocytes could transfer disease into immunoincompetent animals, while more than 107 thymocytes were required to induce only moderate disease in WT recipients; it is highly likely that the endogenous population of CD4+CD25+ T cells prevents the induction of disease in normal animals. In preliminary studies, co-transfer of CD4+CD25+ T cells from BALB/c animals prevents the induction of disease induced by thymocytes from the TCR Tg animals following transfer into nu/nu recipients. The further use of these TCR Tg mice should facilitate the analysis of several important questions regarding the antigenic speci¢city of the CD4+CD25+ T cells. Mice de¢cient in both components of the H/K ATPase have been generated (Spicer et al 2000) and evaluation of the capacity of CD4+CD25+ derived from such mice to prevent disease induced by T cells derived from the TCR Tg should be able to directly answer the question of whether the suppressor and e¡ectors recognize the same antigen. The mechanism by which CD4+CD25+ T cells prevent the development of organ-speci¢c autoimmune disease remains unknown. One of the ¢rst questions one might raise is how do they know where to go? What directs CD4+CD25+ T cells to the site of autoimmune attack? The recognition of organ-speci¢c antigens by CD4+CD25+ T cells might be the most important factor that attracts them to the lymph nodes draining the target organ. However, if they respond to more ubiquitously expressed antigens, what directs them to the speci¢c organ? Do they respond to chemokines produced by antigen presenting cells (APCs) or perhaps produced by the autoreactive e¡ector cells? Do they prevent the initiation of the disease process by preventing the initial events in the process of antigen recognition? Do they play a modulatory role at some stage during the di¡erentiation of autoreactive e¡ector cells following antigen priming? If they are speci¢c for an organ-derived antigen, do they develop immunologic memory for this antigen so that they will be more e¡ective in preventing the development of disease following transfer to secondary recipients? One other important issue of a more general nature is that most models of regulatory T cell function in vivo involve transfer of e¡ector cells to recipients that lack CD25+ T cells. In most cases, cells are transferred to immunoincompetent mice that lack T cells (nu/nu) or T and B cells (SCID or RAG / ). Even d3Tx involves induction of a generalized state of partial lymphocyte depletion. It has therefore been suggested that one of the main mechanisms involved in CD25mediated suppression is competition for space, cytokines, or co-stimulatory signals in the environment of the lymphopaenic recipient (Stockinger et al 2001). It also remains possible that any activated cell population derived from
CD4+CD25+ SUPPRESSOR T CELLS
27
conventional CD4+CD25 T cells might also exert suppressor function in the lymphopaenic environment. To assess directly the role of CD4+CD25+ T cells in autoimmunity and to distinguish their ability to suppress disease from their potential ability to control lymphocyte expansion in the lymphopaenic environment, we have attempted to de¢ne the requirements for induction of disease following selective depletion of CD4+CD25+ T cells from the young adult animal using a depleting anti-CD25 antibody (McHugh & Shevach 2002). Although we were successfully able to deplete CD4+CD25+ T cells for as long as 3^4 weeks, only a minority of animals developed gastritis. One problem with this approach is that the CD4+CD25+ pool might have been repopulated with new CD4+CD25+ thymic emigrants following depletion. Indeed, at 6 weeks following antibody treatment, the percentage of CD4+CD25+ T cells had risen to 4% (normal 10%). To determine whether this low number of CD25+ T cells was able to prevent the induction of disease, we transferred cells from these mice to nu/nu recipients. All the recipients developed signs of gastritis. The disparity between the ability to transfer disease to a lymphopaenic recipient while the lymphocyte-su⁄cient donor did not manifest signs of disease raised the question of whether the lymphocyte-su⁄cient environment was responsible for prevention of disease. Indeed, Annacker et al (2001) have proposed that a primary function of the CD4+CD25+ T cell population is to regulate the homeostatic proliferation of CD4+CD25 T cells in an IL10-dependent manner. However, both CD4+CD25+ and CD4+CD25 T cells proliferated equally well when transferred into a lymphopaenic recipient and co-transfer CD4+CD25+ did not inhibit this early proliferative response of the CD4+CD25 cells (Fig. 1).
FIG. 1. CD4+CD25+ T cells do not a¡ect the lymphopaenia-induced proliferation of CD4+CD25 cells. CFSE-labelled CD4+CD25 (left panel), CFSE-labelled CD4+CD25+ T cells and unlabelled CD4+CD25 T cells (middle panel), or CFSE-labelled CD4+CD25 + unlabelled CD4+CD25+ T cells (right panel) were injected into nu/nu recipients and proliferation was measured by dilution of CFSE on day 7 after transfer. Co-transfer of CD4+CD25+ T cells does not inhibit proliferation of the CD4+CD25 T cells at this time point.
28
SHEVACH ET AL
TABLE 1 Immunization of CD25-depleted Mice with H/K ATPase Results in AIG Treatment
AIG
Anti-CD25 H/K ATPase Anti-CD25+H/K ATPase
+/ ++++
Only 5^10% of CD25-depleted mice spontaneously develop AIG. Immunization of normal mice with the H/K ATPase does not induce AIG, while immunization of CD25-depleted mice results in severe AIG in 100% of the animals.
However, all animals that received CD25 T cells alone developed AIG, while cotransfer of CD25+ T cells completely prevented the development of gastric pathology. In contrast to the lack of e¡ect of CD4+CD25+ T cells on the early (3^21 days after transfer) proliferation of CD4+CD25 T cells, they do exert a potent e¡ect on the expansion of CD25 T cells when the animals are studied 2^6 months after transfer (Annacker et al 2001). However, recipients of CD4+CD25 T cells almost always develop autoimmune disease after 2 months and the CD4+CD25 T cells would have undergone both lymphopaenia-induced proliferation and autoantigen-speci¢c activation and expansion. It is likely that the inhibition of expansion of CD4+CD25 T cells months after transfer by cotransfer of CD4+CD25+ T cells re£ects regulation of autoreactive e¡ector T cell function. So why do we fail to observe the development of autoimmune disease following depletion of CD4+CD25 T cells? One possibility is that autoreactive T cells require an additional signal in order to develop into autoreactive e¡ector cells. Such a signal might be provided by the proliferative response induced following transfer to lymphopaenic recipients. As immunization of normal BALB/c mice with the target autoantigen, the H/K ATPase, never induces AIG in normal mice due to the presence of regulatory T cells (Suri-Payer et al 1988), we immunized mice that had been depleted of CD25+ T cells with the H/K ATPase in incomplete Freund’s adjuvant. All of the immunized animals manifested severe AIG 5 weeks following immunization, while no disease was observed following immunization of control mice (Table 1). We conclude from this study that TCR stimulation can also provide the second signal for activation of the autoreactive e¡ectors in the absence of regulatory T cells. It remains possible that other environmental insults might also be capable of inducing autoimmune disease in the CD25-depleted host (Fig. 2). The implications of these results for the therapeutic use of depleting anti-CD25 antibodies for enhancement of immune responses will be discussed below.
CD4+CD25+ SUPPRESSOR T CELLS
29
FIG. 2. Depletion of CD4+CD25+ T cells is not su⁄cient for the induction of autoimmunity. Treatment of animals with anti-CD25 results in marked depletion of the CD25+ cells, but the treated animals fail to develop autoimmune disease. A second signal is needed for disease induction and this second signal can be provided by lymphopaenia-induced proliferation, immunization with the target autoantigen, or perhaps by other environmental stimuli.
Regulating the regulator The mechanism whereby CD25+ T cells mediate their suppressive e¡ects remains unknown and appears to be mediated by a cell contact-dependent pathway (Thornton & Shevach 1998). In addition, in preliminary studies we have shown that cell contact between activated CD25+ T cells and responder cells requires that the responder cell ¢rst be activated via their TCR (C. A. Piccirillo, E. M. Shevach, unpublished). Suppression may therefore be mediated by a ligand induced on the CD25+ T cells engaging a receptor induced on the responder CD4+ or CD8+ T cells (Fig. 3). A number of molecular pathways are logical candidates for this receptor/ counter-receptor role including members of TNF/TNF receptor (TNFR) superfamily. It is also possible that an unknown ligand is induced on the CD4+CD25+ T cell and then interacts with a cell surface molecule induced on the CD25 T cell that contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) that leads to the activation of a phosphatase that mediates suppression. We have employed DNA microarray technology to compare patterns of gene expression in both resting and activated CD25+ and in CD25 T cells (McHugh et al 2002). The major goal of these studies was to search for molecules that might
30
SHEVACH ET AL
FIG. 3. CD4+CD25+ T cells mediate suppression of the activation of CD4+CD25 responders by a cell contact-dependent mechanism. Following activation of the CD4+CD25+ T cells, they express an unknown molecule that mediates suppressor e¡ector function by binding to an unknown receptor on the responder CD4+CD25 responders.
be involved in the e¡ector phase of suppression. As expected, these two populations of T cells di¡ered in only a small number of the 11 000 genes and expressed sequence tags (ESTs) tested. Approximately 1500 genes were modulated equally in the two populations following stimulation with anti-CD3 and IL2, and only 97 were di¡erentially expressed. Several genes were identi¢ed that distinguish the CD25+ population (Table 2). Among these genes, it is of interest that three members of the suppressors of cytokine signalling (SOCS) family (Starr et al 1997) appeared to be preferentially induced after activation of the CD25+ T cells. Elevated levels of SOCS expression may be required to control the size of the CD25+ population in vivo to achieve a ¢ne balance between the necessity to suppress autoreactivity and the ability to allow appropriate responses to foreign antigens. Analysis of the DNA microarray data identi¢ed many candidate genes that could potentially be involved in the suppressive function of the CD25+ T cells. As monoclonal or polyclonal antibodies were available to many of the products of TABLE 2
Genes preferentially expressed in activated CD4+CD25+ T cells
Surface receptors: Secreted molecules: Signal transduction:
CD2, OX40, CD25, IL2Rb, GITR, GIR, Ly6, Galectin1, Thy1 IL10, IL17, ETA1, Enkephalin, ECM1, MIP-1a, MIP-1b CIS, SOCS1, SOCS2, SLAP130
CD4+CD25+ SUPPRESSOR T CELLS
31
TABLE 3 Anti-GITR reverses suppression but does not prevent the induction of suppressor activity Anti-GITR added to
Suppression
A. Co-culture of CD4+CD25+ and CD4+CD25 B. Co-culture of activated CD4+CD25+ and CD4+CD25 C. Preculture of CD4+CD25+ with anti-CD3 and IL2
reversed slightly reversed maintained
(A) The anti-GITR was added to cultures of freshly explanted CD4+CD25+ T cells and CD4+CD25 responders. (B) The anti-GITR was added to cultures of CD4+CD25+ T cells that had been pre-activated with anti-CD3 and IL2 in the absence of anti-GITR and fresh CD4+CD25 responders. (C) The antiGITR was added to the pre-culture of the CD4+CD25+ T cells with anti-CD3 and IL2. The CD4+CD25+ T cells were then washed and added to fresh CD4+CD25 responders in the absence of anti-GITR. All cocultures were activated with anti-CD3 and suppression of proliferation was measured at 72 hours.
the di¡erentially expressed genes, we tested the capacity of these antibodies to reverse suppression in co-cultures of CD25+ and CD25 T cells. Only a polyclonal antiserum to a member of the TNFRSF, the mouse GITR (TNFRSF18, Nocentini et al 1997), extracellular domain was able to reverse suppression induced by freshly isolated CD25+ T cells on the response of both CD4+ and CD8+ responders to anti-CD3 (Table 3). However, the anti-GITR was only minimally e¡ective in neutralization of suppression mediated by preactivated CD25+ T cells. Furthermore, addition of the anti-GITR to the preactivation culture with IL2 and anti-CD3 had no e¡ect on the subsequent suppressor function of the cells. As the GITR is expressed on two populations of cells (resting CD25+ and activated CD25 cells) that do not manifest suppressor activity, it is therefore very unlikely that the GITR is the molecule responsible for mediating suppressor e¡ector function. It was also important to rule out the possibility that reversal of suppression was not mediated by the anti-GITR acting on the CD25 T cell. Culture of CD25+, but not CD25 , T cells with anti-GITR in the presence of IL2, but in the absence of anti-CD3, resulted in a vigorous proliferative response. Thus, anti-GITR is capable of directly inducing a signal in the CD25+ population that allows it to respond to IL2. This study is also consistent with a model in which the anti-GITR functions as an agonist for the GITR providing a signal that instructs the CD4+CD25+ T cells not to mediate their suppressive functions, although it does not prevent them from developing into potent suppressors. The murine GITR is a 228 amino acid type I transmembrane protein with three cysteine pseudorepeats in the extracellular domain and resembles TNFRSF members CD27 and 4-1BB in the intracellular domain. Four di¡erent splice variants of the murine GITR have been identi¢ed (Nocentini et al 2000) and one
32
SHEVACH ET AL
FIG. 4. The GITR/GITR-L interaction regulates the function of CD4+CD25+ T cells. The tissue speci¢c suppression of the GITR-L is still poorly characterized. Three hypothetical models are shown in which the GITR-L is expressed in DC, CD4+CD25 T cells, or CD4+CD25+ T cells. The end result of all three models is the sameattenuation of the suppressor function of the CD4+CD25+ T cells that express the GITR.
of the variants bears a unique cytoplasmic domain due to a reading frame shift resulting in a cytoplasmic domain with signi¢cant homology with the cytoplasmic region of CD4 and CD8 that interacts with p56lck. It has not yet been determined which splice variants are expressed by CD25+ T cells. Thus, interaction of the GITR with the GITR-L may deliver a signal to regulate the suppressive function of CD25+ T cells. The human GITR-L has been cloned, is a member of the TNFRSF, has not been found to be expressed on T or B cells, but was readily identi¢ed in umbilical vein endothelial cells (Gurney et al 1999). We have cloned the murine GITR-L, but have not yet performed a detailed analysis of its expression pattern. It is possible that the murine GITR-L is expressed on other cell types. We have illustrated potential patterns of its expression in Fig. 4 and at present can only speculate about its possible functions. If the GITR-L is expressed on APCs such as dendritic cells or macrophages, it is possible that its expression is
CD4+CD25+ SUPPRESSOR T CELLS
33
up-regulated during a vigorous in£ammatory response. Engagement of the GITR by the GITR-L in such a site may temporarily prevent CD25-mediated suppression and facilitate a productive immune response to a pathogen. An equally viable alternative is that the GITR-L is induced on responder CD25 e¡ector cells during some stage of their di¡erentiation. Engagement of the GITR on CD25+ T cells by the GITR-L on e¡ector cells may diminish suppression during in£ammation during the immune response to an infectious agent. Conversely, expression of the GITR-L by e¡ectors at the site of an autoimmune response may abolish suppression and facilitate the progression of destructive immunopathology, e.g. the progression of insulitis to frank diabetes in IDDM. Lastly, since other members of the TNFRSF and their ligands may be expressed by the same cell type or even on a single cell, it is worth considering the possibility that the GITR-L may be induced at certain times on CD25+ T cells themselves and engage the GITR on the same cell or on a neighbouring CD25+ T cell. Studies are in progress to directly address these questions. Clinical implications The manipulation of regulatory cell function in vivo during the course of a normal or pathological immune response should represent an important area for future developments. Further studies of the normal physiology of regulatory cells may yield important insights into how to control both their numbers and functional activity in vivo. One goal would be to enhance regulatory cell function in autoimmunity, allergy and graft rejection and to inhibit regulatory cell function for enhancement of the immune response to tumour vaccines or weak vaccines to infectious agents. Curiously, a non-depleting anti-CD25 antibody has been used clinically to inhibit the function of CD25 expressed on e¡ector cells, rather than regulatory cells, in transplant models and in autoimmune uveitis (Nussenblatt et al 1999). The potential e¡ects of this antibody on regulatory T cell function in man have not been studied. Although human CD4+CD25+ T cells might be completely eliminated by use of a depleting anti-CD25 antibody as in the murine models, such an approach may be contraindicated in humans over the age of 20 as repopulation of the CD4+CD25+ cell pool from new thymus emigrants may have declined during the ageing process. In addition, anti-CD25 could potentially also deplete CD25+ e¡ector T cells. A second approach would be targeting the as yet unknown molecules responsible for mediating suppressor e¡ector function. An antibody directed to either partner of this purported receptor ligand pair (Fig. 3) might be the ideal agent to transiently inhibit suppressor cell activity and permit immune responses to weak vaccines. The GITR/GITR-L interaction also represents an important potential target for modulation of CD4+CD25+ T cell function (Fig. 5). One possible approach would
34
SHEVACH ET AL
FIG. 5. Manipulation of the GITR/GITR-L interaction may suppress or enhance suppressor T cell function. Engagement of the GITR by agonistic antibodies or by an agonistic GITR-L-Fc soluble molecule would lead to decreased suppression. Conversely, blocking GITR/GITR-L interaction with a soluble GITR-Fc or with an anti-GITR-L antibody would lead to enhancement of suppressor T cell function.
be to inhibit suppressor function with an agonistic anti-GITR antibody and this approach has been validated by the studies of Shimizu et al (2002) and Sakaguchi et al (2003, this volume). A soluble GITR-L-Fc fragment might also have similar agonist properties to transiently neutralize suppression. It is di⁄cult to predict the outcome of blocking the GITR/GITR-L interaction in vivo with either an anti-GITR-L antibody or GITR-Fc. It is not yet known whether the GITR interacts with GITR-L in the normal steady state or in pathologic conditions to down-modulate suppressor cell function. If this is the case, the administration of these reagents should result in enhanced suppressor function and represent a valuable addition to our armamentarium of tools to enhance immunosuppression and treat debilitating autoimmune diseases. Lastly, it should be emphasized that approaches to grow and expand regulatory T cells for enhancement of suppressor function in vivo also represent a useful area for future study. Again, increased understanding of the factors that control regulatory cell numbers, for example manipulation of the function of the SOCS genes, may represent an important adjunct to this therapeutic approach. References Annacker O, Pimenta-Araujo, Burlen-Defranoux O, Barbosa TC, Cumano A, Bandeira A 2001 CD25+CD4+ T cells regulate the expansion of peripheral T cells through the production of IL-10. J Immunol 166:3008^3018
CD4+CD25+ SUPPRESSOR T CELLS
35
Gurney AL, Marsters SA, Huang A et al 1999 Identi¢cation of a new member of the tumor necrosis family factor and its receptor, a human ortholog of mouse GITR. Curr Biol 9:215^218 McHugh RS, Shevach EM 2002 Cutting edge: depletion of CD4+CD25+ regulatory T cells is necessary, but not su⁄cient, for induction of organ-speci¢c autoimmune disease. J Immunol 168:5979^5983 McHugh RS, Shevach EM, Thornton AM 2001a Control of organ-speci¢c autoimmunity by immunoregulatory CD4+CD25+ T cells. Microbes Infect 3:919^927 McHugh RS, Shevach EM, Margulies DH, Natarajan K 2001b A T-cell receptor transgenic model of severe spontaneous organ-speci¢c autoimmunity. Eur J Immunol 31: 2094^2103 McHugh RS, Whitters MJ, Piccirillo CA et al 2002 CD4+CD25+ immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16:311^323 Nishizuka Y, Sakakura T 1969 Thymus and reproduction: sex-linked dysgenesia of the gonad after neonatal thymectomy in mice. Science 166:753^755 Nocentini G, Giunchi L, Ronchetti S et al 1997 A new member of the tumor necrosis factor/ nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proc Natl Acad Sci USA 94:6216^6221 Nocentini G, Ronchetti S, Bartoli A et al 2000 Identi¢cation of three novel mRNA splice variants of GITR. Cell Death Di¡er 7:408^410 Nussenblatt RB, Fortin E, Schi¡man R et al 1999 Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA 96:7462^7466 Piccirillo CA, Letterio JJ, Thornton AM et al 2002 CD4+CD25+ regulatory T cells can mediate suppressor function in the absence of transforming growth factor b1 production and responsiveness. J Exp Med 196:237^246 Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M 1995 Immunological self-tolerance maintained by activated T-cells expressing IL-2 receptor a-chains (CD25) breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151^1164 Sakaguchi S, Hori S, Fukui Y et al 2003 Thymic generation and selection of CD25+CD4+ regulatory T cells: implications of their broad repertoire and high self-reactivity for the maintenance of immunological self-tolerance. In: Generation and e¡ector functions of regulatory lymphocytes. Wiley, Chichester (Novartis Found Symp 252) p 6^23 Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S 2002 Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3: 135^142 Spicer Z, Miller ML, Andringa A et al 2000 Stomachs of mice lacking gastric H,K-ATPase alpha-subunit have achlorhydria, abnormal parietal cells, and ciliated metaplasia. J Biol Chem 275:21555^21565 Starr R, Willson TA, Viney EM et al 1997 A family of cytokine-inducible inhibitors of signalling. Nature 387:917^921 Stockinger B, Barthlott T, Kassiotis G 2001 T cell regulation: a special job or everyone’s responsibility? Nat Immunol 2:757^758 Suri-Payer E, Amar AZ, Thornton AM, Shevach EM 1988 CD4+CD25+ T cells inhibit both the induction and the e¡ector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 160:1212^1218 Suri-Payer E, Amar AZ, McHugh RS, Natarajan K, Margulies DH, Shevach EM 1999 Postthymectomy autoimmune gastritis: ¢ne speci¢city and pathogenicity of anti-H/K ATPasereactive T cells. Eur J Immunol 29:669^677
36
DISCUSSION
Thornton AM, Shevach EM 1998 CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188:287^296
DISCUSSION Shevach: We have recently shown that the persistence of Leishmania major in the skin following healing in resistant C57BL/6 mice is controlled by an endogenous population of CD4+CD25+ regulatory T cells (Belkaid et al 2002). During the course of infection by L. major, CD4+CD25+ T cells accumulate in the chronic dermis where they suppress by both IL10 dependent and independent mechanisms the ability of CD4+CD25 e¡ector T cells to completely eliminate the parasite from the site. The sterilizing immunity that is achieved in mice with impaired IL10 activity is followed by the loss of immunity to re-infection, suggesting that the equilibrium that is established between e¡ector and regulatory T cells in sites of chronic infection may re£ect both parasite and host survival strategies. Banchereau: Is there any role for B cells here? Is it antibody mediated? In the human, IL10 is a powerful plasma cell inducer. Shevach: All these experiments are done in the absence of B cells in RAGde¢cient mice reconstituted only with T cells. Bach: I have a question concerning the interpretation of the various populations of the CD25+ T cells that could exist. You say that IL10 could be involved. We did not ¢nd it to be so in the NOD mouse. Even if you take normal CD25+ T cells before they are exposed to infectious agents, how can you be sure that the cells that react to the infectious agents have anything to do with the CD25+ cells studied in the co-culture? As you mentioned, CD25 is not stable. The CD25+ compartment does not only includes the regulatory cells. It could well be that IL10 is produced by a subset of these cells that have nothing to do with the subset controlling autoimmunity. IL10 knockout mice can express regulatory function towards self, and the NOD mouse data show the same. Shevach: CD25+ cells freshly explanted from a normal SPF mouse and stimulated with anti-CD3 make IL10 mRNA and protein. I don’t know the frequency of these cells, and we haven’t been able to determine this yet by intracellular staining. The IL10 they produce does not appear to be responsible for suppression of any of the in vitro phenomena that have been studied. It also does not appear to be responsible for the suppression of gastritis. In in£ammatory bowel disease, however, it is absolutely responsible for suppression of the disease. Here it appears to play an important role. Cell contact may also be playing a role even in IBD. The only comment I can currently make regarding the use of CD25 as a marker is to say that it is pretty good but it isn’t perfect.
CD4+CD25+ SUPPRESSOR T CELLS
37
Chatenoud: The other distinction is the in vivo model used. On the one side you have the organ-speci¢c autoimmune diseases and you showed very clearly that cytokine-producing cells don’t work. On the other side you have the models, such as colitis, in which microbial agents are implicated in the response and this is the situation where you can ¢nd evidence for cytokine-producing T cells that mediate regulation. Shevach: That is something else. L. major infection of the ear is an intracellular infection, and IL-10 may speci¢cally suppress the responses of infected cells to respond to the anti-parasitic e¡ects of IFNg. Mowat: Presumably the e¡ector mechanism must depend on what needs to be inhibited. If it is an infection in the gut, where there are lots of di¡erent e¡ector cells, you may have to inhibit macrophages and other in£ammatory cells, whereas an autoimmune disease inhibiting a T cell directly may be su⁄cient. Shevach: The model we favour is that the IL10 and TGFb are required to ¢rst put out the in£ammatory ¢re in in£ammatory bowel disease and then cell-contact dependent mechanisms of suppression take over. Bach: The point I wanted to make clear is that I do understand that the cells suppressing in your infectious system are initially CD25+, but the key question is whether it is the same subset as the others? Can we say this at the moment? Shevach: There is expansion in the animal, of course. Abbas: Are you all implying that the endogenous thymic-derived regulatory cells and the peripheral activation-induced cells are di¡erent and work di¡erently? The impression I’m getting is that the peripheral cells are the ones that work via cytokines and the endogenous thymic-derived cells don’t. Shevach: No. That was never true. Powrie: There is no evidence that is the case. Bach: It may well be that in Fiona Powrie’s model it is essentially an antigenstimulated peripheral activation. Even if regulatory cells in a colitis model share some properties with regulatory cells in a day 3 thymectomy model, including the CD25 marker, there is still room for what Abul Abbas said. Powrie: CD25+ cells from the thymus can prevent colitis. Bach: Of course. All T cells come from the thymus, anyway. Powrie: Furthermore, CD25+ cells that prevent in£ammatory bowel disease can be isolated from germ-free mice, suggesting those cells are not driven into the memory pool by replicating bacteria. Bach: Is it necessary for colitis to occur in order to get a pool of memory cells? Powrie: What we really have no idea about is the speci¢city of the cells that regulate in the di¡erent disease models. If we had a clone, we could ask in these di¡erent systems whether or not one clone is able to regulate the di¡erent diseases. Chatenoud: In a way the answer is there, because there is not protection from gastritis.
38
DISCUSSION
Shevach: CD25+ T cells from IL10 / mice e⁄ciently protect against gastritis. Powrie: That doesn’t mean they are di¡erent subsets of cells. It could be one subset of cells requiring di¡erent e¡ector functions depending on what is being regulated. Bluestone: I am getting a little confused here. If we were talking about a Th cell we wouldn’t be having this discussion. CD4+ cells develop in the thymus, and they migrate into the periphery with some precursor frequency for the antigens that they recognize. Depending on the environment, the population may expand. And cytokines are used by CD4+ cells di¡erentially, depending on the sites, and there is an issue of antigen speci¢city. We know these CD25+ cells have a repertoire. Since they have a repertoire, the only di¡erence between them and bona ¢de CD4+ cells are the in vitro data showing a lack of requirement for a speci¢c antigen for them to suppress. Ethan Shevach, you are arguing that this bystander suppression is cytokine independent. This is the only thing that distinguishes the CD25+ cell from any other T cell. Though in vivo it could be very di¡erent. Shevach: CD25+ T cells from IL4 / mice also protect, and anti-TGFb at high concentrations also does not reverse suppression. Delovitch: Perhaps this is the point. When we use the IL10 knockout in each of the three models, perhaps another cytokine is compensating. Has anyone begun to look systematically to see whether this is the issue? Shevach: What are you going to look for? Delovitch: Is there up- or down-regulation of other cytokines or chemokines, or their receptors? Perhaps this is a¡ecting migration. Shevach: It is likely that chemokines play an important role in the migration of CD25+ T cells into the site of in£ammation. The speci¢c chemokines involved have yet to be de¢ned. In the L. major model, chemokines produced or induced by the parasite early in the course of infection may promote the migration of CD25+ T cells into the lesion. Bluestone: It could be made in the lesion. Shevach: Yes, but they all come from the injected CD25+ cells. Abbas: They could be dividing locally. Bluestone: Some time ago Lucienne Chatenoud showed that regulatory cells seem to be able to migrate to sites of in£ammation very e¡ectively. But this doesn’t explain why they are 50% there: they could go to the site and then expand there. Powrie: All we can say at the moment is that they accumulate. Mowat: The phenotype you described was very much that of an activated T cell. You’d expect to ¢nd these more commonly in tissues than in secondary lymphoid organs. Taking CD25+ cells from lymph nodes and spleen may not be what these cells are doing in vivo. They have so many adhesion molecules that would allow them to get into tissues that perhaps this is where they are actually working.
CD4+CD25+ SUPPRESSOR T CELLS
39
Wood: If you take them from grafts, they can function as well (if not slightly better) than cells taken from the periphery. Insitu the cells are certainly as functional. Mowat: If you take a normal mouse gut, it has lots of CD4+CD25+ cells in the normal lamina propria. These may be regulatory cells. This is a normal animal eating a normal diet. Harrison: We have evidence (L. C. Harrison, N. R. Solly & D. Funda, unpublished results) that these cells in the gut require the presence of gd intraepithelial lymphocytes. If intraepithelial lymphocytes (IELs) are absent from the gut, e.g. after neonatal thymectomy or in germ-free mice, CD4+ regulatory cells in the lamina propria cannot be generated, e.g. by oral antigen. Flavell: In the diabetes system, when we looked it was speci¢cally in the pancreatic lymph nodes and islets where the cells capable of blocking in the model were found. Shevach: This is the way life should be! They go where they are needed and they probably expand locally. Mitchison: What is the status of GITR as a marker? Shevach: It’s useless. Just like CD25! It basically marks the CD25+ population in the normal mouse. It is induced with activation, with roughly the same kinetics as CD25. 100% of activated CD25 T cells express GITR after three days of polyclonal activation by anti-CD3. Bluestone: There’s one exception in vivo. There is a drug on the market, an antiCD25 monoclonal antibody that works because it blocks pathogenic processes in vivo. The anti-GITR doesn’t appear to do this in vivo. If anything, it promotes pathogenic responses. Shevach: We are talking about using them as markers here; function is a completely di¡erent story. Mitchison: Why do you say it is useless? It has the same properties as CD25. It may not be improvement, but surely it isn’t useless. Shevach: The most useful marker would be one that di¡erentiates a suppressor from an activated e¡ector. Bach: What is the distribution of GITR among T cells? Shevach: It basically marks the CD25+ population. Sakaguchi: There is still the possibility that CD25 but GITR+ cells in the CD4+ population may have some regulatory activity, although they are less regulatory than CD4+CD25+ T cells. If it is the case, it may explain why some CD4+CD25 T cells, which are CD45RBlow, sometimes show a regulatory activity. Hasenkrug: Could you explain the e¡ect on loss of memory by anti-CD25? Shevach: In the L. major model loss of antigen leads to loss of T cell memory. Bluestone: This has been known in transplantation for a long time; it is not just in infectious diseases. It is generally true that tolerance is active, and in the absence of antigen tolerance is lost.
40
DISCUSSION
Hasenkrug: We are talking about antigen-speci¢c memory. Ra⁄ Ahmed has shown elegantly that antigen is not needed for the maintenance of immunological memory (Murali-Krishna et al 1999). Shevach: This is for CD8+ cells and viruses. Abbas: It has also been shown for CD4+ cells, and it has been shown with conditional knockout of T cell receptors. This could very well be a quantitative thing. David Sacks’ lab probably uses a large challenge of Leishmania. In order for immunity to be maintained to a large high-dose challenge you may need continuous low level activation. Shevach: I don’t think so. Abbas: It is now well established that in order to maintain T cell memory you don’t need antigen recognition. Shevach: I disagree. It depends on the infection. Hasenkrug: You don’t know what the mechanism is for the loss of memory here. It may not be loss of antigen. Shevach: The antigen goes away. No L. major can be isolated from the ears of mice that have been treated with anti-IL10 receptor. Hasenkrug: That doesn’t mean that this is the cause of the loss of memory, though. Powrie: Does anti-CD25 do the same as anti-IL10 receptor? You were suggesting that anti-IL10 receptor is solely a¡ecting the regulatory T cell. Shevach: We haven’t tested the e¡ects of anti-CD25 depletion in the L. major model. Bach: I’d like to come back to the interesting discussion about the ligand. What do you know about this ligand? Shevach: Not much! We are currently doing expression studies to see where and when it is expressed. As far as I know there is no antibody to the mouse ligand, and no one has really studied the tissue distribution of the mouse ligand. What has been published is with the human ligand, and involves rather cursory blots of tissue extracts, and some subtle things could easily have been missed. The gene was cloned from an endothelial cell library, so endothelial cells were positive. We cloned it from a thymocyte library. Mitchison: Ethan, I suppose you know that recombinant immunotoxins targeting CD25 are used to treat Sezary’s syndrome (Kreitman 2001). Do you know anything about any side e¡ects of this treatment? Shevach: Robert Nussenblatt and collaborators at the NEI/NIH (Nussenblatt et al 1999) have been treating an autoimmune uveitis with anti-CD25 to inhibit e¡ector cell function. What Bob told me is that in about a dozen patients they have had remarkable therapeutic success. These patients have been taken o¡ other immune suppressors. They treat the patients only with the humanised antiCD25 antibody, which is non-depleting and blocks the action of IL2. In the
CD4+CD25+ SUPPRESSOR T CELLS
41
peripheral blood of the patients, they ¢nd cells coated by the antibody. Presumably, these are the normal CD25+ T cells and this has nothing to do with the therapeutic e¡ects of the antibody, which is probably blocking the ability of IL2 to stimulate e¡ector cells. Ha£er: At the Federation of Clinical Immunology Society meeting Roland Martin presented phase I trials with anti-CD25 monoclonal antibody in multiple sclerosis patients (MS). There was a decrease in new lesions on magnetic resonance imaging. One interesting ¢nding was a marked increase in expression of CTLA4 on CD4+ cells in the peripheral blood. Bach: There has been a lot published on the use of anti-CD25 antibody in transplantation. It is interesting that so far there have been no data suggesting any side e¡ects in terms of induction of autoimmunity. Another drug that had the potential to elicit autoimmunity was cyclophosphamide. In experimental models this drug-enhanced autoimmunity in the NOD mouse. So far I have just seen one paper indicating that cyclophosphamide in humans will enhance autoimmunity. Ha£er: It’s a major treatment for autoimmune diseases. Returning to my previous comment, we are going to start anti-CD25 treatment in MS patients. An obvious question is to look at these regulatory T cells, and whether this antibody has the paradoxical e¡ect of increasing their function. Bluestone: What will you use as a marker? Ha£er: We will look at suppressor function using CD25high populations. Bluestone: That’s a problem. We have talked to a lot of people who do these studies. As a minimum, you block the receptor with the antibody. What most people have found is that the receptor levels go down signi¢cantly after treatment with anti-CD25 in transplants. You need another marker. Ha£er: That is a good point, we may want to try other markers of these T cells if they can be found. Abbas: Most of the transplant studies have been done with either cyclosporin or rapamycin. I wonder if anyone has looked at the ability of cyclosporin to block suppressor function? Chatenoud: The meaningful experiments are those in vivo showing that each time one treats with a monoclonal antibody, such as anti-CD3 in the NOD mouse or CD40 ligand in the transplant situation, cyclosporine given in the ¢rst few days after the treatment will prevent the tolerance induction. It doesn’t happen if cyclosporine treatment is begun after the end of the treatment with the biological agent. Abbas: But those experiments haven’t looked at the e¡ects of cyclosporine on regulatory T cells. Wood: In our system where we use antigen and anti-CD4 to set up tolerance before we challenge with the graft, if we give a high dose of cyclosporine or
42
DISCUSSION
FK506 at the time we are inducing unresponsiveness, we can’t identify functional CD25+ cells at the time of transplant. If we don’t give the cyclosporine of FK506 we generate CD25+ alloantigen-speci¢c cells. Abbas: Then the combination of cyclosporine and anti-CD25 would accelerate graft rejection, if you accept all these data. Bluestone: No, because the anti-CD25 still blocks/depletes the e¡ector cell. Chatenoud: You need to look at how the combination is done. Usually, the cyclosporine is given at the end of the antibody treatment. Bach: There was a paper by G. Opelz, who established a transplant registry that allowed him to compare the e¡ect of various drug combinations in a large set of patients (Opelz 1995). Interestingly, when two groups of patients were compared, one of which had anti-CD3 and cyclosporine given at the same time, and anti-CD3 antibody alone and starting cyclosporine later, the second group did signi¢cantly better than the ¢rst one. There are also data on the e¡ects of corticosteroids. The idea is that the systematic association of cyclosporine and corticosteroids in protocols aiming at tolerance induction is not very good, although in practice there are many patients who become quasi-tolerant after some years. Rapamycin, as far as we know, does not interfere with the induction of regulation. Bluestone: Everyone is talking about single markers, but is there a cocktail that one could use? The one we use is CD62L in conjunction with CD25+. E¡ector T cells, for the most part, don’t express CD62L. These cells do look like activated cells in some ways, but in other ways they resemble na|« ve cells. Shevach: I don’t think so. CD62L can go down and come up on an e¡ector cell. None of these markers are absolute. If one looks in a chronic situation where you have e¡ector cells, what can you say about CD62L expression? Is it the perfect marker for a na|« ve cell? In our hands, CD62low CD25+ cells also have suppressive functions. Powrie: What about CD103 (aE integrin)? Shevach: It is expressed on every intraepithelial lymphocyte. Mowat: When you were talking earlier about the 30% of CD4+CD25+ cells that were aE positive, was this from peripheral tissues? Shevach: Yes, peripheral lymph node. Mowat: Even in the lamina propria of the gut, only about 30^40% of the CD4+ cells are aE-positive. Shevach: CD103 doesn’t go up in the CD25 cells after they are activated, in contrast to GITR and OX40. Bach: I have a question concerning CD122. You mentioned that CD25+ T cells express the b chain of IL2. To what extent do they do this in the mouse, and can you comment about the role of the IL2 receptor in the function of these cells?
CD4+CD25+ SUPPRESSOR T CELLS
43
Shevach: In the mouse, the antibody to the IL2 receptor b chain is a rather weak reagent and doesn’t stain very well. CD25+ T cells express high levels of CD122 mRNA. In the functional experiment I showed, the anti-GITR doesn’t induce the IL2Rb, yet the cells respond to 10 units of IL2, which would require the expression of the entire IL2R complex. Functionally, they behave as if they express CD122. Several groups have shown that you can stain all human CD25+ cells with antiCD122. Chatenoud: The di¡erence between the expression of the a chain alone or the a, b, g is that the a⁄nity is not the same. The ¢rst data that I recall from the one of the initial papers by with Shimon Sakaguchi is that the regulatory CD4+CD25+ emigrating from the thymus only expressed the a chain of the receptor. This means they may need a lot of IL2 in order to proliferate. Shevach: They don’t appear to express the b chain because the antibody used is a poor one. If you look at the mRNA level they have the b chain. Chatenoud: The issue can be solved on a pharmacological basis: what is the a⁄nity of the receptor they express? High, intermediate or low? Powrie: In the human thymus they express the b chain. Chatenoud: This could just be a di¡erence between humans and mice. It is an important question, because this might represent a way to di¡erentiate conventionally activated cells that express a high-a⁄nity IL2 receptor from those only expressing the a chain. The issue is still open. Shevach: One could do the pharmacological experiments, but functionally it is much more complicated. We all trigger these cells in vitro with lots of IL2, but they have something that prevents them from responding to IL2 unrelated to the a⁄nity of their receptors. This is a tricky business. Harrison: Didn’t you once say that when they are activated their SOCS2 expression rises? Shevach: Yes, it goes up a lot. Harrison: Perhaps that is why they don’t respond to growth factors? Bluestone: The other thing they express highly is LKLF. They won’t go into cycle as long as they are expressing this. Bach: Shimon Sakaguchi, did you say that when you add IL2 they proliferate, and then they do not suppress any more? Sakaguchi: If you add a high dose of IL2, along with TCR stimulation, the CD25+CD4+ regulatory T cells lose regulatory activity. In addition to this e¡ect of IL2 on the suppression, IL2 and IL2 receptors on CD25+ cells are important for their survival. If you inject anti-IL2 antibody in vivo only once, the CD25+ cell pool gradually decreases and in two or three months autoimmune disease develops. Abbas: There are data coming out from several di¡erent labs using IL2 or IL2 receptor knockouts, suggesting that IL2 is required for the maintenance of these
44
DISCUSSION
regulatory cells. Other people are suggesting that it is needed for suppressive function. Mowat: What about IL15 knockouts? Abbas: There is no evidence for abnormalities in regulatory T cells. References Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL 2002 CD4+CD25+ immunoregulatory T lymphocytes control Leishmania major persistence and the development of concomitant immunity. Nature 420:502^507 Kreitman RJ 2001 Toxin-labeled monoclonal antibodies. Curr Pharm Biotechnol 2:313^325 Murali-Krishna K, Lau LL, Sambhara S, Lemonnier F, Altman J, Ahmed R 1999 Persistence of memory CD8 T cells in MHC class I-de¢cient mice. Science 286:1377^1381 Nussenblatt RB, Fortin E, Schi¡man R et al 1999 Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA 96:7462^7466 Opelz G 1995 E⁄cacy of rejection prophylaxis with OKT3 in renal transplantation. Collaborative Transplant Study. Transplantation 60:1220^1224
Regulation of experimental autoimmune encephalomyelitis (EAE) by CD4+CD25+ regulatory T cells Adam P. Kohm, Pamela A. Carpentier and Stephen D. Miller1 Department of Microbiology-Immunology and the Interdepartmental Immunobiology Center, Northwestern University Medical School, Chicago, IL 60611, USA
Abstract. Multiple endogenous mechanisms exist to inhibit thymic development of functional autoreactive T cells. In spite of this, autoreactive CD4+ T cell populations persist in normal individuals and retain the capacity to initiate autoimmune disease. Thus, additional regulatory mechanisms operative in the peripheral immune system are required to protect against both the generation of self-directed immune responses and the initiation of autoimmune diseases. One such mechanism involves the active inhibition of T cell responses by CD4+CD25+ regulatory T (Treg) cells. In this study, we investigated the protective role of Treg cells during experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS). Our ¢ndings indicate that Treg cells confer signi¢cant protection from the development of MOG35^55-induced EAE that may result from the promotion of a protective Th2 response and decreased homing of autoreactive cells to the CNS. Importantly, Treg cells di¡erentially expressed elevated levels of ICAM1 and P selectin, molecules which may facilitate T^T cell interactions and contribute to the mechanism by which Treg cells inhibit CD4+ T cell responses. Collectively, these ¢ndings support a role for Treg cells as an active regulatory mechanism that may protect individuals from the onset of MS, as well as other autoimmune diseases. 2003 Generation and e¡ector functions of regulatory lymphocytes. Wiley, Chichester (Novartis Foundation Symposium 252) p 45^54
Several endogenous regulatory mechanisms are operative during thymic development of CD4+ T cells which aid in preventing the generation of selfreactive T cells. However, the emergence of autoreactive T cell populations appears to be inevitable, since these populations persist in normal individuals and 1This
chapter was presented at the symposium by Stephen D. Miller, to whom correspondence should be addressed. 45
46
KOHM ET AL
retain the capacity of initiating and/or propagating various autoimmune diseases (Kreuwel & Sherman 2001). To combat this, numerous protective mechanisms, such as activation-induced anergy and various regulatory cell populations, have evolved with the collective goal of inhibiting the generation and/or e¡ector functions of autoreactive CD4+ T cells. One such immunoregulatory population is the T regulatory (Treg) cell which is typically de¢ned as the CD4+CD25+CD62Lhigh population of cells in na|« ve mice. While Treg cells may be divided into subpopulations based upon the expression of several surface molecules, such as CD62L, CD38, and CD45RB, each subpopulation appears to retain a functional equivalent immunosuppressive phenotype in vitro (Kuniyasu et al 2000). While there is a general agreement that Treg cells inhibit CD4+ T cell proliferation in a TCR-dependent manner (Thornton & Shevach 2000), there is less agreement on whether Treg cells target APC function or directly in£uence e¡ector T cell responses via T^T cell interactions (reviewed in Shevach 2002). Further controversy surrounds the mechanism by which Treg cells exert their immunosuppressive function with proposed functional mediators including interleukin (IL)10, surface CTLA4 expression, surface CD25 expression that functions as an IL2 ‘sink’, co-stimulatory molecule blockade, and surface or secreted TGFb expression (Shevach 2002). Regardless, Treg cells appear to inhibit both the initiation of na|« ve CD4+ T cell responses, as well as restimulation of previously activated cells, and therefore may be active regulators of autoimmune responses at the a¡erent and/or e¡erent levels. In the current study, we investigate the contribution of Treg cells to the regulatory mechanisms associated with the initiation and progression of experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS). MOG35^55-induced EAE in C57BL/6 mice (Mendel et al 1995) is a CD4+ Th1 cell-mediated autoimmune disease (Begolka et al 1998) in which MOG35^55-speci¢c autoreactive T cells enter the CNS to initiate a cascade of in£ammation, tissue destruction, and demyelination leading to clinical paralysis. Collectively, our ¢ndings support a role for Treg cells in conferring protection against the progression of MOG35^55-induced EAE. This protective Treg cell phenotype may be mediated, in part, by promoting a disease-protective Th2-like immune response and/or preventing CNS in£ammation, possibly via mechanisms involving elevated levels of ICAM1 and P selectin. Together, these ¢ndings support a role of Treg cells in conferring protection against the onset of autoimmune demyelination. Treg cells inhibit autoantigen-speci¢c Th1 responses in vitro In vivo work from several groups strongly supports a role for Treg cells in conferring protection against autoimmune diseases (Sakaguchi et al 1995,
CD4+CD25+ Treg CELLS PROTECT AGAINST EAE PROGRESSION
47
TABLE 1 E¡ect of Treg cells on proliferation and IFN-c production of a MOG35^55-speci¢c Th1 line Regulatory cells employed a
MOG35^55 Th1 e¡ector function b
Phenotype
Source
Pre-treatment
Proliferation
IFNg Production
CD4+CD25
Spleen
None
+++
+++
Non-Treg
Spleen
rIL2
+++
+++
Lymph node
None
+++
+++
Lymph node
rIL2
+++
+++
CD4+CD25+
Spleen
None
Treg
Spleen
rIL2
Lymph node
None
Lymph node
rIL2
a CD4+CD25+ Treg or CD4+CD25 non-Treg cells were derived from either the spleens or peripheral lymph nodes of na|« ve C57BL/6 mice and co-cultured with a given number of a MOG35^55-speci¢c Th1 line either directly or after incubation in recombinant IL2 (rIL2) for 24 hours. b +++, normal proliferation or IFNg production as compared to cultures with no added cells; , inhibited proliferation or IFNg production as compared to cultures with no added cells.
Suri-Payer et al 1998, Salomon et al 2000, Read et al 2000, Furtado et al 2001). To begin dissecting the role of Treg cells in regulating self-directed immune responses during EAE, we utilized a Th1 line speci¢c for an immunodominant epitope of myelin oligodendrocyte glycoprotein (MOG35^55) known to initiate EAE in C57BL/6 mice. In agreement with ¢ndings from previous studies employing mitogenic stimulation, Treg cells isolated from either the spleen or lymph nodes of na|« ve mice inhibited both the proliferation of and interferon (IFN)g production by MOG35^55-speci¢c T cells in vitro (Table 1). While one interpretation of the Treg cell-induced inhibition of IFNg production may be that Treg cells directly inhibit the e¡ector function/activation of target CD4+ T cells, it is also possible that Treg cells simply function to block the expansion of an antigenspeci¢c population of T cells. Importantly, previous ¢ndings suggest that TR cells fail to prevent the initial activation of target CD4+ T cells, but subsequently induce cell cycle arrest (Thornton & Shevach 2000). During this scenario, the target CD4+ T cells may receive adequate activation signals to di¡erentiate into fully functional e¡ector cells, but the function of these cells may be limited by the
48
KOHM ET AL
induction of cell cycle arrest at some point following 24 hours of activation. Such a mechanism may explain the observed Treg-induced e¡ects on both proliferation and cytokine production, since additional signalling events within the target T cell may accompany the induction of cell cycle arrest to in£uence functional aspects of the cell. However, currently it is still unclear whether the measured reduction in IFNg production is the result of direct e¡ects on cytokine production or whether it is simply a consequence resulting from the inhibition of antigen-speci¢c cell expansion. Elevated CD25 (IL2 receptor) expression is a hallmark of the Treg cell phenotype (Sakaguchi et al 1995) and a number of studies have reported that the addition of exogenous rIL2 to Treg cell/CD4+ T cell co-cultures reverses the suppressive phenotype of regulatory cells (Thornton & Shevach 1998, Itoh et al 1999). Such an observation is supported by the ¢ndings that Treg cells may inhibit the production of IL2 (Thornton & Shevach 1998). However, the possibility remains that the apparent in£uence of Treg cells on IL2 production may be the result of an alternative overriding mechanism a¡ecting multiple parameters of T cell function. Alternatively, intracellular signals originating from IL2 receptor stimulation may directly in£uence Treg cell e¡ector function. However, ¢ndings from the current study do not support this hypothesis, since overnight incubation in the presence of rIL2 prior failed to in£uence Treg cell function (Table 1). In light of this, the present studies support the expression of CD25 as a phenotypic, but not functional, marker of Treg cells. However, since the kinetics of IL2 exposure may be a critical factor in this model system, we currently cannot discount the functional contribution of elevated CD25 expression to Treg cell function. Regardless of the exact mechanism by which Treg cells exert their e¡ector function, in vitro ¢ndings support a protective role for Treg cells during autoimmune responses by preventing autoreactive T cell function. Treg cells confer protection against EAE disease progression Several previous studies have investigated the role of Treg cells in regulating T cell e¡ector function in models of autoimmune disease as well as transplant rejection. Consistent with their proposed role as active regulators of autoimmune responses, the depletion of Treg cells in neonatal animals results in the spontaneous induction of autoimmune gastritis in both the thymectomy and nu/nu model systems (Sakaguchi et al 1995, Suri-Payer et al 1998) and Treg cells also block the gastritis resulting from the transfer of H/K ATPase-speci¢c e¡ector T cells. Similarly, the co-transfer of Treg cells in an adoptive model of diabetes conferred signi¢cant protection against the onset of diabetes in the non-obese diabetic (NOD) mouse (Salomon et al 2000), suggesting that Treg cells may in£uence both na|« ve and established immune responses. Thus, Treg cells may block the initiation of
CD4+CD25+ Treg CELLS PROTECT AGAINST EAE PROGRESSION
49
TABLE 2 CD4+CD25+ Treg cells inhibit the progression of MOG35^55-induced EAE in na|« ve C57BL/6 recipients Cells transferred to na|« ve C57BL/6 recipients a
Incidence of disease b
Mean day of onset (SEM) c
Mean peak clinical score (SEM)d
None 2106 CD4+CD25 non-Treg 2106 CD4+CD25+ Treg
5/5 5/5 4/5
15.40.25 15.60.25 16.81.29
2.20.20 2.40.25 1.40.4*
a
Na|« ve C57BL/6 mice were primed with MOG35^55/CFA 3 days following adoptive transfer of 2106 CD4+CD25 non-Treg cells or CD4+CD25+ Treg cells puri¢ed from na|« ve C57BL/6 donors. Data are representative of multiple experiments. b Number of clinically a¡ected animals/total number of immunized mice. c Mean day of ¢rst appearance of clinical signs of disease. d Mean clinical score for animals at the peak of disease. *P50.05 vs. recipients of both no cells and of 2106 CD4+CD25 non-Treg.
aberrant immune responses, as well as inhibiting the function of established autoreactive e¡ector cells. To extend these ¢ndings, we investigated the role of Treg cells in regulating the progression of EAE. MOG35^55-induced EAE (Mendel et al 1995) is a CD4+ Th1mediated autoimmune disease (Begolka et al 1998) in which autoreactive T cells speci¢c for myelin components enter the CNS resulting in a cascade of in£ammation, tissue destruction, and demyelination. To determine the role of Treg cells in regulating the progression of MOG35^55-induced EAE, we isolated Treg cells from lymph nodes of na|« ve C57BL/6 donors and 2106 cells were adoptively transferred into na|« ve recipients 3 days prior to active induction of EAE. Consistent with previous ¢ndings, supplementation of the Treg cell population suppressed the development of clinical paralysis (Table 2), prevented CNS in£ammation and increased the number of T cells secreting Th2-like cytokines, such as IL4 and IL5 (data not shown). This elevated number of MOG35^55-speci¢c Th2 cells may be a result of Treg cell-mediated inhibition of the pathogenic Th1-like responses which may then ablate inhibitory in£uences on the expansion of both antigen-speci¢c and bystander Th2 responses. However, the number of cells secreting EAE-promoting Th1 cytokines, such as IFNg and tumour necrosis factor (TNF)a (Karin et al 1994, Begolka et al 1998), were similar in both the lymph nodes and spleen at the peak of disease in both Treg and non-Treg recipients. This ¢nding is surprising, since Treg cells e¡ectively inhibit the expansion of antigen-speci¢c T cell populations in vitro as previously discussed. While it is possible that Treg cells directly in£uence Th2 cell function, no studies have examined the e¡ect of Treg cells on either na|« ve T cell di¡erentiation or the e¡ector function of di¡erentiated Th1 and Th2 cells, with the exception of the
50
TABLE 3 Treg cells
KOHM ET AL
Adhesion molecule and chemokine receptor expression on CD4+CD25+
Adhesion molecule/chemokine receptor a4-integrin (CD49d)
ICAM1 (CD54) ICAM2 (CD102) VLA4 (a4b1 integrin) (CD49d/CD29) E selectin (CD62E) P selectin (CD62P) L selectin (CD62L) CD44 LFA1a (CD11a)
Relative expression on CD4+CD25+ Treg cells as compared to CD4+CD25 Non-Treg cells a + ++ + ++ ++
CXCR3 CCR5 a Expression levels the same ( ), elevated (+) or signi¢cantly elevated (++) on CD4+CD25+ Treg cells as compared to CD4+CD25 non-Treg cells.
MOG35^55-speci¢c Th1 cells used in the current study (Table 1). Thus the possibility exists that Treg cells may di¡erentially in£uence either the di¡erentiation or function of these two populations. In light of the possible mechanisms by which Treg cells may in£uence T cell function, additional studies are necessary to further dissect the mechanism by which Treg cells modulate CD4+ T cell function and autoimmune disease progression. Adhesion molecule and chemokine receptor expression on Treg cells Chemokine gradients originating from the site of antigenic challenge serve as a probable means of regulating Treg cell tra⁄cking in vivo. However, there are few reports of di¡erential chemokine receptor expression on Treg cells in comparison to non-Treg cells. In support of this possibility, a recent study reported the speci¢c expression of CCR8 by Treg cells, in comparison to non-Treg cells (Iellem et al 2001). To extend these ¢ndings, we examined the expression of additional chemokine receptors on Treg cells but observed no alterations in the level of either CXCR3 or CCR5 expression on the Treg cell surface, in comparison to na|« ve CD4+CD25 T cells (Table 3). Importantly, our future studies will continue to investigate both the regulation and function of chemokines on resting and activated Treg cell populations.
CD4+CD25+ Treg CELLS PROTECT AGAINST EAE PROGRESSION
51
An alternative mechanism that may in£uence Treg cell homing is the di¡erential expression of adhesion/integrin molecules. Our results support this possibility, since we have found that both ICAM1 and P selectin expression were signi¢cantly elevated on resting Treg cells, in comparison to non-Treg cells (Table 3). These ¢ndings were surprising, since previous reports concerning P selectin expression have been limited to activated platelets and endothelium (Shebuski & Kilgore 2002). However, since P selectin is known to facilitate T cell^endothelium interactions (Luscinskas et al 1995), elevated expression of this adhesion molecule may prove to be one mechanism promoting the direct interaction of Treg cells with target CD4+ T cells in vivo. This is an attractive hypothesis, in light of previous ¢ndings suggesting that Treg cells must directly interact with target T cells to exert their suppressive phenotype, and we are currently examining the contribution of P selectin/P selectin ligand interactions to governing Treg function both in vitro and in vivo using the EAE model. Acknowledgements This work was supported in part by U.S. Public Health Service National Institutes of Health Research Grants NS30871 and NS26543.
References Begolka WS, Vanderlugt CL, Rahbe SM, Miller SD 1998 Di¡erential expression of in£ammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J Immunol 161:4437^4446 Furtado GC, Olivares-Villagomez D, Curotto de Lafaille MA, Wensky AK, Latkowski JA, Lafaille JJ 2001 Regulatory T cells in spontaneous autoimmune encephalomyelitis. Immunol Rev 182:122^134 Iellem A, Mariani M, Lang R et al 2001 Unique chemotactic response pro¢le and speci¢c expression of chemokine receptors CCR4 and CCR8 by CD4+CD25+ regulatory T cells. J Exp Med 194:847^853 Itoh M, Takahashi T, Sakaguchi N et al 1999 Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 162:5317^5326 Karin N, Mitchell DJ, Brocke S, Ling N, Steinman L 1994 Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production. J Exp Med 180:2227^2237 Kreuwel HT, Sherman LA 2001 The T-cell repertoire available for recognition of self-antigens. Curr Opin Immunol 13:639^643 Kuniyasu Y, Takahashi T, Itoh M, Shimizu J, Toda G, Sakaguchi S 2000 Naturally anergic and suppressive CD25+CD4+ T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int Immunol 12:1145^1155 Luscinskas FW, Ding H, Lichtman AH 1995 P-selectin and vascular cell adhesion molecule 1 mediate rolling and arrest, respectively, of CD4+ T lymphocytes on tumor necrosis factor alpha-activated vascular endothelium under £ow. J Exp Med 181:1179^1186
52
DISCUSSION
Mendel I, Kerlero de Rosbo N, Ben-Nun A 1995 A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: ¢ne speci¢city and T cell receptor V beta expression of encephalitogenic T cells. Eur J Immunol 25:1951^1959 Read S, Malmstrom V, Powrie F 2000 Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal in£ammation. J Exp Med 192:295^302 Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M 1995 Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151^1164 Salomon B, Lenschow DJ, Rhee L et al 2000 B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12:431^440 Shebuski RJ, Kilgore KS 2002 Role of in£ammatory mediators in thrombogenesis. J Pharmacol Exp Ther 300:729^735 Shevach EM 2002 CD4+CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2:389^400 Suri-Payer E, Amar AZ, Thornton AM, Shevach EM 1998 CD4+CD25+ T cells inhibit both the induction and e¡ector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 160:1212^1218 Thornton AM, Shevach EM 1998 CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188:287^296 Thornton AM, Shevach EM 2000 Suppressor e¡ector function of CD4+CD25+ immunoregulatory T cells is antigen nonspeci¢c. J Immunol 164:183^190
DISCUSSION Abbas: I can see why you think that P selectin might be involved in the homing of these T cells to the site of in£ammation. But what is it doing in the in vitro suppression assay? Miller: That’s a great question. Perhaps it is putting the target cells and e¡ector cells together, to allow the suppressive signal to be delivered. Abbas: Do e¡ector Th1 cells express PSGL1? Miller: Yes. E¡ector Th1 cells do express the P selectin ligand, PSGL1, but we haven’t used the antibody to try to inhibit the regulation by the wild type T regulatory cells. This is in progress. Mitchison: You still have to ¢nd out whether the e¡ects seen in vivo are the result of a Th2 shift, or a direct e¡ect on the expansion of Th1 cells. Miller: The anti-IL4 experiment needs to be done in vivo to see whether this is the actual mechanism, or whether it is something to do with the limited expansion of antigen-speci¢c cells in the T regulatory cell recipients. Shevach: The way you immunize mice de¢nitely generates IFNg production in bulk cultures. So what happened in those supernatants? You say you didn’t suppress IFNg, but what happens if you look in the supernatants instead of the Elispots?
CD4+CD25+ Treg CELLS PROTECT AGAINST EAE PROGRESSION
53
Miller: Thus far we have only assayed responses by Elispot and have not looked at IFNg in the culture supernatants. Shevach: How does 7D4 monoclonal anti-CD25 deplete? It is an IgM antibody. My impression was that IgMs don’t deplete well. Miller: It depletes perfectly well. In fact, the other anti-CD25 antibody doesn’t deplete as e⁄ciently in our hands. Powrie: PC61 de¢nitely depletes. Sercarz: Ordinarily we get these ordered relapses in the SJL model. In this case, when you have depleted the CD25s, do you get an explosion of many responses directed against multiple myelin epitopes involved in epitope spreading? Miller: That is a great question; we are looking at this now. Bach: SJL mice have another defect, which is in their NKT cells. It is interesting to note that both NOD mice and SJL mice have a defect in NKT cells. Is this because of a problem in the thymus? As far as NKT cells are concerned, we believe the NKT defect is IL7 dependent. Abbas: You enhanced PLP disease in the SJL mice in which T regulatory cells were depleted using anti-CD25. Can you reveal disease with PLP in the SJL strain? Have you treated a normally PLP-resistant strain with anti-CD25? Miller: You need a system where the animal can respond to the epitope presented by that MHC. I don’t know of an epitope like that in SJL mice. Bluestone: What about B10.S? Miller: That could be possible because B10.S is semi-resistant to PLP139induced EAE. Shevach: Some of the epitopes in BALB/C are known and they are pretty resistant. Miller: I would use the BALB/c because this is the strain that Jim Allison has shown can be made susceptible using anti-CTLA4. Bluestone: I’d like to ask a question about the tra⁄cking issue. Might P selectin and tra⁄cking be a red herring? Miller: At this point we are not sure. We know that EAE transfer is not dependent on P and E selectin. It has been published that the anti-P and anti-E delivered in combination will not inhibit EAE transfer. A colleague of mine at Northwestern has P selectin and E selectin double knockouts, and we have shown that they get EAE much more severely than wild-type mice. Bluestone: I have a general question. We have all become pretty enamoured with the adoptive transfer model, but at some level it is surprising to me. We are taking a million cells, putting them into an animal that must have 2 or 3 million regulatory cells already. This is enhancing the frequency by 50%, and all of a sudden it goes from a big disease to one where there is little or no in£ammation anymore. The other thing is that we see the transferred cells home primarily to the lymph nodes and not to the spleen, yet we know that regulatory cells are in the spleen. Is there
54
DISCUSSION
something about the way that we purify the cells, and then put them back in i.v., that causes them to fail to home normally? There seems to be something odd about the way that we set up the experiments, in terms of where these cells go. Shevach: The way one normally puri¢es CD25+ cells by positive selection leaves them covered with £uorescent beads. Bluestone: I don’t know a good way around this per se, except that we always try complement positive selection experiments with a depletion experiment which helps. It strikes me that we are going to be misled in some of our chemokine and tra⁄cking experiments if we rely on the adoptive transfer model only. Von Herrath: If you give them i.v. the majority will initially be in the lung. Bach: In many other models when you do transfer experiments in immunode¢cient animals there is the pitfall of homeostasis-driven proliferation. This doesn’t apply here though. Mowat: Does the P selectin mouse have any autoimmune phenotype? Miller: Other than our ¢nding that they are hypersensitive to MOG peptideinduced EAE, not that I am aware of. I don’t know whether anyone has really looked at this in terms of spontaneous autoimmunity.
The role of CD28 and CTLA4 in the function and homeostasis of CD4+CD25+ regulatory T cells Elisa Boden, Qizhi Tang, Helene Bour-Jordan and Je¡rey A. Bluestone1 UCSF Diabetes Center, University of California, San Francisco, 513 Parnassus Avenue, Box 0540, HSW Room 1114, San Francisco, CA 94143-0540, USA
Abstract. CD4+CD25+ T cells regulate a variety of autoimmune and alloimmune responses including the development of autoimmune diabetes in non-obese diabetic (NOD) mice. We have examined the role of CD28/CTLA4/B7 interactions in the expansion and survival of CD4+CD25+ regulatory T cells (Treg) in this setting. CD28/ B7 interactions are essential in the development of Treg in the thymus and for their survival in the periphery. The CD28-mediated homeostasis of these cells is independent of IL2, OX40, CD40L, and survival factor Bcl-XL. In addition, analysis of Treg from CTLA4-de¢cient mice suggests that CTLA4 expression is not required for their development or function. However, non-activating anti-CTLA4 antibodies blocked the suppressor activity of regulatory cells in vitro. Thus, clinical application of co-stimulatory blockade using agents such as CTLA4Ig in the treatment of autoimmune disease may result in complicated outcomes. 2003 Generation and e¡ector functions of regulatory lymphocytes. Wiley, Chichester (Novartis Foundation Symposium 252) p 55^66
The ability of the immune system to di¡erentiate between self and non-self provides defence against foreign pathogens while preserving the integrity of host tissues. Several mechanisms have been implicated in the induction of T cell tolerance to self-antigen that prevents the development of autoimmunity. Central tolerance is achieved in the thymus via deletion of T cells with high a⁄nity receptors for thymic self-antigens (Kappler et al 1987, Kisielow et al 1988). Peripheral tolerance provides a second level of protection, whereby selfreactive T cells that have escaped thymic deletion are rendered anergic or are deleted upon encounter with self-antigen in the periphery (Rocha & von Boehmer 1991). We now know that peripheral self-tolerance is actively maintained by a subset of CD4+ T cells with immunoregulatory function that 1This
paper was presented at the symposium by Je¡rey A. Bluestone, to whom correspondence should be addressed. 55
56
BODEN ET AL
constitutively express the interleukin (IL)2 receptor a chain, CD25 (Sakaguchi et al 1995, Asano et al 1996). CD4+CD25+ regulatory T cells (Treg) constitute 5^ 15% of peripheral CD4+ T cells in both mice and humans and exhibit potent in vitro and in vivo regulatory activity (Sakaguchi et al 1995, Thornton & Shevach 1998, Dieckmann et al 2001, Jonuleit et al 2001, Levings et al 2001, Stephens et al 2001, Taams et al 2001). These cells have been shown to regulate a number of autoimmune syndromes in mouse and rats and, most recently, have been implicated in the regulation of several diseases in humans (Herold et al 2002). This presentation addresses the role of Treg in NOD mice. The potential importance of cell surface molecules including CD28 and CTLA4 is discussed in the context of regulatory T cell development and function. The data suggest that the homeostasis of these cells is maintained as a dynamic population likely controlled by continued interaction with nominal antigens. CD4+CD25+ control of autoimmune diabetes in NOD mice is CD28-dependent The role of CD28 co-stimulation has been studied in the spontaneous autoimmune T cell-mediated diabetes of NOD mice. Surprisingly, although CD28 interaction with B7 molecules is believed to play a major role in T cell activation, CD28 knockout (KO) and B7-1/B7-2 KO NOD mice develop early onset and higher incidence of diabetes compared to their littermate controls. Similar ¢ndings were obtained in transgenic NOD mice that express the gene for production of soluble CTLA4Ig and in NOD mice treated with murine CTLA4Ig treatment at 2^4 weeks of age corresponding to the ¢rst visible signs of the autoreactive process (Lenschow et al 1996, Salomon et al 2000). CD4+CD25+ regulatory T cells constitute about 5% of the circulating CD4+ T cells in NOD mice (Salomon et al 2000). Although this number is signi¢cantly lower than that observed in other strains, NOD Treg are functionally competent since adoptive transfer of puri¢ed regulatory cells suppress disease mediated by diabetogenic CD4+ T cells. Examination of NOD mice in which the CD28/B7 pathway was disrupted demonstrated a profound decrease in the number of peripheral CD4+CD25+ T cells. Reversal of disease was achieved by reconstitution of the CD4+CD25+ T cell population from wild-type NOD mice, implicating CD28/B7 interaction in the peripheral homeostasis of CD4+CD25+ cells (Salomon et al 2000). Role of CD28 pathway in homeostasis of Treg cells The previous studies using knockout mice could not distinguish a role for CD28 in thymic development versus peripheral homeostasis of Treg. We therefore injected normal mice with CTLA4Ig or with a combination of anti-B7-1 and anti-B7-2
CD28 AND CTLA4
57
monoclonal antibodies (mAbs) and monitored the number of CD4+CD25+ T cells in the periphery and thymus. The mice treated with CD28 antagonists demonstrated a 60^80% reduction in Treg in the periphery. This was not simply a result of a loss of CD25 expression as similar results were obtained using CSFE (carboxy£uorescein succinimidyl ester) to track transferred Treg in vivo. In addition, CD28/ B7 blockade in thymectomized wild-type mice resulted in a similar reduction in Treg consistent with a direct role for CD28 in peripheral expansion and/or survival of the Treg population. However, these results did not rule out a potential role for CD28 in Treg development. In fact, CD28 KO mice showed a clear reduction of CD4+CD25+ cells in the thymus. The Treg population was reduced to a similar degree in the thymus and in the periphery following treatment of wild-type mice with CD28 antagonists. These data suggest an important role for CD28 in both the development and maintenance of the Treg subset. Several mechanisms can be envisioned to explain the e¡ects of CD28 blockade on regulatory T cell development and activity. First, it is possible that CD28 controls proliferation or survival of the Treg. Alternatively, CD28 may control expression of other cell surface markers that are essential for Treg function. In order to address the ¢rst possibility, we examined the e¡ect of CD28 blockade on Treg homeostatic proliferation in vivo. The majority of in vitro studies show that Treg are anergic to TCR-mediated stimulation (Read et al 1998, Takahashi et al 1998, Taams et al 2001). However, the cells are clearly able to proliferate in vivo as demonstrated by the use of CSFE-labelling to follow Treg populations. In these studies, we demonstrated, based on dilution of the CSFE dye, that between 5^10% of the CD4+CD25+ cells go into cycle within one week after adoptive transfer into normal hosts. Interestingly, treatment of mice with anti-B7 antibodies blocked the Treg proliferation. This was not simply due to inhibition of IL2 production as injection of mice with excessive IL2 did not a¡ect the loss of Treg cells. Moreover, the e¡ects of CD28 blockade did not appear to be due to increased apoptosis since overexpression of Bcl-XL did not prevent Treg loss in this setting. Thus, it appears that CD28 co-stimulation is essential for the development and expansion of the Treg. The basis for CD28-based Treg homeostasis remains unclear but cannot be explained simply by its e¡ects on cell survival or IL2driven proliferation. Rather, an unknown growth factor that regulates CD4+CD25+ T cell growth in vivo may be downstream of CD28/B7 signalling pathway. It is possible that this factor does not exist in our current in vitro cultures, explaining why most investigators characterize these cells as anergic. Role of other co-stimulatory pathways in Treg homeostasis Interruption of the CD40^CD154 (CD40L) interactions, similar to CD28/B7 blockade, has been shown in experimental rodent and primate transplant models
58
BODEN ET AL
to represent a powerful strategy to inhibit allograft rejection (Hancock et al 1996). In rodents, peri-operative treatment with anti-CD40L can promote inde¢nite survival of murine cardiac allografts (Hancock et al 1996). In these studies, it has been suggested that this blockade is mechanistically linked to suppression of B7 expression and thus, blockade of CD28. Therefore, we examined the role of the CD40 pathway in Treg function. Studies in NOD mice showed that in contrast to CD28 blockade, CD40L blockade abrogated disease. Analyses of the CD4+CD25+ subset in CD40L KO mice demonstrated normal numbers and function of Treg both in vitro and in vivo. Similarly, the co-stimulatory molecule, OX40, expressed on Treg cells and shown to be involved in cell survival (Maxwell et al 2000, Rogers et al 2001) was studied. Although Treg express OX40, OX40 KO mice have normal numbers and function of the Treg cells. Role of CTLA4 in Treg homeostasis CTLA4 is a CD28 homologue that binds to CD28 ligands, B7-1 and B7-2. However, CTLA4 engagement results in the attenuation of T cell activation as demonstrated by the development of a fatal lymphoproliferative disease in CTLA4-de¢cient mice (Tivol et al 1995, Waterhouse et al 1995). Bone marrow chimeric mice containing CTLA4-de¢cient and CTLA4-expressing T cells do not develop disease (Bachmann et al 1999). Thus, CTLA4 expression on a subset of T cells can down regulate T cell activation in a dominant fashion similar to the immunoregulatory action of CD4+CD25+ T cells. Furthermore, while CTLA4 is up-regulated on most T cells only after T cell activation, it is constitutively expressed by CD4+CD25+ regulatory T cells (Salomon et al 2000, Takahashi et al 2000), suggesting a possible role for CTLA4 in the function and maintenance of these cells. Previous reports established that CD28 is required to up-regulate CTLA4 expression (Alegre et al 1996). Therefore, the reduction of regulatory T cells in CD28-de¢cient mice could be attributed to altered CTLA4 expression in CD28de¢cient CD4+CD25+ T cells. To discriminate between the e¡ects of B7 blockade on CD28 versus CTLA4, the e¡ect of anti-B7 antibody treatment on Treg was studied in CTLA4-de¢cient mice. Typically, CTLA4-de¢cient mice die at 3 to 4 weeks of age as a result of a generalized lymphoproliferative disease (Tivol et al 1995, Waterhouse et al 1995). However, blockade of CD28/B7 interactions delays T cell activation and thereby prolongs the life of CTLA4-de¢cient mice (Tivol et al 1997). Therefore, these mice were treated with anti-B7 antibodies beginning 9 days after birth and the regulatory T cells were studied over time. In addition, a third cell-surface marker, CD62L (L-selectin) was used to di¡erentiate between regulatory T cells and activated CD25-expressing cells. CD62L is down regulated on activated T cells, but has been described as a marker expressed on
CD28 AND CTLA4
59
T cells with regulatory activity (Lepault & Gagnerault 2000). Although the treatment with anti-B7 mAbs reduced the percentage of CD4+CD25+CD62L+ T cells in CTLA4 KO mice, the majority of CD4+CD25+CD62L+ T cells recovered by one month after treatments were ended. Thus, CTLA4 does not regulate the depletion or recovery of regulatory T cells upon in vivo B7 blockade. This observation is consistent with studies demonstrating that the administration of anti-CTLA4 antibodies to wild-type NOD mice in a treatment regimen that blocks CTLA4 function in vivo (Karandikar et al 1996), did not deplete CD4+CD25+ T cells from the spleen and lymph nodes. Most importantly, the regulatory population in anti-B7-treated CTLA4-de¢cient mice was reconstituted in these animals prior to the beginning of generalized T cell activation and proliferation, as the majority of the CD4+CD25+ T cells were CD62L+ on day 28 after the end of anti-B7 treatment. Thus, CTLA4 is not necessary for the development or homeostasis of regulatory T cells in the periphery and the e¡ects of B7 blockade are due directly to the absence of CD28 ligation. CTLA4 has been reported to have a critical role in the regulatory function of Treg cells (Read et al 2000, Takahashi et al 2000). The contribution of CTLA4 to regulatory T cell function in vitro has been studied using CD4+CD25+ T cells from CTLA4-de¢cient mice. In these studies, regulatory T cells were reported to have only 50% of the suppressor activity of wild-type regulatory T cells in vitro (Takahashi et al 2000). It is important to note that in these previous studies activated T cells expressing CD25 were not excluded from the CD4+CD25+ population tested for suppressor activity and may have compromised the regulatory activity of this population. In vivo, CTLA4 blockade using mAbs has been reported to abrogate the ability of CD4+CD25+ T cells to protect from autoimmunity in a model of intestinal in£ammation (Read et al 2000). However, the exacerbation of autoimmune disease in this model could be attributed to CTLA4 blockade on self-reactive responder T cells rather than the impairment of regulatory T cell function. We examined the role of CTLA4 in the suppressor function of regulatory T cells using CTLA4-de¢cient mice expressing a transgene encoding a soluble form of the CTLA4Ig fusion protein (Lenschow et al 1996). CTLA4Ig binds B7-1 and B7-2, preventing CD28 co-stimulation and thereby delaying massive T cell activation in these mice. These transgenic mice maintain normal numbers of regulatory T cells in the periphery and thymus. This may be due to low levels of CTLA4Ig in the serum, resulting in incomplete CD28/B7 blockade that is su⁄cient to delay lymphoproliferative disease, but not the development of regulatory T cells. The regulatory T cells from CTLA4 de¢cient, CTLA4Ig transgenic mice were examined functionally. CFSE-labelled wild-type responder T cells were stimulated with anti-CD3 and T-depleted antigen presenting cells (APCs) in the
60
BODEN ET AL
presence or absence of CD4+CD62L+CD25+ regulatory T cells from CTLA4de¢cient CTLA4Ig transgenic mice. CTLA4-de¢cient CD4+CD62L+CD25+ T cells were able to suppress proliferation of wild-type responder cells almost completely, suggesting that CTLA4 is not essential for regulatory T cell function in vitro. To ensure that this result was not due to compensatory mechanisms occurring in mice genetically de¢cient in CTLA4, we attempted to alter the suppressive capability of wild-type cells by blocking CTLA4 using anti-CTLA4 Fab fragments. In order to prevent the e¡ect of CTLA4 blockade on responder T cells, CD4+CD62L+CD25 responder T cells from CTLA4-de¢cient CTLA4 Ig transgenic mice were labelled with CFSE and used as responder cells. Co-culture with wild-type CD4+CD62L+CD25+ T cells inhibited the proliferation of these responder cells from CTLA4-de¢cient mice. Addition of anti-CTLA4 Fab fragments completely abrogated the suppressor function of wild-type regulatory T cells. Taken together, our results demonstrate that while CTLA4-de¢cient regulatory T cells are functional in vitro, CTLA4 blockade negates suppressor function of wild-type regulatory T cells. Regulatory T cells from CTLA4-de¢cient mice express higher levels of membrane bound TGFb1 than wild-type regulatory T cells The inhibitory cytokine, transforming growth factor (TGF)b has been implicated in the function of regulatory T cells and it has been suggested that TGFb functions downstream of CTLA4 signalling in this setting (Read et al 2000, Nakamura et al 2001). We were interested to know whether CTLA4 de¢cient regulatory T cells expressed membrane-bound TGFb It has been shown that CD4+CD25+ T cells express higher levels of the latent form of TGFb (LAP) than CD4+CD25 T cells in the resting state. Activated CD4+CD25+ T cells show increased expression of cell-surface bound TGFb compared with CD4+CD25 T cells (Nakamura et al 2001). Interestingly, we found that nearly all of the membrane-bound LAP on resting wild-type CD4+CD25+ T cells and the active membrane-bound TGFb1 on activated wild-type CD4+CD25+ T cells was contained in the CD62Llow fraction. Wild-type CD4+CD62L+CD25+ T cells did not express TGFb. In contrast, CTLA4-de¢cient CD4+CD62L+CD25+ T cells expressed markedly increased membrane-bound LAP in resting state and TGFb after activation. It is important to note that although the CD62Lhigh subset of CTLA4-de¢cient CD4+CD25+ T cells showed up-regulation of TGFb on the cell surface, the majority of TGFb-expressing cells were actually among the CD62Llow fraction of CD4+CD25+-expressing T cells. Nonetheless, the increased expression of TGFb on CTLA4 de¢cient cells might be a compensatory mechanism by which CTLA4-de¢cient Treg could function in the absence of CTLA4 signalling.
CD28 AND CTLA4
61
However, we could not demonstrate abrogation of CTLA4-de¢cient or wild-type regulatory T cell suppressor function with anti-TGFb antibody. Concluding remarks We have demonstrated that CD28 plays a critical role in both the development and peripheral homeostasis of Treg. The peripheral pool of CD4+CD25+ regulatory T cells is very dynamic and CD28 regulates its size, in part, through controlling the homeostatic proliferation of these cells. The mechanism of this regulation is not clear, but it does not appear to be mediated through IL2 or survival factor such as Bcl-XL. CD28 function in regulatory T cell homeostasis could be integrated in a model where the added strength of signal via the T cell receptor (TCR) (signal 1) and co-stimulatory signals (signal 2) determine regulatory T cell survival in the periphery and lead to positive selection of regulatory T cells in the thymus. We propose that, like na|« ve T cells, regulatory T cells require signalling via the TCR to survive in the periphery. However, the threshold for the overall strength of signal allowing cell survival may be higher for regulatory T cells than for na|« ve cells, and CD28 co-stimulation may be necessary to reach this threshold. We have shown that CTLA4/B7 interaction does not play a critical role in peripheral regulatory T cell homeostasis. In addition, CTLA4-de¢cient CD4+CD62L+CD25+ T cells are functional regulatory cells in vitro with suppressor activity as e⁄cient as their WT counterparts. However, CTLA4 blockade of WT regulatory T cells completely abrogates suppressor function of these cells. The discrepancy in the data is di⁄cult to reconcile. One explanation of this apparent contradiction in data is that the CTLA4 signalling necessary for suppressor activity is somehow bypassed in CTLA4-de¢cient regulatory T cells. Indeed, CTLA4-de¢cient CD4+CD62L+CD25+ T cells express both increased level of membrane-bound LAP at resting stage and increased levels of active membrane-bound TGFb1 after activation when compared with wild-type regulatory T cells. Thus, it is possible that membranebound TGFb might provide a strong inhibitory signal that bypasses CTLA4 activation in de¢cient T cells. Although numerous aspects of the biology of regulatory T cells remain unclear, the role of CD28 in Treg development and homeostasis indicates a novel regulatory function for CD28 in the maintenance of peripheral tolerance and the prevention of autoimmunity. In addition, a new level of complexity in the function of CD28/ CTLA4/B7 interactions has now been identi¢ed. Increased understanding of the delicate balance of various mechanisms governing the homeostasis and activation of both pathogenic and regulatory T cell subsets will be necessary to develop e¡ective and safe treatments for autoimmune diseases.
62
BODEN ET AL
Acknowledgements This work was supported by JDF grant #4-1999-841 (J.A.B.). E.B. is an HHMI medical student fellow. Q.T. is supported by NIAID fellowship #F32 AI 10360.
References Alegre ML, Noel PJ, Eisfelder BJ et al 1996 Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J Immunol 157:4762^4770 Asano M, Toda M, Sakaguchi N, Sakaguchi S 1996 Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 184:387^396 Bachmann MF, Kohler G, Ecabert B, Mak TW, Kopf M 1999 Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J Immunol 163:1128^1131 Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G 2001 Ex vivo isolation and characterization of CD4+CD25+ T cells with regulatory properties from human blood. J Exp Med 193:1303^1310 Hancock WW, Sayegh MH, Zheng XG, Peach R, Linsley PS, Turka LA 1996 Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci USA 93:13967^13972 Herold KC, Hagopian W, Auger JA et al 2002 Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346:1692^1698 Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH 2001 Identi¢cation and functional characterization of human CD4+ CD25+ T cells with regulatory properties isolated from peripheral blood. J Exp Med 193:1285^1294 Kappler JW, Roehm N, Marrack P 1987 T cell tolerance by clonal elimination in the thymus. Cell 49:273^280 Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA 1996 CTLA-4: a negative regulator of autoimmune disease. J Exp Med 184:783^788 Kisielow P, Bluthmann H, Staerz UD, Steinmetz M, von Boehmer H 1988 Tolerance in T-cellreceptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes. Nature 333:742^746 Lenschow DJ, Herold KC, Rhee L et al 1996 CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 5:285^293 Lepault F, Gagnerault MC 2000 Characterization of peripheral regulatory CD4+ T cells that prevent diabetes onset in nonobese diabetic mice. J Immunol 164:240^247 Levings MK, Sangregorio R, Roncarolo MG 2001 Human CD25+ CD4+ T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 193:1295^1302 Maxwell JR, Weinberg A, Prell RA, Vella AT 2000 Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J Immunol 164:107^112 Nakamura K, Kitani A, Strober W 2001 Cell contact-dependent immunosuppression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 194:629^644 Read S, Mauze S, Asseman C, Bean A, Co¡man R, Powrie F 1998 CD38+ CD45RBlow CD4+ T cells: a population of T cells with immune regulatory activities in vitro. Eur J Immunol 28:3435^3447
CD28 AND CTLA4
63
Read S, Malmstrom V, Powrie F 2000 Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal in£ammation. J Exp Med 192:295^302 Rocha B, von Boehmer H 1991 Peripheral selection of the T cell repertoire. Science 251: 1225^1228 Rogers PR, Song J, Gramaglia I, Killeen N, Croft M 2001 OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 15:445^455 Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M 1995 Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151^1164 Salomon B, Lenschow DJ, Rhee L et al 2000 B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12:431^440 Stephens LA, Mottet C, Mason D, Powrie F 2001 Human CD4+CD25+ thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol 31:1247^1254 Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN 2001 Human anergic/ suppressive CD4+CD25+ T cells: a highly di¡erentiated and apoptosis-prone population. Eur J Immunol 31:1122^1131 Takahashi T, Kuniyasu Y, Toda M et al 1998 Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 10:1969^1980 Takahashi T, Tagami T, Yamazaki S et al 2000 Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192:303^310 Thornton AM, Shevach EM 1998 CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188:287^296 Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH 1995 Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541^547 Tivol EA, Boyd SD, McKeon S et al 1997 CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-de¢cient mice. J Immunol 158:5091^5094 Waterhouse P, Penninger JM, Timms E et al 1995 Lymphoproliferative disorders with early lethality in mice de¢cient in CTLA-4. Science 270:985^988
DISCUSSION Bach: I want to ask about another co-stimulation pathway, ICOS: do you know anything about the involvement of this pathway? Bluestone: Richard Flavell sent us some ICOS knockout mice, and these have regulatory cells which seem to work ¢ne in vitro. Ha£er: Human anti-ICOS hasn’t blocked in our systems. Bluestone: Every knockout we have looked at except CD28 and IL2 has had normal regulatory cells. Banchereau: What about the TGFb knockout? Bluestone: Jim Allison has done this and says that the regulatory cells are ¢ne. This suggests that TGFb is not functionally very important in this setting.
64
DISCUSSION
Shevach: One possibility everyone ignores is that TGFb may not be an e¡ector molecule. Instead, it may act back on the CD25+ cells to enhance their function. Bluestone: But then anti-TGFb should inhibit. Shevach: It depends on the system. In a suboptimal system perhaps some enhancement by TGFb is needed. TGFb is de¢nitely not required for suppression. Bluestone: Perhaps animals that are missing TGFb when they develop and learn to function without it. CTLA4 knockouts don’t need CTLA4 to suppress. Powrie: If you take T cells that can’t respond to TGFb, they can’t be suppressed in vivo. Shevach: In vitro they can be readily suppressed. Bluestone: It is still a conundrum for us how CTLA4 works in these cells. Chatenoud: Unless something has no redundancy at all in the system, such as IL7, the knockouts are not meaningful. IL2 knockouts reject skin grafts. Does this mean that IL2 is not important for graft rejection? Abbas: That is not a fair statement. You are just looking at one function of IL2. Many of us would argue that this is the wrong function. The knockout mouse drops dead, so clearly IL2 is not redundant for life. Chatenoud: What I am saying is that although it is true that knockouts may provide some answers these have to be interpreted in the context of the high intrinsic redundancy of the cytokine network. Bluestone: Ideally, we want a conditional knockout where we could take a cell in the periphery and selectively knockout TGFb. Abbas: A lot of people make the statement that if a gene is knocked out then other genes can compensate. I understand as a theoretical idea that other things that were not very active can kick in and become active. But I am constantly looking for examples of where something that was previously silent kicks in because a gene was deleted from the germline. It’s hard to ¢nd one. Flavell: I have an example. We knocked out Rac2. The expression of Rac1, a related molecule, then goes up. We thought we’d be clever and we took the cells in vitro from a conditional Rac2 knockout, and we added Tat Cre, which goes through the membrane of the cell and deletes it in real time. As we were watching the cells, Rac1 came up. It is compensated for within a day or two of the deletion event. Bluestone: I also wouldn’t discount the possibility that there are di¡erent subsets of regulatory cells with varying ability to function in the absence of other molecules. The good news then is that CD28 must be really important! It doesn’t get compensated forno matter what. Von Herrath: Let’s turn the question about these knockout mice around. One possibility we should look at is that these CD25high cells could still be quite heterogeneous. Depending on what you knock out, and the environment you look in, you might get di¡erent e¡ector mechanisms or regulation, for example if
CD28 AND CTLA4
65
certain knockout mice are more susceptible to pathogens or simply harbour an altered gut £ora. This might particularly apply to the in vivo experiments. Bluestone: It’s a question of redundancy. Is this redundancy at the level of the cell or at the level of the animal? If I could block those CTLA4 knockout regulatory cells with anti-TGFb, I would be very happy and I would say that this is the redundancy. So far I have not been able to do this. Abbas: The data you showed indicated that it is the CTLA4 knockout that expresses more membrane TGFb. So you are going to put to rest the idea that CTLA4 is a signal for TGFb production. Bluestone: Correct. But I would argue that CTLA4 can lead to TGFb production by regulating TCR signalling. Think of CTLA4 as a brake. If you put the brake on it may not totally stop, but starts producing TGFb. CTLA4 puts a partial break on T cells, just as cyclosporine does when used in suboptimal doses, and TGFb is not a direct result of CTLA4 signalling but is a consequence of suboptimal TCR signalling. Under a variety of conditions, such as anti-CD3 treatment, there is suboptimal TCR signalling, which causes TGFb and IL10 production. Regulatory cells may be a consequence of some kind of suboptimal negative selection in the thymus, as opposed to super-optimal activation. Powrie: Then your result is the wrong way round. When you take away CTLA4 you have more TGFb. If TGFb is turned on by an attenuated TCR signal, you would not expect to see more. Bluestone: Your points are well taken but there may be a spectrum here. When CTLA4 is made during development it is keeping the cells in a totally resting state. There are three states of a cell in CTLA4 knockouts. First, a totally na|« ve resting state where nothing is made. Second, a fully activated cell, which kills the animal. Then there is an odd population that probably would have been deleted in the normal animal, but because the animal is missing CTLA4 it actually makes it some way through thymic development and doesn’t delete. Instead, it starts making TGFb. Delovitch: In the NOD mouse model the developing T cells in the thymus are de¢cient in TCR signalling upon TCR stimulation and show de¢cient upregulation of CTLA4. On the basis of your reasoning, this would increase the subpopulations of regulatory T cells, but this is not the case. How can you explain this? Bluestone: I don’t know how good the evidence is that NOD mice start out with a de¢ciency in regulatory cells, as opposed to one that develops over time. Shevach: You activated the CD25 positive cells and negative cells from the CTLA4 knockout, and looked at cell surface TGFb. What do the resting cells look like? Bluestone: The only thing we ¢nd on the resting cells that is di¡erent between the knockout and the wild-type is LAP. We didn’t ¢nd TGFb on the resting cells.
66
DISCUSSION
Bach: You didn’t mention the nice story you have with the B7-2 knockout mice. Do you have any more data on these? Bluestone: B7-2 knockout NOD mice don’t get diabetes. The bad news is that they die of paralysis. The reason for this is that they seem to have skewed their repertoire towards targeting peripheral nerves rather than the pancreas. We thought this was a regulatory cell phenomenon. It turns out that you can intermix the regulatory cells and do adoptive transfers, and block both diseases the same way. What is taking place here may have to do with tra⁄cking: somehow B7-2 is important in up-regulating a chemokine or homing receptor. Since there is B7-1 expressed in the nerves, I think the cells are going to the nerves where they are activated. Mowat: Do CTLA4 knockout cells release active TGFb into supernatants as well as having it on the membrane. Bluestone: We have not actually looked at that. We found message but everyone said that this doesn’t mean anything. We did cell surface expression and tried antibody blocking as a way to look for active TGFb, but we haven’t found any e¡ect yet.
CD4+CD25+ regulatory cells from human peripheral blood express very high levels of CD25 ex vivo Clare Baecher-Allan*, Julia A. Brown, Gordon J. Freeman{ and David A. Ha£er*1 *Laboratory of Molecular Immunology, Center for Neurologic Diseases, Brigham and Women’s Hospital and {Department of Adult Oncology, Dana Farber Cancer Institute, and Harvard Medical School, 77 Ave Louis Pasteur, Boston, Massachusetts, 02115, USA
Abstract. Selective isolation of only those CD4+ T cells that display the highest levels of CD25 by FACS results in a highly homogeneous regulatory population as de¢ned by functional activity and the expression of multiple surface antigens. Thus greater than 98% of CD4+CD25high cells express CD45RO in the absence of CD45RA expression. Upon TCR stimulation CD4+CD25high cells are both anergic and tolerogenic as they inhibit proliferation and cytokine secretion by activated CD4+CD25 responder T cells in a contact-dependent manner. In contrast, CD4+ cells that express lower levels of CD25 are more heterogeneous in their levels of expression of CD45RO, HLA-DR and CD122, and do not exhibit anergic or suppressive characteristics. Providing either CD28 costimulation or IL2 to a maximal anti-CD3 stimulus results in a modest induction of proliferation and the loss of observable suppression by CD4+CD25high regulatory cells. Unlike CTLA4 blockade, blocking the interaction of PD-1 with its ligand PD-L1 a¡ects the level of suppression. However, since this reduction in suppression by aPD-L1 can be overcome by increasing the number of CD4+CD25high T cells in the co-culture assay, the mechanism of CD4+CD25high regulation can proceed in the absence of PD-1/PD-L1 interactions, although it is not as e⁄cient. 2003 Generation and e¡ector functions of regulatory lymphocytes. Wiley, Chichester (Novartis Foundation Symposium 252) p 67^91
Autoreactive T cells capable of recognizing tissue-speci¢c antigens are not necessarily deleted in the thymus as they can be cloned from lymph nodes of mice and the circulation of humans (Ito et al 1993, Kaslow et al 1998, Ota et al 1990). These self-reactive T cells must require exquisite regulation and their activation can result in autoimmune disease. Besides careful control of the expression of 1This
paper was presented at the symposium by David Ha£er. Correspondence should be addressed to Clare Baecher-Allan. 67
68
BAECHER-ALLAN ET AL
co-stimulatory molecules necessary for activation of na|« ve, autoreactive T cells, accumulating evidence suggests that populations of regulatory T cells also function in a critical role to modulate autoimmune responses. It was thus of interest when Kojima and Prehn discovered that thymectomy on neonatal day 3 led to the development of multi-organ autoimmune disease (Kojima & Prehn 1981). Subsequently, it was demonstrated that the neonatal thymectomized mice lacked CD4+CD25+ T cells and adoptive transfer of this population into day 3 thymectomized animals or co-transfer with disease inducing CD4+CD25 lymphocytes into nude mice prevented autoimmune disease (Sakaguchi et al 1985, Asano et al 1996, Sakaguchi et al 1995). Adoptive transfer of these regulatory cells has been shown to o¡er protection from diabetes as naturally occurs in the NOD mouse (Salomon et al 2000), from colitis upon co-transfer with CD45RBhigh cells into SCID recipients (Read et al 2000), and from gastritis upon co-transfer with a gastral-speci¢c e¡ector T cell clone (Suri-Payer et al 1998). Thus, the CD4+CD25+ cell subset can regulate self-responses of autoreactive T cells. CD4+CD25+ regulatory cells have been the subject of intense study as their function appears critical in maintaining self tolerance. Murine CD4+CD25+ regulatory T cells have been shown to suppress proliferation of co-cultured CD25 T cells only upon stimulation with soluble as compared to the more highly cross-linked plate-bound anti-CD3 (Thornton & Shevach 1998, Itoh et al 1999). Furthermore, in vitro studies have demonstrated that the suppressive ability of murine CD4+CD25+ T cells is inhibited by providing anti-CD28 co-stimulation or exogenous interleukin (IL)2 in conjunction with TCR stimulation and thus allows responder cell proliferation (Thornton & Shevach 1998, Itoh et al 1999). They inhibit IL2 production by responder T lymphocytes within 16 hours of coculture, and are themselves unable to secrete IL2 (Thornton & Shevach 1998, Papiernik et al 1998). In vivo and in vitro studies addressing the potential role of CD28 in the biology of CD4+CD25+ T cells suggest that CD4+CD25+ T cells require CD28 and B7 for development and peripheral homeostasis as CD28/ or B7-1/ B7-2/ NOD mice exhibited a severe de¢cit of these regulatory cells with associated worsening of diabetes (Salomon et al 2000). Here, we report the identi¢cation of a subset within the CD4+CD25+ T cells in the circulation of normal humans that exhibit strong in vitro regulatory function (greater than 95% inhibition of aCD3 induced proliferation) with similar characteristics to murine CD4+CD25+ regulatory cells. This CD4+CD25high T cell subset in humans comprises approximately 1^2% of circulating CD4+ T cells, unlike in rodents where between 6^10% of CD4+ T cells demonstrate regulatory function. While the entire population of CD4+CD25+ T cells expressing both low and high CD25 levels exhibit regulatory function in the mouse, only the CD4+ population that expresses the highest levels of CD25 demonstrates regulatory
HUMAN REGULATORY T CELLS
69
function in humans. These CD4+CD25high cells inhibit proliferation and cytokine secretion induced by TCR cross-linking of CD4+CD25 responder T cells in a contact dependent manner. Although higher numbers of CD4+CD25+high T cells are required, these regulatory cell can still suppress proliferation in the absence of the PD-1/PD-L1 or CTLA4/B7 pathways. Thus, regulatory CD4 T cells expressing high levels of the IL2 receptor exist in human peripheral blood, providing the opportunity to determine whether alterations in this population of T cells are involved in the induction of human autoimmune disorders. Methods Cell culture reagents. Cells were cultured in RPMI 1640 media supplemented with 2 nM L-glutamine, 5 mM HEPES, and 100 U/mg per ml penicillin/streptomycin (all from BioWhittaker, Walkersville, Maryland), 0.5 mM NaPyruvate, 0.05 mM non-essential amino acids (both from Gibco, Rockville, Maryland), and 5% human AB serum (Gemini Bio-Products, Woodland, California) in 96 well U-bottom plates (CoStar, Corning, New York). The aCD3 (clone UCHT1 for plate-bound assays and clone Hit3a for soluble conditions) and anti-CD28 (clone 28.2, at 5 mg/ml) antibodies were purchased from Pharmingen (San Diego, California). The anti-CD28 (clone 3D10) was provided by Genetics Institute, Cambridge Massachusetts. (In subsequent assays, the UCHT1 antiCD3 mAb was shown to give the same results as the Hit3a mAb when tested in soluble form, data not shown.) For plate-bound anti-CD3 stimulation, 50 ml of the anti-CD3 antibody diluted into PBS (Gibco) at the indicated concentration of 5.0 mg/ml or 0.05 mg/ml, was added to the each culture well, placed at 378C for 4 h, and then washed two times with PBS.The anti-PD-L1antibody (2A3) (Latchman et al 2001) was used at 10 mg/ml. The mouse anti-human CTLA4 Fab (monoclonal antibody 20A) was provided by Genetics Institute (Cambridge, Massachusetts) and has been shown to functionally block interaction with B7-1/2 (Anderson et al 2000). Recombinant human IL2 (rhIL2, Teceleukin, obtained from the National Cancer Institute) was added to those indicated cultures to a ¢nal concentration of 50 U/ml. Cell isolation and stimulation. Human blood mononuclear cells were isolated from freshly drawn human blood by Ficoll-Hypaque (Amersham Pharmacia, Piscataway, New Jersey) gradient centrifugation. The CD4CD25, CD4CD25low, and CD4CD25high populations were isolated from 1108 peripheral blood mononuclear cells by sorting using a FACS Vantage SE (Becton Dickenson, Franklin Lakes, New Jersey). These cells were incubated with 400 ml each antiCD4-CyChrome (#555348, IgG1, Pharmingen) and anti-CD25-PE (#IM0479, IgG2a, Immunotech, Brea, California). Control samples (110 6) were stained
70
BAECHER-ALLAN ET AL
with anti-CD4-CyChrome and IgG2a (#33035X, Pharmingen) or anti-CD25PE and IgG1-CyChrome (#33818X, Pharmingen). The analysis and sort gates were restricted to the population of lymphocytes by means of their forward (FS) and side scatter (SS) properties. Large, activated T cells were excluded. Upon re-analysis, the FS/SS properties of the CD4+CD25high cells were not appreciably di¡erent from those of the CD4+CD25 population indicating that these cell populations are similar in size. T cell depleted accessory cells were isolated by negative selection of peripheral blood mononuclear cells by incubation with anti-TCR pan a /b antibody (Immunotech) followed by gentle removal by Bio-Mag Goat anti-mouse IgG coated magnetic beads (Polysciences, Inc., Warrington, Pennsylvania) then by irradiation at 3300 rads. The indicated number of CD4+CD25 or high cells (from 2.5^5103/well) were plated with a 10-fold excess of T cell depleted accessory cells. Extremely low numbers of cells were added to these cultures as they were incubated for up to 7 days. To determine proliferation, we removed half of the culture supernatant (100 ml) from each well before adding 1 mCi of [3H]thymidine (NEN, Boston, Massachusetts) for the ¢nal 16 h of culture before harvesting on the day designated in each ¢gure legend. All assays exhibited less then 10% SEM and were repeated in a minimum of three independent experiments using blood from di¡erent donors. Transwell analysis. The CD4+CD25, CD4+CD25high and Tcell-depleted accessory cells populations were isolated as described above and cultured in transwell plates, purchased from Costar (Corning, New York). Both chambers of each transwell received Tcell depleted accessory cells (5105/well) and soluble anti-CD3 (10 mg/ ml) plus soluble anti-CD28 (5 mg/ml) as described. The proliferation of CD4+CD25 cells (510 4) plated in the lower chamber of each transwell was monitored in the presence or absence of direct contact with 510 4 CD4+CD25high regulatory cells. [3H]thymidine (4 mCi) was added at day 4, and the wells were harvested at day 5. FACS analysis of surface antigens. Human peripheral blood mononuclear cells were isolated post Ficoll gradient separation and stained with anti-CD4-CyChrome (IgG1, #555348, Pharmingen) and either anti-CD25-PE (IgG2a, #IM0479) or anti-CD25-FITC (IgG2a, #IM0478), both purchased from Immunotech. As the third colour, the samples stained with anti-CD4-CyChrome and anti-CD25-PE were also stained with either IgG1-FITC (#IM0639) or anti-CD62L-FITC (IgG1, #IM1231) from Immunotech, IgG2b-FITC (#MG2b01, Caltag), or antiCD45RA-FITC (IgG2b, #31264X, Pharmingen). As the third colour, the samples stained with anti-CD4-CyChrome and anti-CD25-FITC were also stained with either IgG1-PE (#33815X), IgG2a-PE (#555574), anti-HLA DR-PE (IgG2b,
HUMAN REGULATORY T CELLS
71
#32415X), or anti-CD122(IL2Rb)-PE (IgG1, #18745B) from Pharmingen; antiCD45RO-PE (IgG2a, #IM1307), anti-CD58(LFA3)-PE (IgG2a, IM1430), or antiCD71-PE (IgG1, #IM2001) from Immunotech, or IgG2b-PE (#6603450) from Coulter. The samples were run on an EPICS Flow Cytometer, collecting data on 2105 lymphocytes (gated by forward and side scatter properties) and analysed using the Cell Quest software. Although appropriate isotype controls were run for each sample, since they gave similar results, only the IgG1 isotype third colour stain is shown. Cytokine analyses by ELISA. The supernatants that were removed before addition of [3H]thymidine, and were diluted and analysed on Immulon 4 ELISA plates (Dynex Technologies, Chantilly, Virginia) using the antibody pairs: IFNg(M700A, M-701-B Biotin, Endogen, Woburn, Massachusetts), IL10 (#18551D, 18562D-Biotinylated, Pharmingen) and IL13 (554570, Biotinylated #555054, Pharmingen), developed with an avidin-peroxidase conjugate (1:10 000 dilution) (A-7419, Sigma, St. Louis, Missouri) and TMB peroxides substrate (#50-76-06, Kiekegaard and Perry Laboratories, Gaithersburg MD). Instead of IL4, IL13 was assayed as a prototypical Th2 cytokine due to limitations in the detection of IL4 in culture supernatants of humanTcells likely due to its consumption and the fact that these assays were set up with very low numbers of Tcells per well. IL2 mRNA analyses by reverse transcription/semi-quantitative PCR (RT/SQ-PCR). 60 wells of cultured CD4+CD25, CD4+CD25high, or co-cultured cells were stimulated with soluble anti-CD3/anti-CD28 (and Tcell-depleted accessory cells) as before. After 5 days RNA was isolated from the collected cells by solubilization in TRIzol reagent and converted into cDNA via the Superscript II Reverse Transcriptase protocol using Oligo dT (Itoh et al 1999, Papiernik et al 1998, Latchman et al 2001, Anderson et al 2000, Baecher-Allan & Barth 1993, Takahashi et al 2000, Sallusto et al 1999) (all reagents purchased from Gibco BRL, Rockville, Maryland). Actin and IL2 messages were ampli¢ed using the actin primers: 50 :AACCCCAAGGCCAACCGCGAGAAGATGACC and 30 :GGT GATGACCTGGCCGTCAGGCAGCTCGTA and the IL-2 primers: 50 : TACAG GATGCAACTCCTGTCTTGCATTGCA, and 30 : GTTGCTGTCTCATCAGCA TATTCACAC ATG. PCR (100 ml) was performed using 2.5 units Taq DNA Polymerase, 1.5 mM MgCl2, 0.2 mM dNTPs, 0.5 mM primers, and cycling parameters of 948C 20 then the indicated number of cycles of: 948C 20 s, 608C 30 s, 728C 1min. Upon combining all reagents, the initial PCR reaction was split into 5 wells, one for removal every three cycles within the desired range. (Additional PCR controls [not shown], and past work demonstrated that a three cycle delay in the appearance of a PCR product under these conditions were
72
BAECHER-ALLAN ET AL
indicative of a fourfold di¡erence in input template; Baecher-Allan & Barth 1993). Reaction products were analysed on 2% Agarose/TBE gels. Results Restricting the isolation of CD4+ cells to those cells that express the highest levels of CD25 results in a highly pure population as de¢ned by the analysis of surface molecules including CD45RO and MHC Class II (HLA-DR). Approximately half of the circulating human peripheral blood lymphocytes express CD4, and of these roughly 10% express the IL2 growth factor receptor a chain, CD25. Peripheral blood lymphocytes do not stain very strongly for CD25. Unlike what is seen in the mouse, in the human, the CD25+ population is not as clearly discernable (Fig. 1a) (Thornton & Shevach 1998, Takahashi et al 2000). Rather, the CD4+ T cells with the highest level of CD25 (CD4+CD25high) appear as a tail to the right from the major population containing both CD4+CD25low and CD4+CD25 cells. The CD25high cells represent 1^2% of the total CD4+ T cell population, while the CD25low cells can represent up to 16% of CD4+ T cells. The CD4+CD25/low/high T cells were analysed for expression of additional surface antigens to gain insight into their mechanism of action and to more fully characterize this regulatory population in humans. The di¡erent levels of surface antigen expression were compared among the CD4+CD25, CD4+CD25low and CD4+CD25high cell subsets (Fig. 1b). CD45RO, which can be associated with proliferative responses to recall antigens, was expressed at signi¢cantly higher levels by the CD4+CD25high population (99%) as compared to the CD4+CD25low (89%) or CD4+CD25 (33%) subset. In contrast, the expression of CD45RA, considered a marker for na|« ve T cells, showed the opposite expression pro¢le. Greater than 50% of the CD4+CD25 subset and 25% of the CD4+CD25low subset expressed CD45RA in contrast to only 4% of the CD4+CD25high T cells. These three T cell populations de¢ned by varying levels of CD25 expression exhibited marked di¡erences in a number of additional surface antigens which have been used to de¢ne functionally distinct populations (Fig. 1b). The CD4+CD25high cells expressed the highest levels of the peripheral lymph node homing receptor, L selectin (CD62L) (Sallusto et al 1999). The CD4+CD25high cells also expressed the highest frequency and intensity of the IL2R b chain (CD122) and LFA3 (CD58) compared to the other T cell subsets. The IL2R b chain was expressed by only 6% of CD4+CD25 cells, by 28% of the CD4+CD25low cell subset, and by over 85% of the CD4+CD25high cells. Unlike mouse T cells, activated human T cells express HLA Class II molecules on their surface allowing them to assume the role of antigen-presenting cells (Ko et al 1979). Importantly, the low level of HLA-DR expression observed in human blood was found to be limited to the CD4+CD25high cells (*20%) compared to
HUMAN REGULATORY T CELLS
73
FIG. 1. Human peripheral blood contains CD4+ cells expressing high and low levels of CD25. Human CD4+CD25high cells are CD45RO+, CD45RA, and express surface antigens associated with activated cells. (a) Mononuclear cells from freshly drawn human blood were stained with di¡erent combinations of anti-CD4-CyChrome, mIgG1-CyChrome, mIgG2aPE, and antiCD25-PE. The cells in these analyses were gated on lymphocytes via their forward and side scatter properties. The CD4+CD25, CD4+CD25low and CD4+CD25high populations were sorted using the indicated sorting gates. (b) Human peripheral blood mononuclear cells were stained with either anti-CD25-PE, anti-CD4-CyChrome and anti-CD45RA-FITC or antiCD62L-FITC; or anti-CD25-FITC, anti-CD4-CyChrome and anti-CD45RO-PE, anti-CD58PE, anti-CD71-PE, anti-CD122-PE, or anti-DR-PE. Control samples stained with IgG2bFITC, IgG2a-FITC, or IgG2b-PE and IgG2a-PE as the third colour are not shown as they were identical to the staining pattern for the IgG1 isotype control. The histogram analysis of the CD4+CD25 and CD4+CD25low populations were scaled to 150 while the scale for the analysis of the CD4+CD25high population was set at 30. The analysis was performed with CellQuest software. (From Baecher-Allan et al 2001, with permission.)
less than 2% of the CD4+CD2 and CD4+CD25low populations. The CD4+CD25high subset also exhibited preferential expression of the transferrin receptor which is usually expressed on the surface of activated lymphocytes and all cells entering proliferation (Bayer et al 1998). Thus, the CD4+CD25high
74
BAECHER-ALLAN ET AL
regulatory cells express a number of surface antigens associated with activation, migration, and antigen presentation. Thus if the potentially regulatory cell population was to be selected without regard to the level of CD25+ expression, it would be highly heterogeneous. Thus, we used FACS to isolate highly pure, populations of cells that di¡ered in their levels of expression of CD25. CD25+ regulatory cells comprise the *1^2% of CD4+ T cells in human peripheral blood that express the highest levels of CD25 CD4+CD25high, CD4+CD25low and CD4+CD25 T cells were sorted using the gates shown (Fig. 1a) in order to address whether either population exhibited regulatory cell characteristics such as hyporesponsiveness and suppression of proliferation as described in the murine system. The CD4+CD25+ (high or low) cells, CD4+CD25 cells, or a one to one mixture (co-cultures) were stimulated by sub-maximal cross-linking of the TCR (plate-bound anti-CD3 at 0.05 mg/ml,) and monitored for proliferation by [3H]thymidine incorporation. The CD4+CD25low cells responded to TCR cross-linking with a strong proliferative response and did not suppress the proliferation of the co-cultured CD4+CD25 cells at either 5 (data not shown) or 7 days (Fig. 2). In striking contrast, the CD4+CD25high cells cultured alone did not respond to this sub-maximal TCR stimulation. Moreover, the CD4+CD25high T cells were able to strongly inhibit the proliferation of
FIG. 2. Human peripheral blood contains both CD4+CD25high regulatory cells and CD4+CD25low non-regulatory cells. The CD4+CD25low (top) and the CD4+CD25high (bottom) T cells were stimulated alone at 3103 cells/well and in co-culture with 3103 CD4+CD25 responder T cells in the presence of 3104 T cell-depleted accessory cells. The CD4+CD25 cells were also stimulated alone. The data is representative of three independent experiments, and is presented as the mean of proliferation at day 7+SEM. The stimulus used for activation was plate bound anti-CD3 at the submaximal concentration of 0.05 mg/ml. (From Baecher-Allan et al 2001, with permission.)
HUMAN REGULATORY T CELLS
75
FIG. 3. Measurement of the kinetics of CD4+CD25 suppression of proliferation mediated by CD4+CD25high cells. CD4+CD25high and CD4+CD25 cells (5103/well) were cultured alone or together at various ratios in the presence of soluble anti-CD3 (5 mg/ml) and soluble anti-CD28 (5 mg/ml) and 5104 T cell-depleted accessory cells. In the co-cultured wells, the number of CD4+CD25 responder T cells remained constant while the number of CD4+CD25high cells varied by serial threefold dilution. (a) Proliferation was determined at day 3 (squares), day 5 (diamonds) and day 7 (circles) post initiation of culture, with [3H]thymidine added during the last 16 h. (b) IFNg levels were assayed by ELISA from supernatants removed from the cultures just before [3H]thymidine addition. (From Baecher-Allan et al 2001, with permission.)
CD4+CD25 responder T cells (Fig. 2). This inhibition was highly signi¢cant as the CD4+CD25high T cells reproducibly reduced proliferation of CD4 cells by 69% at day 5 and over 98% by day 7, compared to the response of the CD4+CD25 cells cultured alone. Kinetics of CD4+CD25high T cell regulatory function A series of experiments were performed to examine both the kinetics and the degree of suppression mediated by CD4+CD25high T cells. Using soluble antiCD3/anti-CD28 stimulation, di¡erent numbers of CD4+CD25high cells (serial threefold dilutions) were co-cultured with a constant number of CD4+CD25 responder cells. Proliferation was monitored at days 3, 5 and 7 (Fig. 3a). Although there was almost no detectable proliferation on day 3, by day 5 there were barely detectable levels of proliferation which showed little inhibition. In
76
BAECHER-ALLAN ET AL
contrast, the inhibitory e¡ect of the CD4+CD25high T cells was striking by day 7. The CD4+CD25high T cells inhibited the proliferative response of the co-cultured CD4+CD25 cells in a dose-dependent manner (Fig. 3a). These data show that 93% and 80% suppression occurs at the (1:1) and at the (0.3:1) cell ratio (CD4+CD25high regulatory cells to CD4+CD25 responder cells) respectively. Although, the suppression dropped to only 31% when the cells were co-cultured at a ratio of 1:9, this is similar to what is seen upon titration of the murine CD4+CD25+ regulatory cells. The kinetics of cytokine secretion in these co-cultures was also monitored from supernatants removed just before 3H-thymidine addition. CD4+CD25high T cells stimulated with soluble anti-CD3/anti-CD28 did not secrete IFNg, IL10 or IL13, while CD4+CD25 responder cells were found to secrete only IFNg. Upon titration of the regulatory cells into the co-culture, there was a dose-dependent inhibition of IFNg secretion (Fig. 3b) which was apparent by the ¢fth day of culture and more prominent by day 7. Thus the suppression of IFNg secretion was observable well before suppression of proliferation.
CD4+CD25high cells require contact in order to regulate CD4+CD25 T cells CD4+CD25high T cells were found to exert their regulatory function on CD4+CD25 T cells in a contact-dependent manner. These studies were performed using transwell chambers to either allow the two T cell populations to be in contact in the same well or to be separated by a membrane that is permeable to soluble molecules. As can be seen in Fig. 4, if CD4+CD25high cells were stimulated in the upper chamber, there was little e¡ect on the growth of the CD4+CD25 cells in the lower chamber. In contrast, when the two populations were co-cultured in the same lower well, there was a marked inhibition of proliferation.
CD4+CD25high cells inhibit IL2 mRNA production in co-cultures We addressed whether co-culture with human CD4+CD25high cells resulted in a decrease in the levels of IL2 mRNA as has been shown in the analysis of mouse CD4+CD25+ cells (Thornton & Shevach 1998). RNA samples of anti-CD3/antiCD28 (soluble)-stimulated cultures of CD4+CD25, CD4+CD25high or cocultures, were analysed for their levels of actin and IL2 mRNA by semiquantitative RT/PCR (Baecher-Allan & Barth 1993). As shown in Fig. 5, the levels of IL2 mRNA were signi¢cantly decreased in the co-cultures even though it contained twice the amount of cDNA as in the CD4+CD25 only sample as indicated by the levels of actin product.
HUMAN REGULATORY T CELLS
77
FIG. 4. Analysing the dependence of CD4+CD25high T cell-mediated suppression on cell contact. CD4+CD25high and CD4+CD25 cells (5103/well) were stimulated in the lower chamber of a transwell plate in the absence of additional T cells, or in the presence of CD4+CD25high cells that were either stimulated in the same lower well or in the separate upper chamber of the transwell. The data represents total cpm from the cultures at day 5. (From Baecher-Allan et al 2001, with permission.)
FIG. 5. Quanti¢cation of IL2 mRNA levels in cultures of CD4+CD25 or co-cultures. SQ/ PCR analysis of mRNA isolated from CD4+CD25 (left), CD4+CD25high (middle), or co-cultures (right lane) was performed to determine the relative levels of actin (top) and IL-2 message (bottom). The actin PCR samples were analysed after 24 and 27 cycles of ampli¢cation while the IL2 PCR samples were analysed after ampli¢cation of 27 and 30 cycles. (From Baecher-Allan et al 2001, with permission.)
78
BAECHER-ALLAN ET AL
Di¡erences in the stimulation and the presence or absence of co-stimulation, greatly a¡ects the proliferation and regulation of CD4+CD25 T cell proliferation We next examined whether di¡erences in strength of signal could overcome either the suppression mediated by CD4+CD25high cells. Cultures were stimulated with two di¡erent doses of plate-bound anti-CD3 in order to compare the e¡ect of varying the quantity of the same quality of TCR signal (i.e. that delivered by plate-bound anti-CD3). TCR stimulation through plate bound anti-CD3 at 5 mg/ ml (maximal response) or 0.05 mg/ml (sub-maximal) alone (Fig. 6) did not reverse the non-responsive state of the CD4+CD25high cells. However, co-cultures stimulated with maximal plate-bound anti-CD3 exhibited only 69% inhibition, while stimulation with sub-maximal plate-bound anti-CD3 exhibited greater than 99% inhibition of proliferation. Providing either co-stimulation with CD28 crosslinking or the addition of IL2 to the maximal anti-CD3 (5 mg/ml) stimulus resulted in both CD4+CD25high proliferation (albeit at a low level) and the complete loss of regulation. Thus signalling through the TCR with a strong stimulus caused either the target cell population to become refractory to inhibition or the regulatory cell population to lose its e¡ector function. Soluble anti-CD3 stimulation resulted in both CD4+CD25high cell nonresponsiveness and 495% inhibition of co-culture proliferation similar to what was observed in cultures stimulated with sub-maximal plate-bound anti-CD3. As predicted, the addition of IL2 to soluble anti-CD3 stimulated co-cultures resulted in a loss of regulatory function. Surprisingly, however, the suppression apparent in soluble anti-CD3 stimulated co-cultures could not be reversed by providing soluble anti-CD28 co-stimulation. A second anti-CD28 mAb (3D10) was also unable to abrogate suppression in conjunction with soluble anti-CD3 stimulation demonstrating that this phenomenon was not reagent speci¢c (data not shown). It appears that the signal generated by the soluble anti-CD3 condition is so ‘weak’ that even with anti-CD28 cross-linking, suppression can still occur. CD4+CD25high T cells were also found to inhibit secretion of IFNg (Th1) and IL13 (Th2) cytokines (Fig. 7). IL10 was produced with only the strongest stimulation conditions, and often in the absence of suppression of proliferation. However, it is important to note that IL10 can be secreted by other types of regulatory T cells such as Treg1 cells as well as non-T cell populations (Groux et al 1997a, 1996). Analysis of IFNg secretion indicates that it mirrored the level of proliferation with each stimulus (Fig. 7a). In general, when the proliferation was inhibited by co-culture with the CD4+CD25high cells, the secretion of IFNg was also decreased. However, the soluble anti-CD3 alone co-culture condition was an exception since there was little decrease in IFNg secretion in light of a striking inhibition of proliferation. IL13 was only secreted by CD4+CD25 under conditions of strong TCR signalling by maximal plate-bound anti-CD3 or under conditions of weaker TCR
FIG. 6. The strength and quality of the TCR signal a¡ects the ability of the CD4+CD25high cells to suppress the proliferation of the co-cultured CD4+CD25 cells. CD4+CD25high and CD4+CD25 cells (2.5103/well) were cultured alone or together in the presence of the indicated stimuli and 2.5104 T cell depleted accessory cells. The cells were stimulated in wells that had been coated with either 5 mg/ml (maximal) or 0.05 mg/ml (submaximal) anti-CD3 mAb, or by the addition of soluble anti-CD3 at 5 mg/ml. In some cases as noted, additional stimulatory signals were provided by anti-CD28 or recombinant human IL2 at 50 U/ml. Proliferation was determined at day 6, with 3H-thymidine added for the last 16 h of culture. These stimuli have been shown to have similar e¡ects on the CD4+CD25 and CD4+CD25high populations in three multiple experiments. (From Baecher-Allan et al 2001, with permission.)
HUMAN REGULATORY T CELLS 79
80
BAECHER-ALLAN ET AL
FIG. 7. The CD4+CD25high cells do not secrete cytokine, but can suppress the secretion of IFNg and IL13 by co-cultured CD4+CD25 cells in a dose dependent manner. Culture supernatants were removed from the proliferation cultures depicted in Fig. 3 before the addition of 3H-thymidine incorporation (at day 5). Levels of (a) IFNg, (b) IL10 and (c) IL13 were determined from culture supernatants by ELISA. All data represent the mean +SEM of duplicate assays. (From Baecher-Allan et al 2001, with permission.)
HUMAN REGULATORY T CELLS
81
signals augmented with exogenous IL2 or anti-CD28 co-stimulation (Fig. 7c). In all conditions where the CD4+CD25 cells secreted IL13, the corresponding coculture resulted in a signi¢cant decrease in IL13 secretion regardless of whether there was inhibition of proliferation. Notable is the complete suppression of IL13 in co-cultures stimulated with soluble anti-CD3 + IL2 even though there was little to no inhibition of proliferation. Thus it appears that IL13 secretion may be more sensitive, than IFNg secretion or proliferation, to the e¡ects of coculture with regulatory cells under conditions of di¡erent strengths of signal. As discussed above, it was important mechanistically to further examine whether IL10 was secreted by the CD4+CD25high regulatory cells in co-culture assays, as this cytokine is inhibitory to T cell activation (Asseman et al 1999, Powrie et al 1993). No culture stimulated with soluble anti-CD3 secreted IL10 even though these cultures exhibited marked suppression (Fig. 7b). Furthermore, while IL10 was produced in the cultures of CD4+CD25 cells alone and co-cultures stimulated with plate-bound anti-CD3 supplemented with IL2 or anti-CD28, it was not secreted by stimulation of the CD4+CD25high cells (alone) under any condition. Thus, there was no correlation between suppression and the secretion of IL10. Role of CTLA4 and PD-L1 in CD4+CD25high mediated regulation We examined whether the PD-1, PD-L1 and CTLA4 receptors on CD4+CD25high T cells were important for CD4+CD25high mediated suppression of CD4+ T cells. We chose to examine the PD-1, PD-L1 and CTLA4 receptors on CD4+CD25high T cells, as their engagement is known to induce cell cycle arrest. PD-1 and its ligand, PD-L1, are induced on subsets of activated T cells and are involved in programmed cell death (Ishida et al 1992, Agata et al 1996). PD-1^PD-L1, interaction delivers a negative signal that down regulates T cell proliferation and cytokine production in the context of suboptimal TCR stimulation (Freeman et al 2000). CTLA4 is similarly expressed by activated T cells and can deliver a negative signal that results in down regulation of T cell activation (Green¢eld et al 1998). Thus, inhibitory anti-PD-L1 or anti-CTLA4 mAbs were tested to determine if they a¡ected the suppression induced by CD4+CD25high T cells (Fig. 8). When analysed directly from the blood, CD4+CD25high T cells did not express CTLA4 or PD-L1 on the cell surface (data not shown). In the mouse, CTLA4 has also been found to be constitutively expressed but in the cytoplasm of CD4+CD25+ regulatory T cells rather than on the cell surface (Read et al 2000, Takahashi et al 2000). However, due to the observed kinetics of suppression and the fact that peak levels of CTLA4, PD-1 and PD-L1 expression can be induced on T cells by 2^3 days post activation (Agata et al 1996, Green¢eld et al 1998, Vibhakar et al 1997), it was possible that these molecules could be involved in regulation by
FIG. 8. Blocking anti-CTLA4 Fab or anti-PD-L1 antibody in the inhibition of regulatory function of the CD4+CD25high cells. CD4+CD25high and CD4+CD25 cells (5103/well) were cultured alone or together at the indicated ratios in the presence of soluble anti-CD3 (5 mg/ml), soluble anti-CD28 (5 mg/ml) and 5104 T cell-depleted accessory cells. These cells were also cultured in the presence of mIgG (squares, 5 mg/ml), antiCTLA4 Fab (diamonds, at 5 mg/ml), anti-PD-L1 (circles, at 10 mg/ml), or anti-CTLA4 and anti-PD-L1 (triangles). Proliferation (a) was determined after 7 days of culture and the concentration of IFNg (b) and IL13 (c) were assayed from supernatants removed on day 6, as above. The insert graph within (a) displays the data as percent proliferation, where the mean of proliferation of co-cultures supplemented with the indicated blocking reagents was divided by the di¡erent baseline mean of proliferation of the cultures of CD4+CD25 cells only supplemented with the same antibody reagents. (From Baecher-Allan et al 2001, with permission.)
82 BAECHER-ALLAN ET AL
HUMAN REGULATORY T CELLS
83
CD4+CD25high cells. Adding anti-CTLA4 Fab mAb to CD4+CD25high/ CD4+CD25 co-cultures did not alter the levels of suppression of proliferation (Fig. 8a). Similarly, anti-CTLA4 Fab mAb had no e¡ect on IFNg secretion (Fig. 8b) while inducing a paradoxical decrease in the secretion of IL13 by CD4+CD25 T cells, as previously described (Anderson et al 2000) (Fig. 8c). Since engagement of PD-1 on the T cell surface leads to decreased proliferation (Freeman et al 2000), CD4+CD25 T cells exhibited a marked increase in proliferation upon blocking the interaction of PD-1 with PD-L1. However, as a result of adding increasing numbers of regulatory cells to the co-cultures, it can be seen that the CD4+CD25high T cells could still suppress proliferation in the presence of anti-PD-L1. Importantly, signi¢cantly more regulatory T cells were required to attain the similar percent inhibition of proliferation seen with the addition of the isotype control (Fig. 8a insert). These data suggest that PD-L1/ PD-1 interactions may mediate a small part of the inhibitory interaction. The blockade of PD-L1 enhanced the secretion of both IFNg and IL13 by responder cells only, which was subsequently, inhibited upon co-culture with CD4+CD25high regulatory T cells in a dose dependent fashion. The addition of both anti-CTLA4 and aPD-L1 together mirrored that of ‘anti-PD-L1 only’ cultures for proliferation and IFNg secretion while the levels of IL13 more closely mirrored the e¡ect of blocking CTLA4 (Fig. 8c). Discussion Here, we describe the isolation and characterization of the human counterpart to the murine CD4+CD25+ regulatory subset from human peripheral blood. These CD4+CD25high T cells were hypo-responsive to TCR engagement yet were able to totally inhibit [3H]thymidine incorporation or cytokine secretion by co-cultured CD4+ T cells. Depending upon the strength of the TCR signal, the addition of CD28 co-stimulation with stronger TCR stimuli resulted in a loss of regulation. Importantly, the di¡erent strengths and qualities of these stimuli may act to alter the e¡ector cell function or the target cell susceptibility or both. Moreover, CD4+CD25high T cells did not secrete detectable IFNg, IL13 or IL10 with any stimulation condition, but rather were able to inhibit the secretion of IFNg and IL13 by co-cultured, activated CD4+ T cells. Human CD4 regulatory function was only observed when the cells expressed high levels of CD25 and were isolated apart from the CD25low T cells. The mouse CD4+CD25+ regulatory subset is isolated from all CD25-expressing cells regardless of their level of CD25 expression (Sakaguchi et al 1995, Thornton & Shevach 1998, Itoh et al 1999). If similar criteria are followed to isolate these cells from human blood, the resulting CD25+ cells (high and low together) did not exhibit a hypo-responsive phenotype or signi¢cant suppressive function. CD4+
84
BAECHER-ALLAN ET AL
T cells expressing low levels of the IL2 receptor (CD25) strongly proliferated to sub-maximal TCR stimulation and showed no suppressive ability. Furthermore, restricting the isolation of regulatory cells to those CD4+ cells expressing high levels of CD25 increases the homogeneity of the regulatory population, expressing a number of surface antigens that are usually associated with activated T cells. Interestingly, the CD4+CD25high T cells we identi¢ed expressed high levels of both IL2 receptor a chain (CD25), and IL2 receptor b chain (CD122), making up the high a⁄nity IL2R. Thus these regulatory T cells may be poised for a quick response or alternatively, constantly turned on and performing continual low level regulatory activity. As the functional anergy and suppression by murine CD4+CD25+ regulatory cells and the CD25high subpopulation of human CD4+ cells are essentially identical, we conclude that they represent homologous populations. The mechanism of suppression mediated by CD4+CD25high cells appears to be linked to TCR signals encountered by each T cell population. Thornton and Shevach demonstrated that although murine CD4+CD25+ cells failed to proliferate after TCR stimulation alone, they could proliferate quite well if exogenous IL2 was also provided (Thornton & Shevach 1998). And yet this addition of IL2 or anti-CD28 abolished the suppression of the proliferation of the co-cultured cells. Interestingly, in the human, we found that although antiCD28 co-stimulation also inhibited suppression, we found it only did so in the context of certain TCR signals. Our data demonstrate that the addition of costimulatory signals did not abrogate regulatory function if the coincident TCR signal strength was low, thus linking the mechanism of suppression to TCR strength of signal. In contrast, the addition of IL2 to co-cultures ablated suppression in all cases regardless of the strength of the TCR stimulus. In the case of pathogen responses, either B7-1 or B7-2 expressed on the surface of activated human T cells, may provide important co-stimulation that would augment the strength of the signals and thus ablate suppression by CD4+CD25high cells (Green¢eld et al 1998, Hollsberg et al 1997). This suggests that suppression by regulatory cells during signi¢cant in£ammatory responses in vivo may be kept in check by the secretion of IL2 by antigen-responsive T cells or TCR signal strength. Thus, with time as activated T cells no longer secreted IL2, the CD4+CD25high cells may be able to exert suppression and turn o¡ the previously antigen-activated T cells. In contrast to strong, non-self, immune responses, the response to self-antigen is weak. Suppression of potentially autoreactive T cell responses is desirable in contrast to responses against foreign microbial antigens where the signals are stronger and suppression could be detrimental. We are currently determining whether the strength of the TCR signal alters the sensitivity of the responder cell to suppression or whether it inactivates the regulatory cell.
HUMAN REGULATORY T CELLS
85
The mechanism of action by which CD4+CD25+ T cells so e¡ectively inhibit proliferation of CD4 T cells remains unknown, but is independent of cytokine secretion. Although IL10 was secreted by CD4+CD25 cells, the presence or absence of IL10 did not correlate with suppression in co-cultures. To rule out the possibilities that IL10 was consumed or was in very low abundance, additional experiments demonstrated that the addition of blocking aTGFb or aIL10 antibodies had no e¡ect on the ability of CD4+CD25high cells to suppress the proliferation of co-cultured CD4+CD25 cells (data not shown). Thus, the cytokine independent suppression by CD4+CD25high cells is an important distinction as secretion of these two cytokines has been found to be integral to the function of other types of regulatory T cells (Groux et al 1997b). The mechanism of regulation by CD4+CD25+ cells may require contact with multiple molecules on the surface of the CD25high regulatory cell. Our experiments show no role for CTLA4 and a small role for PD-1 in the functional suppression by regulatory CD4+CD25high T cells. The involvement of this molecule in the mouse system is extremely controversial as two groups demonstrated exactly opposing e¡ects of blocking CTLA4 in vitro, while it appeared to have an e¡ect in the in vivo NOD autoimmunity model (Thornton & Shevach 1998, Takahashi et al 2000) (Salomon et al 2000, Read et al 2000). In contrast, blocking the interaction of PD-1 with one of its ligands, PD-L1, did reduce the level of suppression observed in these co-cultures. Somewhat expected as a result of its inhibitory e¡ect on proliferation (Freeman et al 2000), blocking PD1 engagement by anti-PD-L1 increased 3H-thymidine incorporation by target CD4 T cells. Furthermore, as signi¢cantly more regulatory CD4+CD25high T cells were required to suppress the proliferative response in the presence of anti-PD-L1, it indicates that these cells may utilize this pathway in addition to others in order to reach their main suppressive objective. Since increasing the number of regulatory cells resulted in complete suppression, there are multiple mechanisms that can be used by these cells or there are subpopulations within the CD25high population that use di¡erent single methods to suppress responses. The possibility exists that combined blockade of the two de¢ned ligands for PD-1, might have a more pronounced e¡ect (Latchman et al 2001). In summary, we report that it is the CD25high subpopulation of CD4+CD25+ T cells in the circulation of humans that exhibit practically identical in vitro characteristics to the CD4+CD25+ regulatory cells isolated in mice. With TCR cross-linking, CD4+CD25high cells did not proliferate and totally inhibited proliferation and cytokine secretion by activated CD4+CD25 responder T cells in a contact-dependent manner. Furthermore, the e¡ect of the type of TCR stimulation and the ability to abrogate only a portion of the suppression mediated by these CD4+CD25high cells via blockade of the PD-1 pathway indicates that regulation by CD4+CD25+ cells is the result of highly complex, multifactorial interactions.
86
BAECHER-ALLAN ET AL
The work by Thornton and Shevach establishing an in vitro model system that mimics the function of CD4+CD25+ T cells in in vivo models, demonstrated that although murine CD4+CD25+ cells failed to proliferate after TCR stimulation alone, they could proliferate quite well if exogenous IL2 was also provided (Thornton & Shevach 1998). And yet this addition of IL2 or anti-CD28 abolished the suppression of the proliferation of the co-cultured cells. Interestingly, in the human, we found that although anti-CD28 co-stimulation also inhibited suppression, we found it only did so in the context of certain TCR signals. As the suppression by murine CD4+CD25+ regulatory cells and the CD25high subpopulation of human CD4+ cells are essentially identical, we conclude that they represent homologous populations. Acknowledgements We would like to thank Dr Guifang Cai for technical assistance in analysing cytokine expression levels and Drs Howard Weiner and Vijay Kuchroo for critical review of the manuscript. The work was supported by the NIH grants: RO1NS2424710, PO1AI39671 and PO1NS38037 (DAH), and AI39671, AI41584 and CA84500 (GJF); and grants from the National Multiple Sclerosis Society (RG2172B6 and RG2949A) and the Juvenile Diabetes Foundation for Research (1-1989-124). References Agata Y, Kawasaki A, Nishimura H et al 1996 Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8:765^772 Anderson DE, Bieganowska KD, Bar-Or A et al 2000 Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population. Nat Med 6:211^214 Asano M, Toda M, Sakaguchi N, Sakaguchi S 1996 Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 184:387^396 Asseman C, Mauze S, Leach MW, Co¡man RL, Powrie F 1999 An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal in£ammation. J Exp Med 190:995^1004 Baecher-Allan CM, Barth RK 1993 PCR analysis of cytokine induction pro¢les associated with mouse strain variation in susceptibility to pulmonary ¢brosis. Reg Immunol 5:207^217 Baecher-Allan CM, Brown JA, Freeman GJ, Ha£er DA 2001 CD4+CD25high regulatory cells in human peripheral blood. J Immunol 167:1245^1253 Bayer AL, Baliga P, Woodward JE 1998 Transferrin receptor in T cell activation and transplantation. J Leukoc Biol 64:19^24 Freeman GJ, Long AJ, Iwai Y et al 2000 Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027^1034 Green¢eld EA, Nguyen KA, Kuchroo VK 1998 CD28/B7 costimulation: a review. Crit Rev Immunol 18:389^418
HUMAN REGULATORY T CELLS
87
Groux H, Bigler M, de Vries JE, Roncarolo MG 1996 Interleukin-10 induces a long-term antigen-speci¢c anergic state in human CD4+ T cells. J Exp Med 184:19^29 Groux H, Sornasse T, Cottrez F et al 1997a Induction of human T helper cell type 1 di¡erentiation results in loss of IFN-gamma receptor beta-chain expression. J Immunol 158:5627^5631 Groux H, O’Garra A, Bigler M et al 1997b A CD4+ T-cell subset inhibits antigen-speci¢c T-cell responses and prevents colitis. Nature 389:737^742 Hollsberg P, Scholz C, Anderson DE et al 1997 Expression of a hypoglycosylated form of CD86 (B7-2) on human T cells with altered binding properties to CD28 and CTLA-4. J Immunol 159:4799^4805 Ishida Y, Agata Y, Shibahara K, Honjo T 1992 Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11:3887^3895 Ito Y, Nieda M, Uchigata Y et al 1993 Recognition of human insulin in the context of HLADRB1*0406 products by T cells of insulin autoimmune syndrome patients and healthy donors. J Immunol 151:5770^5776 Itoh M, Takahashi T, Sakaguchi N et al 1999 Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 162:5317^5326 Kaslow HR, Guo Z, Warren DW, Wood RL, Mirche¡ AK 1998 A method to study induction of autoimmunity in vitro: co-culture of lacrimal cells and autologous immune system cells. Adv Exp Med Biol 438:583^589 Ko HS, Fu SM, Winchester RJ, Yu DT, Kunkel HG 1979 Ia determinants on stimulated human T lymphocytes. Occurrence on mitogen- and antigen-activated T cells. J Exp Med 150:246^255 Kojima A, Prehn RT 1981 Genetic susceptibility to post-thymectomy autoimmune diseases in mice. Immunogenetics 14:15^27 Latchman Y, Wood CR, Chernova T et al 2001 PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2:261^268 Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Ha£er DA 1990 T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 346:183^187 Papiernik M, de Moraes ML, Pontoux C, Vasseur F, Penit C 1998 Regulatory CD4 T cells: expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency. Int Immunol 10:371^378 Powrie F, Menon S, Co¡man RL 1993 Interleukin-4 and interleukin-10 synergize to inhibit cellmediated immunity in vivo. Eur J Immunol 23:3043^3049 Read S, Malmstrom V, Powrie F 2000 Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal in£ammation. J Exp Med 192:295^302 Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T 1985 Organ-speci¢c autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; de¢cit of a T cell subset as a possible cause of autoimmune disease. J Exp Med 161:72^87 Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M 1995 Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151^1164 Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A 1999 Two subsets of memory T lymphocytes with distinct homing potentials and e¡ector functions. Nature 401:708^712 Salomon B, Lenschow DJ, Rhee L et al 2000 B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12:431^440
88
DISCUSSION
Suri-Payer E, Amar AZ, Thornton AM, Shevach EM 1998 CD4+CD25+ T cells inhibit both the induction and e¡ector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 160:1212^1218 Takahashi T, Tagami T, Yamazaki S et al 2000 Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192:303^310 Thornton AM, Shevach EM 1998 CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188:287^296 Vibhakar R, Juan G, Traganos F, Darzynkiewicz Z, Finger LR 1997 Activation-induced expression of human programmed death-1 gene in T-lymphocytes. Exp Cell Res 232:25^28
DISCUSSION Abbas: You used the term ‘strength of signal’ somewhat operationally. When you are saying that stronger signals make cells resistant, is that because you are inducing more responder cells into the responding population and there is a limit to how you can shut o¡? Or is this because each individual cell is accumulating so many signalling intermediates that you can’t knock them down below the necessary threshold. To some extent you can distinguish those. You can do single-cell assays to look at how many are induced into the responding population and how many are reduced. This is what thymidine incorporation will not tell you. Ha£er: We have done CFSE labelling, and these data suggest that the Treg also inhibit cells entering the cell cycle. This would argue that it is not the increase in cells. Abbas: So it is not just the increase in the number of cells responding. Ha£er: Still, there could be that e¡ect. Bluestone: One part of the data that is not clear to me given the hypothesis is that your earliest experiments showed the cells were most e⁄cient when you looked at seven days instead at ¢ve, but they only worked if they were added early to the culture. Why do you only see the most dramatic e¡ect at day 7? Ha£er: We see it at day 5 but there is much more suppression at day 7. Bluestone: Since thymidine incorporation is the last 8 h of cultures, this would argue that you are working at the latest stages. Yet it is active very early, which would argue that you have now suppressed some kind of signal. The most logical thing is IL2 production. Shevach: IL2 is shut down in 12 h in the mouse. Roncarolo: The problem is that in our hands, when we look at suppression at day 7, and use activated CD25 cells as a control, they will suppress as well. This level of suppression at day 7 is not really speci¢c. If we look earlier, however, we really see the e¡ect of the regulatory cells. Bluestone: In this system, which really seems to depend on long-term culture to see the suppression, are we looking at a direct or indirect e¡ect? IL2 production
HUMAN REGULATORY T CELLS
89
should have been turned o¡ very rapidly by these things, and I would have imagined that day 5 would have been equally potent to day 7. Ha£er: We see very good suppression on day 5. It still goes down about 80%. It is just that it goes down to 0 at day 7. Also we see very early turn-o¡ of IL2 mRNA transcription in the e¡ector cells when we look using PCR. I wouldn’t say that we don’t get suppression on day 5; I think we get good suppression on day 5, it just seems to go further. Perhaps the last bit of suppression seen between days 5 and 7 is IL2 consumption. If we go to day 7 with e¡ector cells stimulating CD25low cells, we haven’t seen suppression on day 7. Bluestone: We don’t have to go back too many years ago to the work on ConA suppressors. There was always this IL2 consumption caveat. In these in vitro assays we will do well not to forget history here and make sure we do the experiments in a way in which we can rule out relatively trivial artefactual mechanisms by which these things are working in vitro. Ha£er: What we are trying to do is recreate a model in vitro which re£ects what is happening in vivo. What happens in the mouse system? Shevach: Every one is dead after 72 h. Suppression is fairly rapid, and is ¢rst manifest as a cell cycle arrest for 24^48 h. The G1^S arrest is then followed by cell death; we recover very few viable cells after 72 h of culture. Abbas: Has the IL2 consumption issue been laid to rest? Shevach: In my mind it has, because we don’t see mRNA for IL2 in co-cultures. Roncarolo: We did an experiment in which we transduced CD25 cells with CD25. We got an extremely high level of expression. Even if you have an extremely high level of CD25, they don’t acquire suppressor activity. At least by the expression of the CD25, which can be related to the IL2 consumption, it doesn’t seem to induce suppression. Shevach: We use that control in every experiment. Von Herrath: Is there no di¡erence between the IL2 receptor as expressed on activated CD25+ cells compared with the lineage-derived CD25+ cells that we get out? As far as we can tell, are these IL2 receptors the same? Abbas: You can look at the biological response to IL2 to see whether they respond the same. Shevach: The CD25+ cells don’t respond to IL2. That is the problem. They are much harder to activate. It requires ¢ve to 10 times more IL2 to trigger proliferation of CD25+ T cells than that needed to trigger a similar response of CD25 T cells to a ¢xed concentration of anti-CD3. Mitchison: What about survival as distinct from proliferation? Do the CD25+ cells need IL2 to survive? Shevach: They die quickly without it. Ha£er: They don’t grow well, even with it. Sakaguchi: In vivo they require IL2 for their survival, in our hands.
90
DISCUSSION
Wauben: I would like to go back to your comments on the MHC class II expression on human regulatory T cells. The rat is an excellent model to study MHC class II expression on these cells, since activated rat T cells do express, like human T cells, MHC class II. If we isolate CD25+ T cells from the rat thymus, and then isolate the high CD25+ expressing cells, we ¢nd high expression of MHC class II on these cells. These cells are the best suppressors in our hands. We use the rat T cell clones that are speci¢c for an HSP peptide or MBP peptide as a readout system for antigen-speci¢c suppression. Furthermore, we ¢nd that suppression is dependent on the antigen concentration used in this assay. If you use an optimal concentration of HSP or MBP peptide, it is very hard to down-regulate the response. So we suggest that there are multiple levels of regulation and that the multiple levels of regulation we have described for T cell^T cell presentation (Taams et al 1999) also count for CD25+ T cell-induced regulation. Ha£er: Might it be possible that what we have seen in humans, in terms of regulation by these cells, might be because they are a type of Treg, and that is why they are doing it? Wauben: I’ll address this in my paper. In the co-culture work, did you titrate the antigen concentration to see whether a low or high amount of stimulus present gives a di¡erence in the suppression e¡ect? Ha£er: Yes, we have, but we haven’t yet done mixing experiments. Abbas: To my knowledge virtually all the knowledge on human T cells presenting antigen is based on peptides. I don’t know of a native foreign globular protein antigen being processed and displayed by a T cell in association with class II MHC. Ha£er: What about GP120, published in Nature a number of years ago (Kwong et al 1998)? Abbas: It may be true, but it is a little dangerous to extend this story to the whole world of possible antigens. Wauben: That isn’t necessary. Perhaps we are looking for a particular antigen that is expressed at the site of infection. If you think, for example, the HSPs that are up-regulated, it could be possible that these are presented in the context of MHC class II. Ha£er: When you have in£ammation in an organ and there is tissue breakdown, there are peptides. No matter how much we purify MBP, there are always enough breakdown products just from serum enzymes which degrade the protein to peptides. Mitchison: How about suppressing CD8+ cells? Ha£er: They can do it in mice. Roncarolo: If you restimulate your e¡ector cells after they have been suppressed, they become anergic. There are two independent groups in Germany who claim that when CD25 cells are primed with CD25+ cells, they become IL10 producing
HUMAN REGULATORY T CELLS
91
or TGFb producing (they disagree on the cytokines). They become regulatory cells. When I read those papers, I thought that some of the in vivo e¡ect we see might be related to the fact that the CD25+ cells are the ¢rst step towards IL10 or TGFb producing Treg cells. Ha£er: We have not been able to measure secreted TGFb from the regulatory cells. We have not done those other experiments. Roncarolo: Have you seen them in the e¡ectors? Ha£er: They are not in the culture. Abbas: What you are saying is that the regulatory cells act on the e¡ectors and turn the e¡ectors into TGFb-producing cells. Is that correct? Roncarolo: They say that when they take the human CD25+ cells and suppress the na|« ve cells, and take the CD25 cells and put them in a suppressor assay, they become Treg1 cells. They produce IL10 and TGFb, but the two groups disagree on which cytokines are important for the suppression of these cells. They both come to the conclusion that they generate Treg1 cells. There is speculation that this is how it works in vivo. Powrie: We published that CD45RBlow cells can inhibit IL10 knockout CD45RBhigh cells. Under these circumstances, the progeny of the RBhigh population do not have to secrete IL10 to be suppressed. Shevach: We have tried hard to do this experiment in the mouse but we can’t recover viable cells from the in vitro cultures. References Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA 1998 Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648^659 Taams LS, van Eden W, Wauben MH 1999 Dose-dependent induction of distinct anergic phenotypes: multiple levels of T cell anergy. J Immunol 162:1974^1981
Control of immune pathology by regulatory T cells Fiona Powrie, Simon Read*, Christian Mottet, Holm Uhlig and Kevin Maloy Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford, OX1 3RE, UK and *Department of Biochemistry and Molecular Biology, University of Melbourne, Melbourne 3010, Australia
Abstract. CD4+CD25+ Treg cells inhibit colitis in the severe combined immune de¢cient (SCID) T cell adoptive transfer model. Cells with this function are present in the thymus suggesting that Treg cells capable of inhibiting bacteria-induced immune pathology are similar to those that inhibit organ-speci¢c autoimmunity. CD4+CD25+ Treg cells inhibit both T cell-dependent and T cell-independent intestinal in£ammation. The latter point illustrates that in addition to direct e¡ects on other T cells, Treg cells can also prevent immune pathology in vivo by inhibiting the actions of innate immune cells. Treg cells suppress intestinal in£ammation through mechanisms that involve interleukin 10 and transforming growth factor b and blockade of the negative regulator of T cell activation CTLA4 abrogates Treg cell function in vivo. Importantly adoptive transfer of CD4+CD25+ Treg cells to mice with established colitis reverses in£ammation and restores normal intestinal architecture suggesting that CD4+CD25+ Treg cells may be utilized for cellular therapy of in£ammatory diseases. 2003 Generation and e¡ector functions of regulatory lymphocytes. Wiley, Chichester (Novartis Foundation Symposium 252) p 92^105
The same immune e¡ector mechanisms that have evolved to protect the host from infectious agents can also induce immune pathology. This immunological balancing act is a feature of immune regulation in the intestine where there is a need to mount protective immunity towards pathogens whilst not activating damaging in£ammatory responses towards harmless commensal bacteria. An intact immune system is key to normal intestinal homeostasis, as mice with a variety of immunological defects, particularly those a¡ecting T cells, develop an in£ammatory bowel disease (IBD)-like syndrome (Powrie 1995, Blumberg et al 1999). Evidence emerging from these studies suggests that a breakdown in tolerance to resident bacteria can lead to the development of a chronic in£ammatory response in the intestine. Whilst numerous mechanisms may contribute to immune regulation in the intestine, our own work highlights an important role for CD4+ regulatory T cells (Treg) in this process. 92
IMMUNE PATHOLOGY
93
Suppression of colitis by CD4+CD25+ Treg: role of immune-suppressive cytokines and CTLA4 Transfer of CD4+CD45RBhigh T cells to immune de¢cient recipients leads to the development of a wasting disease and colitis 6^8 weeks after T cell transfer (Powrie et al 1993, Morrissey et al 1993). Immune pathology in the intestine resembles that seen in IBD in humans and includes epithelial cell hyperplasia, goblet cell depletion and transmural in£ammation. Colitis is associated with a Th1 response in the intestine and treatment with anti-interferon (IFN)g, anti-tumour necrosis factor (TNF)a or anti-interleukin (IL)12p40 monoclonal antibodies (mAbs) inhibits disease (Singh et al 2001). The dysregulated Th1 response is driven by resident bacteria as colitis fails to develop in T cell-restored immunede¢cient recipients raised under germ-free conditions (Singh et al 2001, Aranda et al 1997). Development of colitis induced by transfer of CD4+CD45RBhigh T cells can be inhibited by co-transfer of the CD4+CD45RBlow population, indicating that cells within the antigen-experienced T cell pool in normal mice can control pathologic T cell responses. Treg cell function enriches within the CD25+ subset of peripheral CD4+CD45RBlow cells as well as CD4+ thymocytes (Singh et al 2001, Read et al 2000). This population, originally identi¢ed by Sakaguchi et al (1995), has been found to suppress a number of T cell-mediated responses, including autoimmune disease, allograft rejection, anti-tumour immunity and T cell activation in vitro (Maloy & Powrie 2001, Shevach 2000). However control of intestinal in£ammation is not restricted to CD4+CD25+ cells as CD4+CD25 T cells also prevent colitis, albeit with reduced potency (Read et al 2000). Regulatory activity amongst CD4+CD25 cells has been noted in other experimental systems (Stephens & Mason 2000, Curotto de Lafaille & Lafaille 2002) and further work is required to establish the relationship between these phenotypically distinct subsets. The precise mechanisms by which Treg cells regulate immune responses are poorly understood (Maloy & Powrie 2001, Shevach 2000). In vitro studies have demonstrated that they inhibit the activation of other T cells either directly, via cognate cell contact-dependent mechanisms, or, indirectly via inhibition of antigen presenting cell (APC) function. With regard to control of intestinal in£ammation there is clear evidence that the immune suppressive cytokines IL10 and TGFb play a role as administration of anti-TGFb (Powrie et al 1996) or antiIL10R mAb (Asseman et al 1999) abrogates the ability of CD4+CD45RBlow cells to inhibit colitis. Furthermore, CD4+CD45RBlow cells from IL10/ mice fail to inhibit intestinal in£ammation and when transferred alone to immune de¢cient recipients induce colitis (Asseman et al 1999). These studies suggest that IL10 synthesis by cells contained within the CD4+CD45RBlow population is crucial for their immune suppressive function.
94
POWRIE ET AL
It is now apparent that T cells can express a number of receptors that upon ligand binding inhibit T cell activation. One such example is CTLA4, a member of the CD28 family that also binds to CD80 and CD86. CTLA4/ mice develop a fatal lymphoproliferative disorder demonstrating that CTLA4 plays a non-redundant role in immune regulation (Salomon & Bluestone 2001). Strikingly, expression of CTLA4 amongst peripheral CD4+ T cells is restricted primarily to CD25+ cells (Read et al 2000, Salomon & Bluestone 2001, Takahashi et al 2000). CTLA4 may contribute to Treg function as treatment with anti-CTLA4 antibody abrogates the ability of CD4+CD25+ cells to inhibit colitis (Read et al 2000). Precisely how antiCTLA4 antibody works to a¡ect Treg cell function in vivo is not known. One possibility is that it acts to cross-link CTLA4, sending an agonistic inhibitory signal to Treg cells. However, this is di⁄cult to reconcile with the fact that antiCTLA4 Fab1 fragments also abrogate Treg function in vivo (R. Greenwald, S. Read, F. Powrie and A. Sharpe, unpublished data). CTLA4 expression is not restricted to Treg cells, it is also present on e¡ector T cells making it possible that anti-CTLA4 acts to enhance the development or function of Th1 e¡ector cells that mediate intestinal in£ammation. However, blockade of CTLA4 does not alter the kinetics of wasting disease or increase the incidence or severity of colitis in CD4+CD45RBhigh restored mice (Read et al 2000). Takahashi et al reported that inhibition of T cell activation in vitro by CD4+CD25+ cells could be blocked by inclusion of anti-CTLA4 Fab molecules even under circumstances in which CTLA4 was present only on the Treg population (Takahashi et al 2000). These results, together with our own, favour the view that blockade of CTLA4 on Treg cells leads to loss of suppressor activity. If CTLA4 is involved in the function of CD4+CD25+ Treg cells then how is it working? One possibility is that signalling via CTLA4 alters the threshold of T cell receptor (TCR) signalling to favour the survival or enhance the activation of the suppressor function of Treg cells. Further understanding of this awaits identi¢cation of the molecular mechanism(s) by which these cells inhibit T cell activation. However, a signal through CTLA4 does not seem to be essential for the function of CD4+CD25+ Treg cells in vivo as CD4+CD25+ cells from CTLA4/ mice still inhibit colitis (R. Greenwald, S. Read, F. Powrie and A. Sharpe, unpublished data). This may re£ect alterations in the selection of Treg cells in the thymus in the absence of CTLA4 or the use of alternative negative regulatory molecules. Suppression of the innate immune response by CD4+CD25+ Treg cells Colitis in T cell-restored immune de¢cient mice is characterized by an accumulation of CD4+ T cells and dendritic cells (DCs) in the mesenteric lymph nodes (MLNs) and colon of a¡ected mice (Malmstrom et al 2001). 20^30% of DCs
IMMUNE PATHOLOGY
95
in the MLN appear to be activated and express CD134L. Binding of CD134L to its receptor CD134 provides co-stimulatory signals to activated T cells (Gramaglia et al 1998). CD134L expression by DCs in the MLNs may be involved in the perpetuation of intestinal in£ammation as administration of an anti-CD134L mAb, known to block CD134^CD134L binding, prevents the accumulation of activated DCs and inhibits development of colitis (Malmstrom et al 2001). Similarly, transfer of CD4+CD25+ Treg cells also prevents the accumulation of activated DCs in immune de¢cient mice transfused with CD4+CD45RBhigh T cells. Indeed there are similar numbers of CD134L+ DCs in the MLNs of SCID mice given a mixture of potentially pathogenic and regulatory T cells as found in unmanipulated SCID mice (Malmstrom et al 2001). These results suggest that, like administration of anti-CD134L, Treg cells act to impede the ability of DCs to induce a sustained T cell response. To determine whether CD4+CD25+ Treg cells can mediate e¡ects on the innate immune system directly, we established a T cell-independent model of intestinal in£ammation using Helicobacter hepaticus infection. H. hepaticus, is a Gramnegative spiral bacterium that colonizes the intestinal crypts of the caecum and colon, establishing a life-long infection (Fox et al 1994). Infection of immunode¢cient 129 SvEv RAG/ mice with H. hepaticus leads to intestinal in£ammation in the colon and the caecum (Maloy et al 2003). This is accompanied by accumulation of macrophages, neutrophils, DCs and NK cells both locally in the intestine and in the spleen. Pathology is the consequence of dysregulated in£ammatory response towards H. hepaticus as treatment with antiTNF or anti-IL12p40 prevents disease development. Importantly, transfusion of 129 SvEv RAG/ mice with CD4+CD25+ Treg cells prior to H. hepaticus infection prevents immune pathology in the intestine. The protective e¡ect of Treg cells is not a consequence of reduced colonisation levels of the bacteria as Treg cell transfer had no measurable e¡ect on H. hepaticus DNA levels in the caecum or colon. Similar to suppression of T cell-mediated intestinal in£ammation treatment with anti-IL10R or anti-TGFb inhibits the immunosuppressive function of Treg cells. Furthermore, CD4+CD25+ Treg cells from IL10/ mice failed to inhibit colitis, suggesting that IL10 production by Treg cells themselves is required. The protective CD4+CD25+ Treg cells were isolated from mice free from H. hepaticus infection indicating that Treg cells can suppress immune pathology triggered by organisms to which they have not been exposed. Whether they do this through recognition of self-peptides or peptides derived from foreign antigens or both is not known. These studies provide the ¢rst evidence that CD4+CD25+ Treg cells inhibit immune pathology mediated by cells of the innate immune system. Whilst Treg cells have been shown to mediate direct e¡ects on T cells in vitro, the ¢nding that Treg cells negatively regulate the chronic activation of innate immune cells suggests
96
POWRIE ET AL
the activities of Treg cells in vivo are likely to be complex, involving e¡ects on multiple cell types. The requirement for Treg cells to have to control activation of the innate immune system to inhibit intestinal in£ammation may explain the obligate roles of IL10 and TGFb in this process. Treg cell-mediated suppression of T cell activation in vitro is less dependent on immunosuppressive cytokines, as is inhibition of organ-speci¢c autoimmune diseases (Maloy & Powrie 2001, Shevach 2000). It may be that the e¡ector mechanisms utilised by Treg cells to control immune pathology are dictated by the nature of the in£ammatory response that is regulated. It is highly likely that Treg activity is not an all or nothing phenomenon but that Treg cells act to quantitatively regulate both innate and adaptive immune responses to allow protective immunity to proceed without harmful immune pathology. As a consequence of this delicate balancing act, Treg cells may in some circumstances impede protective immunity towards pathogens. Indeed, CD4+CD25+ Treg cells were found to suppress protective immunity towards Pneumocystis carinii in T cell restored immunode¢cient mice (Hori et al 2002). Cure of colitis by CD4+CD25+ Treg cells The wide-ranging immunosuppressive properties of CD4+CD25+ Treg cells highlights their potential use as therapeutic agents for in£ammatory and autoimmune diseases. However, to be of practical use in the clinic, Treg cells must be able to inhibit ongoing T cell responses and reverse established pathology. To assess this, immunode¢cient mice that had received CD4+CD45RBhigh cells and developed colitis were given a single transfusion of Treg cells. Treated mice typically started to recover with weight gain from 2 weeks after Treg cell transfer. By 10 weeks the histological colonic abnormalities were almost completely resolved with normalization of the epithelial cell hyperplasia and reduction of the in£ammatory in¢ltrate (Mottet et al 2003). After transfer into colitic mice Treg cells were found to proliferate in the MLNs and colon, where they inhibited the proliferation of pathogenic CD4+ T cells. These data suggest that Treg cells may act in both secondary lymphoid tissue and locally at e¡ector sites to resolve in£ammation. Concluding remarks There is now overwhelming evidence that regulatory T cells suppress a variety of pathological e¡ector immune responses. Their ability to reverse established in£ammation makes them attractive candidates as therapeutic agents. Enhancement of their function may inhibit IBD and autoimmune disease whereas their removal may enhance anti-tumour immunity and host resistance to
IMMUNE PATHOLOGY
97
infectious diseases. Whilst there are still many questions outstanding regarding the origin and function of regulatory T cells, their potential therapeutic utility should make e¡orts to further characterize these cells worthwhile. Acknowledgements S. Read, K. Maloy and F. Powrie are funded by the Wellcome Trust and H. Uhlig by EU grant QLRT-CT-1999-00050. C. Mottet is funded by The Swiss National Science Foundation and the Roche Research Foundation.
References Aranda R, Sydora BC, McAllister PL et al 1997 Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients. J Immunol 158:3464^4373 Asseman C, Mauze S, Leach MW, Co¡man RL, Powrie F 1999 An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal in£ammation. J Exp Med 190:995^1004 Blumberg RS, Saubermann LJ, Strober W 1999 Animal models of mucosal in£ammation and their relation to human in£ammatory bowel disease. Curr Opin Immunol 11:648^656 Curotto de Lafaille MA, Lafaille JJ 2002 CD4+ regulatory T cells in autoimmunity and allergy. Curr Opin Immunol 14:771^778 Fox JG, Dewhirst FE, Tully JG et al 1994 Helicobacter hepaticus sp. nov., a microaerophilic bacterium isolated from livers and intestinal mucosal scrapings from mice. J Clin Microbiol 32:1238^1245 Gramaglia I, Weinberg AD, Lemon M, Croft M 1998 Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 161:6510^6517 Hori S, Carvalho TL, Demengeot J 2002 CD25+CD4+ regulatory T cells suppress CD4+ T cellmediated pulmonary hyperin£ammation driven by Pneumocystis carinii in immunode¢cient mice. Eur J Immunol 32:1282^1291 Malmstrom V, Shipton D, Singh B et al 2001 CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice. J Immunol 166:6972^6981 Maloy KJ, Powrie F 2001 Regulatory T cells in the control of immune pathology. Nat Immunol 2:816^822 Maloy KJ, Salaun L, Cahill R, Dougan G, Saunders NJ, Powrie F 2003 CD4+CD25+ TR cells supress innate immune pathology through cytokine-dependent mechanisms. J Exp Med 197:111^119 Morrissey PJ, Charrier K, Braddy S, Liggitt D, Watson JD 1993 CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunode¢cient mice. Disease development is prevented by cotransfer of puri¢ed CD4+ T cells. J Exp Med 178:237^244 Mottet C, Uhlig HH, Powrie F 2003 Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol 170:3939^3943 Powrie F 1995 T cells in in£ammatory bowel disease: protective and pathogenic roles. Immunity 3:171^174 Powrie F, Leach MW, Mauze S, Caddle LB, Co¡man RL 1993 Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal in£ammation in C. B-17 scid mice. Int Immunol 5:1461^1471
98
DISCUSSION
Powrie F, Carlino J, Leach MW, Mauze S, Co¡man RL 1996 A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RBlow CD4+ T cells. J Exp Med 183:2669^2674 Read S, Malmstrom V, Powrie F 2000 Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal in£ammation. J Exp Med 192:295^302 Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M 1995 Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151^1164 Salomon B, Bluestone JA 2001 Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 19:225^252 Shevach EM 2000 Regulatory T cells in autoimmmunity. Annu Rev Immunol 18:423^449 Singh B, Read S, Asseman C et al 2001 Control of intestinal in£ammation by regulatory T cells. Immunol Rev 182:190^200 Stephens LA, Mason D 2000 CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and CD25 subpopulations. J Immunol 165:3105^3110 Takahashi T, Tagami T, Yamazaki S et al 2000 Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192:303^310
DISCUSSION Bluestone: An important question is whether or not CTLA4 function is ligand dependent. As you know, the CTLA4 knockout dies. B7-1 and B7-2 knockout mice do not die, and the double knockout that you used does not die. The argument is that this is because of CD28 problems. When Arlene treats the triple knockout with anti-CD28, they die because now you have activation of T cells but no CTLA4 to turn them down. If this is true, then whywhen B7-1 and B7-2 knockout mice are treated with anti-CD28don’t they die? There is nothing to oppose CTLA4 in a double knockout unless there is another ligand out there. With that asidebecause a lot of the data can’t be explained if there is another ligand out therethe only way this can make sense is if CTLA4 functions in a ligand-independent manner by associating with the TCR complex. The reason the antibody keeps showing us this blocking is because we are disrupting this ligand-independent function of CTLA4. When we do these experiments in fully B7-de¢cient settings we will get the exact same results, that anti-CTLA4 will work. It is not telling us necessarily what we think it is. Powrie: There is a problem there in that if one would transfer CD45RBhigh cells into a B7-de¢cient recipient we probably won’t get any disease. Bluestone: If you use pre-activated cells you probably will. Powrie: Do you think that scenario is likely with a Fab in vivo?
IMMUNE PATHOLOGY
99
Bluestone: When this antibody, even in a F(ab0 )2 fragment, is bound to CTLA4, it has this ability to internalize so rapidly that it seems to internalize everything o¡ the cell surface very rapidly when anti-CTLA4 antibody is bound to it. I don’t quite understand the biochemistry here. But I think the Fabs may do exactly the same thing. Powrie: Another possibility, given Jim Allison’s ¢ndings that CTLA4 regulates the high avidity cells, is that there maybe di¡erential roles for CTLA4 in particular T cell subsets. In the T cell transfer model of colitis it may be that the CD45RBhigh cells are lower avidity (because the higher avidity bacteria-reactive cells are in the memory pool) and that these are not so in£uenced by CTLA4 in this particular cell transfer system. In contrast, the CD25+cells are targeted by anti-CTLA4. I think our data do indicate that in this particular situation antibody does perturb the function of the regulatory cell, as opposed to the pathogenic e¡ector cells. Shevach: I’d like to return to the issue of putting the regulatory cells in late and seeing them work. This may depend on the disease one is looking at. In the model of gastritis we and others work on, we see a loss of gastric parietal cells and an inability to generate new ones. When they go, they cannot be regenerated because part of the pathology is a developmental arrest in gastric mucosa. Regulatory cells will never bring this back. Powrie: A feature of the gut is that it is very regenerative and this is important in clinical settings. In the case of gastritis, perhaps you may be able to combine Treg cells with some stem cell therapy, like in the pancreatic model where cytokines are given that enhance b cell regeneration. Harrison: This does work in the NOD mouse: if you induce regulatory cells up to 10^12 weeks of age the mice have a lower incidence of diabetes. This doesn’t, however, address the question of target tissue regeneration. It would be interesting if the immune system itself, i.e. regulatory T cells, had a role in this! Powrie: It depends on what you are trying to reverse. Harrison: Why do your CD45RBhigh cells go to the gut and cause colitis? Powrie: I think that this is the major antigenic drive in these colonies of very clean mice. They still have an enormous load of commensal bacteria that are a source of stimulation to the innate immune system. When you transfer na|« ve cells into an immunode¢cient mouse, the major drive will come from the commensal £ora. If we look at systems where we tip the balance of immune homeostasis, what the animals develop is in£ammatory bowel disease. There are 40 or 50 models of in£ammatory bowel disease based on manipulating immune molecules or cells. Harrison: But they only get in£ammation in that mucosal site, presumably because of some particular microbial population. Powrie: They do get other in£ammatory lesions, such as lung in£ammation, myocarditis and gastritis. There is a multi-organ pathology. We have studied colitis because it is by far the most severe and frequent.
100
DISCUSSION
Harrison: When you said that the germ-free mice don’t get this disease because they don’t have bacteria, they also don’t have a normal intestine, either. They don’t develop normal mucosal immune function. Is this because of the lack of bacteria? Powrie: Certainly, when they are colonised with bacteria they develop colitis. Harrison: If we induce or inject any of our regulatory cells in the NOD mouse, they always seem to go to the site that we want them to go tothe site of in£ammation. When we have looked at other locations such as salivary glands and other organs, it does seem to be relatively speci¢c for the pancreatic lymph node and the islets. Does anyone know whether these regulatory cells might recognize some product of an in£amed cell, such as heat shock proteins? Powrie: This is an interesting possibility. Alternatives include particular homing receptors. Bach: I’d like to come back to the question of homeostasis that I raised early. Your studies and others are done in lymphopaenic mice. There has been a suggestion that this lymphopaenia can stimulate T cell proliferation and activation through a homeostasis mechanism, and which could lead to proliferation and activation of pathogenic T cells, such as the CD44RBhigh cells. Then the CD44RBlow cells would compensate for this. What are your views on this? Have you any experimental models where you have created less lymphopaenia by adding more CD44RBhigh cells or complementing with other cell types? Powrie: That is not something we have done. Presumably, what you are asking is whether the disease is induced by a homeostatic proliferation of CD45RBhigh cells. Bach: Is there any contribution by the homeostatic mechanism to the exacerbation of pathogenic cells in the lymphopaenic mice. Powrie: There could be. To my mind, it hasn’t been proven how much the £ora in£uences homeostatic proliferation. Do we know, for example, whether homeostatic proliferation occurs in germ-free mice? In immunode¢cient mice in the absence of T cells we can ¢nd evidence of activated DCs that we don’t ¢nd in germ-free mice. The frequency of OX40L+ DCs in the mesenteric lymph nodes of an immunode¢cient mouse is higher than in a normal mouse. I think this activation of the innate immune system may drive the pathogenicity that we see upon transfer of low numbers of CD45RBhigh cells and that this is quantitatively regulated by the CD25+ population. How this relates to homeostatic proliferation is not clear. Shevach: This is a very complicated issue because several things are going on at once. In our hands, CD25+ cells do not control the ¢rst 21 d of the lymphopaeniainduced proliferation seen when CD25 cells are injected into SCID or RAG/ mice. Beyond 21 days, the mice develop autoimmune disease and we therefore have antigen-driven proliferation. Where it has been shown that CD25+ cells control what has been called homeostatic proliferation, it has usually been done
IMMUNE PATHOLOGY
101
between three and six months after transfer, and lots of things have taken place in that mouse, including the development of colitis. Proliferation is antigen driven at this point. Powrie: There is very good evidence that development of colitis is antigen driven and depends on resident bacteria. The role of homeostatic proliferation is not really clear. Harrison: Not necessarily. Bach: Incidentally, in the NOD mouse the regulatory cells are present in the initial weeks of life under SPF conditions. However, can bacteria dampen the immune response in these mice? Harrison: Many of the patients we see with autoimmune disease are lymphopaenic, and many of them have a reduced autologous or syngeneic mixed lymphocyte reaction (SMLR). Have you seen a connection between those two phenomena and a lack of suppressor cells? There used to be a relationship. Shevach: You should see the opposite: an elevated SMLR. Shimon Sakaguchi has shown this in the absence of regulatory cells. The old observation doesn’t make sense. Harrison: If regulatory cells are seeing self peptide on class II MHC, you would expect the SMLR to be low in autoimmune disease. Shevach: Regulatory cells don’t proliferate. Harrison: That is why there is lymphopaenia! Mitchison: Fiona Powrie, can you tell us some more about the TGFb-secreting cells? They are present in the CD45RBlow population. But then they are lost from sight. Do those cells end up in the CD45RBhigh or RBlow population? Powrie: All we can say is that if we transfer CD25+ cells and administer an antiTGFb antibody, this abrogates the ability of the CD25+ cells to suppress. We don’t have compelling data that CD25+ cells themselves or their progeny in vivo produce the TGFb. We are doing the various knockouts and chimeras to be able to address this question. Warren Strober has published data that CD25+cells suppress in vitro as a consequence of membrane bound TGFb, but we have not looked at this ourselves. Mitchison: The indication is that there are two populations of cells, one making TGFb and the other making IL10. Powrie: I don’t think we can say this without single-cell analyses. These two cytokines may mediate the immune regulatory activity of these cells in di¡erent ways. Mowat: When you transfer in the regulatory cells, how quickly do the mice start getting better? They must be losing weight still at that point. Powrie: Two weeks after transfer mice look better and start to gain weight. Mowat: The colonic crypts appear to be quite long still. Does all the pathology go away?
102
DISCUSSION
Powrie: It is not completely normal: there is still some hyperplasia, but it is greatly reduced. Mowat: Is there still in¢ltrate there? Powrie: It is substantially diminished. Von Herrath: In the Helicobacter system the regulatory cells depend on IL10. Is this similar to the controls that Ethan Shevach has done? Can you generate them a priori from the CD25 population? Ethan couldn’t. Powrie: CD25CD45RBlow cells do not inhibit T-cell dependent H. hepaticusinduced in£ammation, at least at the cell doses we have tested. Von Herrath: What happens if you take CD25 cells, activate them to make them positive, and then transfer them? Powrie: We haven’t done this in H. hepaticus infection. We have done this in the cure of colitis, and these cells don’t work. Asseman: You said that CD25+ cells are able to abrogate T cell-independent colitis, and this is dependent on IL10. Is the pathology identical in this T cell independent model? Powrie: In£ammation is less severe in the absence of T cells. Shevach: In that model are the CD25+ cells being triggered through their TCR? Powrie: We can take them from mice that have not been infected with Helicobacter. This suggests that it is not a classic memory cell response to Helicobacter. Shevach: We can cure all kinds of things with normal CD25+ T cells, so that doesn’t count. Powrie: I don’t know what they are responding to. No one does. Shevach: But in this model do you think that the cells are being triggered through their TCRs? Powrie: Yes. I would ¢nd it di⁄cult to see how they are working otherwise. How would you test this in vivo? Abbas: You commented on the IBD model and the therapy aspects. If it is going to be quite this non-speci¢csome antigen is going to trigger CD25+ cells and they can inhibit some or all responsesthen the likelihood of using these cells for cell therapy is pretty slim. Powrie: I don’t think it is an all-or-nothing situation. I think Treg cells go to an in£ammatory site and accumulate there. Whether they inhibit the response will depend on the level of stimulation of the innate immune response. For example, we can induce intestinal in£ammation with anti-CD40 and this cannot be inhibited by CD25+ cells. Bluestone: There are two parts to this. They go to special places, but also for their longevity they need to continue to recognize and be stimulated by antigens. The therapeutic opportunity here is probably one in which where you are not looking
IMMUNE PATHOLOGY
103
(like you are in these models) for a turnaround in a couple of days, but to encourage those cells at the sites to expand, or to get them to the sites and let them do their own expanding. Thus a year later they will still be doing their job and not nonspeci¢cally. Abbas: But wouldn’t you think a site of infection is a ‘special place’? Powrie: I would predict that they would accumulate at a sight of infection. There are data to support this. Ha£er: In human autoimmune disease to begin with there will be basic defects of dysregulation. We don’t know what these are. If you can induce these cells, all you may be doing is bringing them back to a homeostatic status. I wouldn’t look at this in the way that a mouse immunologist looks at a knockout that is there or not there. Instead, I would think in terms of subtle defects that need to be corrected in some way. Mowat: You don’t even need to look at it in terms of therapy. The gut is dealing with this all the time physiologically. In fact, most of the antigens you meet through your gut you are tolerant to. There are probably regulatory cells against commensal £ora and food antigens. Yet we make protective immune responses against things such as Salmonella and invasive antigens. We are doing this all the time physiologically. Powrie: Perhaps the CD25+ cells modulate that, and if you took them out you would make more of a response against Salmonella. In some ways this could be deleterious. What they do is attenuate the overall response to prevent immune pathology in a quantitative way while allowing protective immunity when you have strong innate immune cell activation as with a pathogenic bacterium. Mitchison: So far as tolerance in the gut is concerned, the TGFb-secreting population is just as good a candidate as the CD25+ cell population. That puts Th3 and Treg cells on an equal footing. Powrie: Clearly Treg1 cells can do similar things to CD25+ cells with regard to regulation of this in£ammatory bowel disease model. They are not the only cell type involved in immune regulation. Something like the gut that is exposed to a strong proin£ammatory stimulus may bene¢t from a variety of di¡erent immune mechanisms, not least of all being IgA, which is not in this system at all. TGFb may also be linked with CD25+ cells, so that if one drew Venn diagrams there would be some overlap in e¡ector functions. Bach: What are Th3 cells? If we propose that TGFb may be used by CD25+ cells, what is the basis for the de¢nition of Th3 cells? Powrie: They are based on clones. These are cells that have been grown out from mice that have undergone speci¢c immunization protocols. Bach: What are the properties of these clones? Ha£er: They are cloned out of gut tissue. They secrete TGFb and IL4. They are antigen-speci¢c. It is not clear, though, whether or not we are dealing with a very
104
DISCUSSION
mixed subset with these Treg. I wouldn’t be surprised if one subset of the Th3 cells might be Treg cells, depending on how we de¢ne them. Bach: What do you precisely mean by Treg? Powrie: I mean a population of CD4+CD45RBlow cells capable of preventing colitis in our model system. It seems likely that the term ‘Treg’ encompasses a number of di¡erent T cell populations. The lineage relationships between them is not known. Bach: I heard recently that di¡erent data may be obtained in nude mice and SCID mice. Is the CD25+ cell-induced gastritis seen in both? Powrie: This is the experience of several groups around the world. There are various cell populations present in nude mice that are absent in RAG mice, including some thymic-independent intestinal T cells and B cells. These may play a key role in host defence and immune regulation. If you treat a normal mouse with anti-CD25 you do not get in£ammatory bowel disease or gastritis. The gut has several mechanisms of protection and it is not su⁄cient just to take away the CD25+ cells. Flavell: In your regulation of the innate response, how do you know that it is an ab T cell in the CD25+ group that is actually doing that rather than some innate cell. Evolutionarily it is awkward to think about this. There is a bunch of organisms who have to do this innate regulation without any T cells. One should consider the possibility that it is an innate cell that is involved. Powrie: When we have reanalysed the cells by FACS they are over 99% ab positive. We don’t have to transfer very many cells to see this. Harrison: You raised the di¡erence between the RAG/ mice and nude mice, and mentioned extrathymic-derived T cells, which constitute many of the intraepithelial leukocytes (IELs) in the gut. There are data (Mengel et al 1995, Ke et al 1997) showing that if cells are blocked with gd antibody at the time you try to induce regulatory cells with mucosally administered antigen, you don’t get them. You need to have IELs of the extrathymic variety working in order to generate through mucosa the various varieties of T cells that we are talking about. This is a critical ¢nding in the literature that has been overlooked. It might help us to connect what is happening in the mucosa, in terms of the requirement for a normal mucosa in order to get colitis and on the other hand having a normal mucosa in order to get regulation. These cells are the ¢rst line of defence in the mucosa, so it makes sense that they might condition underlying DCs in the lamina propria to be ‘tolerogenic’ for the induction of CD4+ regulatory T cells. Powrie: That is an important point. How they relate to the CD25+ cells that one can ¢nd in the thymus is another issue. Harrison: There is a thymus^mucosa axis. It is a two-way thing.
IMMUNE PATHOLOGY
105
References Ke Y, Pearce K, Lake JP, Ziegler HK, Kapp JA 1997 gd T lymphocytes regulate the induction and maintenance of oral tolerance. J Immunol 158:3610^3618 Mengel J, Cardillo F, Aroeira LS, Williams O, Russo M, Vaz NM 1995 Anti gd T cell antibody blocks the induction and maintenance of oral tolerance to ovalbumin in mice. Immunol Lett 48:97^102
General discussion I
TGFb Flavell: I wanted to brie£y describe some of our results on TGFb. This work exploits a system that we set up a few years ago, based on transgenic mice that have a dominant-negative TGFb receptor. Leonid Gorelik, who made these mice truncated the type II receptor, which blocks signalling. These mice develop a very profound immune-activated phenotype, which is re£ected in a series of autoimmune diseases. These include in£ammatory bowel disease (IBD; this is bacterial dependent), in£ammation in the lungs, autoantibodies and accumulation of immune complexes in the kidneys. Depending on the genetic background, other phenotypes ensue. On the Balb/C background the mice get liver in£ammatory disease, and the NOD mouse develops very acute diabetes within a few weeks of birth. It is an example of where there is a di¡erence of immune repertoire, consequences are di¡erent. The basic phenomenon is increased tissue-speci¢c and systemic autoimmunity. Bach: Are they hypertrophic? Flavell: They have wasting disease when the IBD develops. However, in the lines that we study this doesn’t occur for several months of life. They develop pretty normally for the ¢rst several months. After that they develop wasting disease. Mitchison: What happens with regard to the role that TGFb is supposed to play in embryonic development? Flavell: We are not a¡ecting the production of TGFb in these mice. All we are a¡ecting is the ability of T cells to respond to it. This transgene is directed only towards the CD4+ and CD8+ T cells. The rest of the body is acting pretty normally. The reason I wanted to mention this mouse in this context is that it allows us to ask, if we have a cell of this nature (I’ll talk about CD8+ cells), whether it can be inhibited in its function to develop an autoimmune response by regulatory T cells. The system we use for this is diabetes. It is a published system developed by Alison Green who did the experiments (Green & Flavell 2000). It is a complex transgenic system, but the basic phenomenon uses induced TNFa gene expression in the islets. These mice then develop diabetes very acutely. If we induce this at birth, they will develop diabetes within 4^6 weeks. Alison noted that the necessary duration of TNFa expression for acute 106
GENERAL DISCUSSION I
107
disease was 28 days. She saw that if one induces for shorter periods, then disease is protracted, taking a lot time to happen. Then when she looked in the draining lymph nodes she saw that regulatory cells (CD4+CD25+) accumulate, increasing in number up to about 20% in the nodes and the islets. They then wane as disease occurs. When she shut o¡ expression early, what happened was that these numbers stayed up: there was a correlation between the numbers of these cells and the time it took to get sick. If she kept those Treg numbers high by shutting o¡ the expression then the regulatory cells were high in number and the mice took a long time to get sick. Adoptive transfer studies were then done to establish that the protective e¡ect was indeed due to these cells. It was a very sensitive system: she could protect with only 2000 of these cells. These cells again are derived from the pancreatic lymph node. Those from other environments are not strongly protective. Using this system Alison and Leonid went on to ask what happens in a system of this nature if one uses, instead of a normal CD8+ cell, a CD8+ cell carrying the dominant-negative TGFb receptor as the autoaggressive cell. In the ¢rst study, they did an adoptive transfer. 2000 cells are su⁄cient to do this. In this study we transferred 10 000 of these pancreatic lymph node Treg cells, ¢ve times more than is required to block normal diabetes. Normally, the recipient mouse develops diabetes about 10 d after the initiation of the transfer process. If the Treg are put in, this process is blocked. Importantly, if you put in 30 000 of the CD8+ cells which derive from the dominant-negative mouse together with the Treg, all of the mice develop disease. The regulatory cells cannot block their function. In order to address this in a di¡erent kind of transfer model she did the experiment in the other direction. She took a recipient mouse that actually carries the regulatory cells. She put 30 000 transgene-positive or transgene-negative autoaggressive cells into this mouse, in both cases derived from the pancreatic lymph node. In the ¢rst experiment transferring mixed CD8+ cells blocks disease completely. We then transferred either activated or na|« ve cells derived from that lymph node. You can imagine that because of the fact that these CD8+ cells have a propensity to get activated, we are not comparing apples with apples. This experiment shows what happens if you take out memory CD8+ cells (CD8+CD44+) and compare these with either the dominant negative memory cells or the wild-types. The wild-type cells are inhibited by this regulatory environment. Mice given the memory cells derived from the transgene positive develop disease instantaneously. The regulatory cells in that recipient mouse can’t inhibit the function of these memory cells if they carry that dominant negative. The same is true when na|« ve cells are used. Transfer of na|« ve dominant negative cells (CD44low CD8high) causes disease. Controls don’t develop disease in this time frame. Both na|« ve and ‘memory’ cells are susceptible to this inhibition, although it looks like the na|« ve cells are more susceptible. Fiona Powrie has data using cells from these mice. In this case it is CD4+ autoaggressive cells.
108
GENERAL DISCUSSION I
Powrie: The basic question we have been asking is if we take CD45RBhigh cells from one of these dominant-negative transgenic mice that can’t respond to TGFb, can they be regulated by the CD25+ cells with regard to colitis induction? The answer is that they can’t. If the responding T cells can’t receive a TGFb-mediated signal, then the CD25+ population is not able to suppress. Harrison: I have a bit of a problem with the logic of that. Why do you assume that the regulatory cells don’t work, and normally when they do they necessarily work through the TGFb pathway in e¡ector cells? It could be that the e¡ector cells are di¡erent in all sorts of ways. It doesn’t necessarily require a signal through TGFb to suppress them. Flavell: Let’s reduce your question to a more general one: do we know that the e¡ect is a direct e¡ect between regulatory cells and these cells? What the experiment says is that the end point of the response requires a signal through TGFb in order for the thing to be shut o¡. In the absence of that this doesn’t work. Abbas: Je¡ Bluestone made this point with CTLA4 earlier. Why can’t you postulate that TGFb or CTLA4 are not the mediators of regulation, but in their absence these cells are hyper-responsive? They just respond so much better that they can’t be suppressed any more. It is this tuning idea, rather than the direct mediator idea. I am not sure you can exclude the idea that these cells are just hyper-responsive, and under the conditions of your experiment they are just responding too much for you to suppress them. Shevach: A bigger response is harder to suppress. Powrie: There is no evidence that there is a bigger response in the RBhigh dominant-negative cells with respect to colitis. Abbas: But you haven’t really done careful dose titrations. In the Gorelik & Flavell (2000) paper they showed that the TGFb dominant-negative receptor expressing cells are hyper-responsive. They give much bigger responses than the wild-type. Powrie: With the na|« ve RBhigh population, if we isolate them, transfer and look at their accumulation, there is no evidence that they accumulate more than normal cells, or that they are more potent in inducing colitis. Bluestone: The arguments made here are no di¡erent than the arguments that you heard when you did the anti-TGFb antibody treatment. You showed that the absence of TGFb in the environment makes it harder to suppress. Bach: One may argue from these data that the presence of TGFb is mandatory for T cell-mediated suppression of colitis. Coming back to Abul Abbas’ question, one does not yet fully understand how TGFb works in this context. Abbas: The point is, if you buy this sort of hyper-responsiveness idea, you could speculate that the actual suppressive molecule is ‘X’, and it has nothing to do with TGFb, but normally when you activate T cells they make a small amount of TGFb that functions to dampen their response. In the absence of TGFb, the cells respond
GENERAL DISCUSSION I
109
much more and exceed the limit of suppressibility; for instance, instead of 10 units of response we get 1000 units of response, and we can only suppress 100. Powrie: It should be possible to overcome this by quantitatively putting in more CD25+ cells. Bluestone: On a per cell basis this may not be possible. More may not be better. Bach: These data should be considered alongside the anti-TGFb antibody data. Shevach: Have you reversed suppression with anti-TGFb? Flavell: We haven’t tried. Shevach: This would get around Abul Abbas’ argument. It should be very easy. Bluestone: The best experiment would involve prede¢ning the repertoire, getting everything out of the periphery and then turning this thing on conditionally. This will tell you for sure. Delovitch: Is the apparent hyper-responsiveness associated with the relative resistance of those cells to activation-induced cell death through TGFb signal? Flavell: It is the reverse. If anything these cells are more susceptible to apoptosis because TGFb is somewhat protective against this e¡ect. Bluestone: Have you done the reciprocal experiment, asking whether the regulatory cells from these animals are functional? This would be a neat thing to know. Flavell: I think it has been done. Shevach: I’d like to present some data on the function of TGFb in vitro in mediating suppression by CD25+ cells (Piccirillo et al 2002). This is a 100% negative study. This work was prompted by my colleague Warren Strober’s observation that antibody to TGFb completely reversed suppression (Nakamura et al 2001). In our hands antibody to TGFb of any type at any concentration always fails to reverse suppression. This is done with freshly explanted CD25+ cells, but more importantly it is done with pre-activated CD25+ T cells that according to Strober are supposed to express abundant membrane TGFb We have also attempted to reverse suppression with a soluble TGFb-R2 receptor (which Richard Flavell was talking about). This particular experiment was done with CD8 responders. If we take CD8 responders and add TGFb we suppress the response of these cells to anti-CD3. If we put in soluble receptor we reverse the suppression mediated by recombinant human TGFb. If we do the same experiment using CD25+ T cells this suppression is not reversed. The next thing we used was T cells derived from SMAD3-de¢cient mice. SMAD3 is a critical model involved in TGFb-mediated signalling. Wild-type T cells responsive to anti-CD3 can be suppressed by TGFb. In contrast the response of SMAD3 knockout CD4+ T cells to anti-CD3 can not be suppressed by a high concentration of TGFb. However, they are fully suppressed by CD4+CD25+ T cells from wild-type mice. We have also done the reverse experiment, asking whether CD25+ T cells from SMAD3 knockout mice will suppress. They
110
GENERAL DISCUSSION I
suppress perfectly normally. This doesn’t exclude the possibility that TGFb acting on the CD25+ cell could potentially have some sort of augmenting e¡ect, but it is not critically needed for their suppressive function. Lastly, we utilized a di¡erent dominant-negative TGFb-R2 dominant negative mouse than the one described by Richard Flavell that is also non-responsive to TGFb. CD4+CD25+ T cells from these mice were also fully suppressible by CD25+ T cells from wild-type mice. We did the converse experiment here as well showing that the CD25+ cells from the dominant-negative R2 receptor mice were fully functional. Lastly, we actually bit the bullet and isolated CD4+CD25+ T cells from very young TGFb knockout mice. We didn’t see any di¡erence between the percentages of CD25+ cells between the wild-type and TGFb knockout mice of the same age. More importantly, when we looked at the CD25 cells from these knockout mice, they had no sign of activation. The functional phenotype of the CD25+ T cells from 10 day old TGFb de¢cient mice was the same as that of CD25+ T cells of wild-type mice. They were both anergic and suppressive. Furthermore, depletion of CD25+ T cells from lymph node and spleen preparations from TGFb knock out mice led to enhanced proliferation. We conclude that TGFb plays very little, if any role in the suppressor e¡ector function of CD4+CD25+ T cells in vitro. Ha£er: Fiona Powrie’s system is very di¡erent, so I can understand some discrepancies there. But Warren’s system is similar to yours and you have exchanged reagents. Shevach: We exchanged reagents and we didn’t see cell surface staining with mice from the same facility. So our di¡erent results are very hard to explain. The concept that suppression is mediated by cells that express a cell surface inhibitory cytokine remains very attractive. The only unifying explanation I can o¡er is that in some circumstances where you have CD25+ cells that are not potent suppressors, TGFb made by either CD25+ or CD25 T cells may feed back and augment the function of the CD25+ cells in vitro. There is some evidence for this. David Horowitz has shown that TGFb induces suppressor cells that functionally resemble CD25+ cells by culturing CD25 cells in TGFb (Yamigawa et al 2001). Bruce Blazar has a paper where he shows that TGFb augments the suppressor function of CD25+ cells (Taylor et al 2002). Our experiments with the SMAD3 knockouts show that TGFb is not needed for suppression, but TGFb could still play a co-stimulatory role in augmentation of suppressor activity of CD25+ T cells. Bach: Shimon Sakaguchi, did you ¢nd TGFb on the membranes of your cells? Sakaguchi: In our hands we can stain the CD25+ cells by anti-TGFb antibody, but the expression i